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Abstract 
UDP-glucuronosyltransferases (UGTs) catalyse glucuronidation reactions between glucuronic acid and 
drug molecules, which contain nucleophilic groups, mostly hydroxyls, amines or carboxylic acids. 
Glucuronidation is the most important reaction in the conjugative drug metabolism. Because these 
conjugates are not usually able to cross cell membranes passively, they need active efflux transport. 
Efflux transporters mostly belong to superfamily of ATP-binding cassette transporters (ABC). 
Subfamily C of ABC transporters (ABCC) are known to be involved in efflux transport of glucuronides. 
Especially MRP2 (ABCC2) and MRP3 (ABCC3) play key roles in the elimination of glucuronide 
conjugates of drugs. MRP2 is localized in the apical membranes of hepatocytes and enterocytes, 
whereas MRP3 is localized in the basolateral membranes of the respective cells. On the other hand, 
UGT1A1 and UGT2B7 are highly expressed in liver and small intestine and are the most important 
UGTs in drug metabolism. It is known, that UGTs and efflux transporters work together forming 
interplay to eliminate drugs. Therefore, studying both of them in the same in vitro system is in important 
focus of drug metabolism studies. 
 
The Madin Darby canine kidney cell line (MDCK) is one of the standard in vitro tools in drug 
metabolism studies. In this study, MDCK was chosen for a cell line to co-express UGTs (UGT1A1 or 
UGT2B7) and efflux transporters (MRP2 and MRP3 simultaneously. Therefore, cloning of the 
UGT2B7 cDNA and the ABCC3 cDNA encoding MRP3 was aimed in this study. On the other hand, 
the UGT1A1 cDNA was already cloned in-house and MRP2 expressing MDCK cells were established 
earlier. 
 
Cloning of the UGT2B7 cDNA was not successful in this study despite of several different strategies 
such as PCR-amplification of the cDNA fragment using kidney or liver sscDNA as template. Cloning 
of the ABCC3 cDNA encoding MRP3 was achieved and a mammalian expression vector containing 
this cDNA was constructed. In addition, the mammalian expression vector containing the UGT1A1 
cDNA was used to establish MDCK-UGT1A1 cells and this cell line was characterized regarding the 
expression of UGT1A1 mRNA and UGT1A1 protein amount. Furthermore, establishment of MDCK-
UGT1A1-MRP2 cell line was attempted in this study without success. 
 
The mammalian expression vector containing the ABCC3 cDNA encoding MRP3 could be used for 
future experiments to achieve novel cell lines such as MDCK-UGT1A1-MRP3 and MDCK-UGT1A1-
MRP2-MRP3 for drug metabolism studies. In addition, the novel cell line MDCK-UGT1A1 could be 
used for drug metabolism studies in further experiments, but also as a cell line for further establishment 
of above cell lines. On the other hand, the cloning of the UGT2B7 cDNA needs optimization and 
several different strategies should be used to achieve the mammalian expression vector containing this 
cDNA. 
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Tiivistelmä 
UDP-glukuronosyylitransferaasit (UGT:t) katalysoivat glukuronidaatioreaktiota, jossa 
glukuronidihappo liittyy lääkeaineiden nukleofiilisiin ryhmiin kuten hydroksyyleihin, amiineihin tai 
karboksyylihappoihin. Glukuronidaatio on kaikkein tärkein metaboliareaktio konjugatiivisessa 
lääkeainemetaboliassa. Glukuronidikonjugaatit eivät pysty pääsääntöisesti läpäisemään solukalvoja 
passiivisesti, joten ne täytyy kuljettaa aktiivisesti ulos soluista. Efflux-transportterit vastaavat 
yhdisteiden aktiivisesta kuljetuksesta ulos soluista. Suurin osa efflux-transporttereista kuuluu 
adenosiinitrifosfaattia (ATP) sitovien efflux-transportterien perheeseen (ABC), joista etenkin C-
alaperhe (ABCC) osallistuu glukuronidikonjugaattien kuljetukseen ulos soluista. MRP2 (ABCC2) ja 
MRP3 (ABCC3) ovat tärkeässä asemassa tässä kuljetuksessa. MRP2 on lokalisoitunut hepatosyyttien ja 
enterosyyttien apikaalimembraanille, kun taas MRP3 on lokalisoitunut vastaavien solujen 
basolateraalimembraanille. Lisäksi UGT1A1 ja UGT2B7 ekspressoituvat suuressa määrin maksassa ja 
ohutsuolessa, ja ovat täten kaikkein tärkeimpiä UGT-entsyymejä lääkeainemetaboliassa. Tiedetään, että 
UGT:t ja efflux-transportterit osallistuvat yhdessä lääkeaineiden eliminaatioon ja muodostavat täten 
yhteispelin. Tämän takia on tärkeää tutkia kumpaakin prosessia samassa in vitro mallissa. 
 
Madin Darby koiran munuaissolulinja (MDCK) on yksi perustyökaluista 
lääkeainemetaboliatutkimuksissa. Tässä tutkimuksessa MDCK-solut valittiin solulinjaksi, jossa 
ekspressoidaan samanaikaisesti UGT:t (UGT1A1 tai UGT2B7) sekä MRP:t (MRP2 ja MRP3). Tätä 
varten tämän tutkimuksen tavoite oli kloonata UGT2B7:n ja ABCC3:n, joka koodaa MRP3:a, cDNA:t. 
Toisaalta, UGT1A1:n cDNA oli kloonattu ja MRP2:ta ekspressoivat MDCK-solut oli muodostettu jo 
aikaisemmin tässä laboratoriossa. 
UGT2B7:n cDNA:n kloonaus ei onnistunut tässä tutkimuksessa, vaikka useita eri strategioita yritettiin, 
kuten cDNA fragmentin PCR-amplifikaatiota maksa- ja munuais-sscDNA:sta. Toisaalta, ABCC3:n 
cDNA, joka koodaa MRP3:a, saatiin kloonattua ja nisäkäsekspressiovektori, joka sisältää tämän 
cDNA:n, saatiin muodostettua. Lisäksi nisäkäsekspressiovektoria, joka sisältää UGT1A1 cDNA:n, 
käytettiin muodostamaan MDCK-UGT1A1 solulinja, jonka UGT1A1 mRNA-ekspressio ja 
proteeniekspressio karakterisoitiin. Toisaalta, MDCK-UGT1A1-MRP2 solulinjaa ei saatu muodostettua 
yrityksistä huolimatta. 
ABCC3:n cDNA:n, joka koodaa MRP3:a, sisältämää ekspressiovektoria voidaan käyttää 
tulevaisuudessa eri MDCK solulinjojen transfektointiin, jotta saataisiin muodostettua esimerkiksi 
MDCK-UGT1A1-MRP3 ja MDCK-UGT1A1-MRP2-MRP3 solulinjat lääkeainemetaboliatutkimusta 
varten. Lisäksi tässä tutkimuksessa muodostettua uutta MDCK-UGT1A1 solulinjaa voidaan käyttää 
tulevaisuudessa lääkeainemetaboliatutkimuksessa, mutta myös yllämainittujen solulinjojen 
muodostamiseen. Toisaalta, UGT2B7:n cDNA:n kloonaus vaatii lisää optimisaatiota. 
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1.  INTRODUCTION 
 
Absorption and disposition (distribution, metabolism and excretion) affect 
pharmacokinetics and toxicity of drugs and thus they are in focus of drug development 
studies (Caldwell et al. 1995; Ruiz-Garcia et al. 2008). One important factor affecting 
absorption of an orally administered drug molecule is permeability (Amidon et al. 1995). 
In addition, permeability affects the metabolism and distribution of a drug molecule (Wu 
and Benet 2005). After entering the human body, drug molecules could undergo 
metabolism and are excreted as metabolites or as unchanged molecules (Caldwell et al. 
1995). Generally, high permeable drugs are metabolized more extensively than low 
permeable drugs that are more prone to excretion without metabolism (Wu and Benet 
2005). In addition, metabolism and permeability affects both the extent of absorption and 
the excretion route of drug molecules (Caldwell et al. 1995; Benet et al. 2011). 
Drug metabolism is divided into two major classes, oxidative metabolism and conjugative 
metabolism (Di 2014). Cytochrome P450 enzymes (CYP) are mainly responsible for the 
oxidative metabolism whereas UDP-glucuronosyltransferases (UGT) are the main 
enzymes responsible for the conjugative metabolism. A drug molecule could be a 
substrate for a single enzyme of one class of enzymes or for multiple enzymes in one 
class of enzymes or for several enzyme classes. Oxidative metabolism does not 
substantially affect lipophilicity of drugs (Smith and Dalvie 2012). On the other hand, 
conjugated metabolites such as glucuronic conjugates are generally hydrophilic and thus 
low permeable. These drug metabolites are particularly prone to enterohepatic circulation, 
when excreted to bile, or to enteric recirculation, when excreted in intestinal lumen 
(Wakabayashi et al. 1994; Fagerholm 2008; Zhang et al. 2013). This is caused by 
deconjugation of a drug metabolite in the intestine and reabsorption of the parent drug. 
Enterohepatic circulation and enteric recirculation can substantially affect 
pharmacokinetics of a drug (Gregus and Klaassen 1987; Fagerholm 2008).  
Highly permeable drugs and drug metabolites can enter and exit cells and human body 
by passive diffusion but low permeable drugs and drug metabolites need usually active 
transport by transporter proteins (Wu and Benet 2005). Especially conjugated drug 
metabolites are excreted out of the cells via efflux transporters leading to excretion into 
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feces or urine (Jeong et al. 2005; Shi and Li 2014). Drug transporters are classified as the 
uptake and efflux transporters (Giacomini et al. 2010; Hillgren et al. 2013). Uptake 
transporters transport compounds into cells and efflux transporters transport compounds 
out of the cells such as enterocytes and hepatocytes. The major classes of uptake 
transporters are organic anion transporting polypeptides (OATPs), organic anion 
transporters (OATs) and organic cation transporters (OCTs). On the other hand, the major 
class of efflux transporters is ABC transporters, which include among others multidrug 
resistance protein 1 (MDR1), breast cancer resistance protein (BCRP) and multidrug 
resistance proteins (MRPs). Especially MRP2 and MRP3 are known to be involved in 
transport of conjugative metabolites such as glucuronides (Zamek-Gliszczynski et al. 
2006a; Zamek-Gliszczynski et al. 2014).  
Methods for in vivo prediction of drug metabolism and excretion are not fully 
standardized and they lack correlation between in vitro and in vivo situation (Lavé et al. 
2009; Pellegatti 2012; Di 2014). Before clinical studies, data of drug metabolism and 
excretion are acquired in vivo and in vitro animal studies and in vitro human studies. 
Because in vivo animal models are mostly used to predict human pharmacokinetics and 
toxicokinetics, more reliable human in vitro models are needed. Firstly, in vivo animal 
studies are expensive and possess ethical consideration compared to in vitro studies (Lavé 
et al. 2009; Pellegatti 2012). Secondly, preclinical animal studies do not result in 
comprehensive correlation between animal and human in vivo situations. 
The aim of this study was to develop new cell models expressing human efflux 
transporters (MRPs) and conjugative drug metabolizing enzymes (UGTs) to study 
metabolism and excretion of drug molecules in vitro. Madin Darby canine kidney cell 
line (MDCK) was chosen to express human proteins, because this cell line is widely 
established for in vitro drug metabolism and transport studies (Fahrmayr et al. 2012; 
Fahrmayr et al. 2013; Brouwer et al. 2013). In addition, this cell line does not express 
proteins of human origin and forms in vitro a polarized monolayer, which allows vectorial 
transport studies of drug molecules and their metabolites. 
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2.  LITERATURE REVIEW 
 
2.1 Glucuronidation  
 
Most of the drugs undergo biotransformation before they are excreted out of body 
(Williams et al. 2004; Di 2014). Ten years ago, approximately 75 % of top 200 prescribed 
drugs were metabolized before excretion. Cytochrome P450 enzymes (CYP) which 
catalyze oxidation reactions are the most important primary clearance way for drugs that 
are metabolized. However, conjugation reaction with glucuronic acid (glucuronidation) 
plays a key role in drug metabolism besides CYPs. Now, it is estimated that 35 % of 
current drugs are inactivated by glucuronidation (Guillemette et al. 2014). Drugs could 
undergo also sulfotransferase-catalyzed conjugation with sulfate, but this does not play a 
key role in drug metabolism compared to glucuronidation (Williams et al. 2004; Di 2014). 
Glucuronidation could occur in molecules that contain hydroxyl-, carboxylic acid- or 
amine-groups (Rowland et al. 2013). The amine group could be located in either 
heterocycle ring or aliphatic chain. In rare cases, glucuronidation could occur in thiol 
groups or in acidic carbon. UDP-glucuronosyltransferases (UGT) catalyze the reaction 
between uridine diphosphate glucuronic acid (UDPGA) and a molecule undergoing 
glucuronidation. This glucuronidation reaction results in glucuronic acid metabolite of 
drugs, called glucuronides. Figure 1 presents a representative glucuronidation reaction of 
SN-38, the active metabolite of irinotecan in humans (Hanioka et al. 2001). 
Figure 1. A representative scheme of glucuronidation reaction representing 
glucuronidation of SN-38 (active metabolite of irinotecan) resulting to SN-38-
glucuronide. UGT1A1 = Uridine 5'-diphospho-glucuronosyltransferase 1A1 and UDPGA 
= uridine diphosphate glucuronic acid. 
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2.1.1 UDP-glucuronosyltransferases 
  
UGTs are located in the endoplasmic reticulum (ER) of cells and they are structured in 
N- and C-terminal domains (Laakkonen and Finel 2010). In addition, they contain an 
envelope helix between the C-terminal domain and the transmembrane segment forming 
proteins of approximately 530 amino acids length. Interestingly, almost the entire protein 
localizes inside ER, which means that molecules undergoing glucuronidation and the 
source of glucuronic acid, UDPGA, need to permeate ER before glucuronidation. In 
addition, molecules have to first permeate inside cells before glucuronidation, which 
means that highly glucuronidated molecules have good permeation and thus are highly 
lipophilic (Wu and Benet 2005; Rowland et al. 2013).  
There are 19 different isozymes, which catalyze glucuronidation reactions, in the 
superfamily of UGTs (Rowland et al. 2013). Based of sequence similarities, they are 
divided into subfamilies 1A, 2A and 2B. These subfamilies consist of UGT1A1, 
UGT1A3-10, UGT2A1-3, UGT2B4, UGT2B7, UGT2B10-11, UGT2B15, UGT2B17 and 
UGT2B28. However, UGT1A5, UGT2A1-3, UGT2B11 and UGT2B28 are thought not 
to be involved in drug metabolism (Guillemette et al. 2014; Stingl et al. 2014; Oda et al. 
2015). In addition, expression of UGT1A7 protein is not detected in liver, small intestine 
or kidney and its mRNA expression is low in these tissues, so it seems that it does also 
not contribute to drug metabolism (Ohno and Nakajin 2009; Court et al. 2012; Sato et al. 
2014). Interestingly, 10 % of Caucasian people carry UGT2B17 deletion and even 30 % 
have no or only little expressed protein, which might also affect its contribution to drug 
metabolism (Gallagher et al. 2007; Fallon et al. 2013).  
All UGTs involved in drug metabolism are expressed in all three major drug metabolizing 
tissues; liver, intestine and kidney but with tissue specific expression pattern and highly 
variable expression levels between different isozymes (Ohno and Nakajin 2009; Court et 
al. 2012; Fallon et al. 2013; Sato et al. 2014;). Relative expression of UGTs involved in 
drug metabolism in liver, kidney and intestine tissues are presented in Table 1. The 
highest expressed UGT in liver is UGT2B7, expression of which is two times higher than 
that of UGT1A1. On the other hand, UGT1A1 is expressed approximately two times 
higher than UGT2B7 in intestine, although UGT2B17 possess superior expression in this 
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tissue. Only three UGTs are expressed in kidney; UGT1A9, UGT2B7 and UGT1A6. In 
addition, UGT1A10 is highly expressed in intestine but not in liver.  
 
Table 1. Relative protein expression levels of UGTs involved in drugs metabolism in 
liver, intestine and kidney. In addition, expression of the UGTs in selected other tissues 
is presented. Relative expression levels in liver according to Harbourt et al. 2012, Ohtsuki 
et al. 2012, Fallon et al. 2013, Achour et al. 2014, Sato et al. 2014  and Oda et al. 2015. 
Relative expression levels in small intestine and kidney according to Sato et al. 2014. 
Expression of UGT1A8 in small intestine and expression of other UGTs in selected other 
tissues according to Ohno and Nakajin 2009 and Court et al. 2012. N.D. = not detected. 
 
2.1.2 UDP-glucuronosyltransferases in detoxification of xenobiotics 
 
General properties of substrates for UGTs are quite well understood, because these 
enzymes accept compounds containing free hydroxyl, amine or carboxylic acid groups. 
Even very small molecules like ethanol could be glucuronidated (Schwab and Skopp 
2014). However, compounds that are glucuronidated normally have molecular weight of 
100-600 Da representing well typical drug molecules (Obach et al. 2008; Stingl et al. 
2014). Especially, small phenol containing compounds are good substrates for UGTs 
(Ethell et al. 2002). In many cases, the substrate specificity of individual UGTs is 
overlapping and it is not possible to predict substrate specificity of a single isozyme 
(Miners et al. 2004; Dong et al. 2012). Despite, there are some typical features of 
UGT 
Relative protein expression 
Expression in selected other 
tissues Liver 
Small 
Intestine 
Kidney 
UGT1A1 3 24 N.D. - 
UGT1A3 2 1 N.D. - 
UGT1A4 3 1 N.D. - 
UGT1A6 2 N.D. 1 
Stomach, trachea, nasal and 
adrenal 
UGT1A8 N.D. low N.D. - 
UGT1A9 2 N.D. 12 Adrenal 
UGT1A10 N.D. 10 N.D. Colon, nasal and trachea 
UGT2B4 3 N.D. N.D. Hearth, prostate and testis 
UGT2B7 6 10 7 Colon, pancreas and uterus 
UGT2B10 1 N.D. N.D. - 
UGT2B15 3 N.D. N.D. 
Breast, trachea, prostate and 
testis 
UGT2B17 1 56 N.D. 
Colon, breast, cervix, nasal 
and adipose 
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compounds glucuronidated by some isozymes: UGT1A4 and UGT2B10 seem to be the 
only isoforms catalyzing efficient glucuronidation reactions of different amines 
(Kaivosaari et al. 2011). On the other hand, UGT1A6 glucuronidates rather small phenol 
containing molecules (Ethell et al. 2002; Dong et al. 2012).  
Because UGTs accept small molecules with certain properties, substrates for them include 
a wide variety of molecules including endogenous compounds, drugs and other 
xenobiotics such as flavonoids and related plant derived molecules, industrial chemicals 
and carcinogenic compounds (Nowell et al. 1999; King et al. 2000; Wu et al. 2011; 
Guillemette et al. 2014; Gramec Skledar et al. 2014; Stingl et al. 2014). In addition, 
products of oxidative metabolism, that introduce hydroxyl group(s) in drug molecules, 
could be also substrates for UGTs (Anderson et al. 2009; Kamdem et al. 2010; Chen et 
al. 2012). However, glucuronidation of oxidative metabolites of drugs is only rarely well 
characterized on the level of individual UGTs.  
Glucuronidation of endogenous compounds and xenobiotics is mostly considered as 
inactivation reaction that mediates subsequent excretion of compounds out of the human 
body (Rowland et al. 2013). However, there are examples of glucuronidation reactions, 
which actually activate compounds pharmacologically, toxicologically or as for 
perpetrators of drug interactions (Table 2).  
For example, glucuronide conjugates could undergo oxidative metabolism and/or 
subsequently inhibit CYPs. Gemfibrozil glucuronide inhibits CYP2C8 (Delaforge et al. 
2005; Baer et al. 2009). The same enzyme is also known to oxidize estradiol-17-
glucuronide (Shitara et al. 2004). In some cases, UGTs might affect carcinogenic 
activation of compounds. Benzidine and its metabolites are conjugated to N-glucuronides 
that are excreted to urine (Zenser et al. 1998). However, it is speculated that 
glucuronidation actually promotes activation of procarcinogenic benzidine in bladder 
because N-glucuronides are acid label and are cleaved under the low pH of the urine. This 
will subsequently release benzidine for carcinogenic activation in bladder.  
Acyl glucuronides, that are glucuronide conjugates of carboxylic acids, have been in high 
interest because they are chemically rather unstable (Sallustio et al. 2000). In some cases, 
it is shown that acyl glucuronides could act as nucleophiles and subsequently react 
covalently with proteins. This might cause toxic effects in tissues, especially in liver, and 
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be related to adverse drug effects. For example, it is shown that diclofenac-glucuronide 
forms protein adducts in livers of human and mouse (Aithal et al. 2004).  
It is widely known that oxidative metabolism could lead in many cases to active drug 
metabolites (Obach 2013). On the other hand, it is rare that conjugative metabolism leads 
to pharmacologically active metabolite. However, a well-known example of a 
pharmacologically active glucuronide is presented in the case of morphine-6-glucuronide 
that was found considerably more potent than morphine itself (Paul et al. 1989). 
Table 2. Selected examples of glucuronides that have pharmacological activity. 
1Delaforge et al. 2005, 2Baer et al. 2009, 3Zenser et al. 1998, 4Aithal et al. 2004, 5Paul et 
al. 1989. 
Glucuronide 
Physiological consequence of 
glucuronidation 
Estradiol-17-glucuronide 
 
 
Substrate for CYP2C8 that catalyzes 
oxidation of estradiol-17-glucuronide to 
2-hydroxy-estradiol-17-glucuronide.1 
Gemfibrozil-glucuronide 
 
 
Irreversible inhibition of CYP2C8.2 
Benzidine-glucuronide 
 
 
Deglucuronidation of benzidine-
glucuronide in urine bladder and 
subsequent activation of benzidine by 
oxidative metabolism to carcinogenic 
compound.3 
Diclofenac-glucuronide 
 
Chemically unstable glucuronide that 
forms protein adducts.4 
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Morphine-6-glucuronide 
 
 
 
 
 
>100 fold analgesic potency compared to 
morphine.5 
 
2.1.3 UDP-glucuronosyltransferases in metabolic clearance of drugs  
 
Glucuronidation plays a key role in the detoxification of drugs, but also in deactivation 
of endogenous compounds. The most prominent function known for UGTs is 
detoxification of bilirubin, which is catalyzed by UGT1A1 (Bosma et al. 1994). Bilirubin 
is the endproduct of hemoglobin catabolism. It is extensively glucuronidated and 
subsequently excreted by efflux transporter MRP2 to bile and feces (Keppler 2014). In 
addition, glucuronidation is an important regulation mechanism for the homeostasis of 
active androgens and estrogens (Raftogianis et al. 2000; Bélanger et al. 2003; Gauthier-
Landry et al. 2015). Nevertheless, conjugation reactions with glucuronic acid play a major 
role in drug metabolism and thus here are presented some examples (Table 3). 
Paracetamol is extensively conjugated with glucuronic acid and subsequent paracetamol-
glucuronide is excreted via urine (McGill and Jaeschke 2013). The main UGTs involved 
in paracetamol glucuronidation are UGT1A6 and UGT1A9, which are highly expressed 
in liver (Court et al. 2001). Especially UGT1A6 plays a key role in glucuronidation of 
paracetamol (Miners et al. 2011). A drug that is extensively conjugated in intestine and 
has a bioavailability only of few percent is raloxifene (Morello et al. 2003; Jeong et al. 
2004; Sun et al. 2013). UGT1A10 and both UGT1A1 and UGT1A9 are mainly 
responsible for glucuronidation of raloxifene in intestine and liver, respectively. 
Entacapone is highly conjugated in human with glucuronic acid (Wikberg et al. 1993; 
Lautala et al. 2000). Conjugation takes place in liver and UGT1A9 is mainly responsible 
for it. UGT2B7 is responsible for high rate conjugation of zidovudine, morphine and 
codeine, which are excreted via urine almost completely as glucuronide conjugates 
(Hoskin and Hanks 1990; Vree et al. 1992; Veal and Back 1995; Court et al. 2003). On 
  9  
 
   
the other hand, ezetimibe is almost solely excreted via feces and the glucuronide 
metabolite is majorly responsible for circulating metabolites (Kosoglou et al. 2005). 
UGT1A1 and UGT1A3 are responsible for the glucuronidation of ezetimibe in intestine 
and liver (Ghosal et al. 2004). 
 
Table 3. Selected examples of drugs, which are metabolized primary via glucuronidation. 
Site of glucuronidation is indicated with slash-lined circle in the compound. In addition, 
primary UGTs responsible for the glucuronidation of the compound, primary tissue for 
the glucuronidation, excretion route of the glucuronide and amount of the glucuronidation 
of total metabolism is presented. 1Court et al. 2001, 2Miners et al. 2011, 3McGill and 
Jaeschke 2013, 4Jeong et al. 2004, 5Sun et al. 2013, 6Morello et al. 2003, 7Lautala et al. 
2000, 8Wikberg et al. 1993, 9Court et al. 2003, 10Vree et al. 1992, 11Hoskin and Hansk 
1990, 12Veal and Back 1995, 13Ghosal et al. 2004, 14Kosoglou et al. 2005. 
Drug UGTs 
Primary tissue 
for 
glucuronidation 
Excretion route 
and amount of 
glucuronidation 
Paracetamol 
 
1A6, 
1A91,2 
Liver3 Urine, 60 %3 
Raloxifene 
 
1A10, 
1A14,5 
Intestine/liver4,5 Feces, 98 %6 
Entacapone 
 
1A97 Liver7,8 Feces, 95 %8 
Codeine  
 
2B7, 
2B49 
Liver9,10 Urine, 80 %10 
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Morphine 
 
 
2B7, 
2B49 
 
Liver11 
 
Urine, 90%11 
Zidovudine 
 
2B79 Liver12 Urine, 70 %12 
Ezetimibe 
 
1A1, 
1A313 
Intestine/ 
Liver13, 14 
Feces, 90 %14 
 
2.1.4 UDP-glucuronosyltransferases and their significance for drug metabolism 
 
The selected examples in Table 3 show that glucuronidation is involved in metabolism of 
clinical highly significant drugs. Stingl and coworkers (2014) reviewed literature and 
searched for drugs that are directly or their metabolites are significantly eliminated via 
glucuronidation. This data was further analyzed by Guillemette and coworkers (2014). It 
was concluded that UGT2B7, UGT1A9, UGT1A3, UGT1A4 and UGT1A1 had 19 %, 14 
%, 13 %, 11% and 11 % contribution, respectively, to glucuronidation of the all drugs 
presented by Stingl and coworkers (2014). When looking for the protein expression data 
of these enzymes in liver and intestine (Table 2), it is clear that UGT2B7 and UGT1A1 
have the highest contribution for the glucuronidation of drugs. On the other hand, 
UGT1A3 and UGT1A4 are expressed also in both tissues but at lower level than UGT2B7 
in liver or lower level than UGT2B7 and UGT1A1 in intestine. In addition, UGT1A9 is 
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highly expressed only in liver. 
Considering the above and results in Table 3, it could be stated that UGT1A1 and 
UGT2B7 are highly significant in view of drug development. Actually, European 
Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) recommend 
to determinate clearance of new investigational drugs via UGTs and especially examine 
contribution of UGT1A1 and UGT2B7 (EMA 2012; FDA 2012). 
 
2.2 Drug transporting proteins  
 
Most of the known xenobiotic efflux transporters are part of the adenosine triphosphate 
(ATP) binding cassette (ABC) superfamily (Schinkel and Jonker 2003; Giacomini et al. 
2010; König et al. 2013). There are 49 different proteins in seven subfamilies of ABC-
superfamily (Vasiliou et al. 2009). The subfamilies ABCB, ABCC and ABCG include 
transporters that are known to be involved in drug disposition (Borst and Elferink 2002; 
Schinkel and Jonker 2003; Giacomini et al. 2010; König et al. 2013). The most important 
proteins in the superfamiliy of ABC-transporters for drug transport are multidrug 
resistance protein 1 (MDR1, P-glycoprotein/ABCB1), breast cancer resistance protein 
(BCRP/ABCG2) and multidrug resistance proteins 2-4 (MRP2-4 /ABCC2-4). 
The second superfamily of drug transporters is the superfamily of solute carrier (SLC) 
transporters (Giacomini et al. 2010; Hediger et al. 2013; König et al. 2013). This 
superfamily of transporters includes 52 families and about 400 different transport 
proteins. The most important proteins of SLC transporters in drug disposition are organic 
anion transporting polypeptides (OATP/SLC21), organic anion transporters 
(OAT/SLC22), organic cation transporters (OCT/SLC22) and multidrug and toxin 
extrusion proteins (MATE/SLC47A) (Damme et al. 2011; Roth et al. 2012). OATPs, 
OCTs and OATs are mainly involved in uptake of drug molecules into enterocytes, 
hepatocytes and kidney cells. On the other hand, MATEs are efflux transporters expressed 
in liver and in kidney. SLC transporters do not contain nucleotide binding domains (NBD) 
and their mechanism of transport is mainly based on ion gradients over the cell membrane. 
For example, MATEs use an inward-directed proton gradient over the plasma membrane 
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to transport their substrates out of the cells (Damme et al. 2011).  
Both uptake and efflux transporters play important roles in the absorption of orally 
administered drugs and elimination of drug molecules and their metabolites (Giacomini 
et al. 2010; Hillgren et al. 2013; König et al. 2013; Zamek-Gliszczynski 2014). The focus 
will be here only on the efflux transporters MRP2-4, BCRP and MDR1. These 
transporters are the best-characterized efflux transporters in the view of disposition of 
drug molecules and their metabolites. Especially, substrate specificity of MRP2-3 will be 
presented here in more detail because they are known to be involved in transport of 
conjugative drug metabolites (Zamek-Gliszczynski 2006a). However, bile salt efflux 
protein (BSEP), MATEs, MRP5 and MRP6 are likely also to be involved in disposition 
of drug molecules and their metabolites, but these proteins need still characterization and 
further research of their significance in disposition of drugs and their metabolites 
(Hillgren et al. 2013).  
 
2.2.1 Structure and mechanism of ATP-binding cassette transporters 
 
MDR1, BCRP and MRP2-4 are located in the plasma membrane of polarized cells such 
as enterocytes, hepatocytes and renal proximal tubule cells, where they can be localized 
either at the blood side (basolateral) or at the luminal side (apical) (Schinkel and Jonker 
2003). These transporters actively transport compounds out of cell using energy released 
by hydrolysis of ATP. Because the transport process is active, ABC-transporters can 
transport against a concentration gradient. 
ABC transporters involved in drug disposition are normally formed of two 
transmembrane domains (TMD), each consists of six transmembrane α-helical segments 
(Schinkel and Jonker 2003). In addition, these transporters also consist of two NBDs, 
which are located intracellularly and are responsible for the hydrolysis of ATP. NBDs are 
highly conserved because they are critical for energy-dependent transport and they form 
the signature protein sequence that is specific for ABC-transporters (Deeley et al. 2006). 
In addition, NBDs do not affect substrate specificity of a transporter. The substrate 
specificity is controlled by TMDs and especially by amino acids located near to, or in the 
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substrate binding site.  
BCRP, MRP2 and MRP3 differ in the number of TMDs and NBDs compared to MDR1 
and MRP4. BCRP is formed only by one NBD and one TMD and is so called a "half-
transporter", it is 655 amino acids of size compared to other drug ABC transporters, which 
are 1300-1500 amino acids of size (Schinkel and Jonker 2003). On the other hand, MRP2 
and MRP3 contain one additional aminoterminal transmembrane segment consisting of 
five transmembrane helices.  
Transmembrane domains of ABC-transporters fold towards each other in cell membrane, 
forming a pore between them (Deeley et al. 2006; Sharom 2008; Rees et al. 2009). In 
addition, nucleotide binding domains fold towards each other and work co-operatively 
during the transport process. Simplified transport mechanism of ABC transporters 
involves binding of the compound to one or two sites of TMD, mainly from the cytoplasm 
but in some cases also through cell membrane. Binding of the substrate is followed by 
binding and hydrolysis of one or two ATPs. Hydrolysis of ATP to adenosine diphosphate 
(ADP) and free phosphate drives a conformation change of the protein and throws the 
molecule through the pore inside of the protein out of a cell. This is followed by release 
of ADP and recover of the original conformation of the transporter and readiness to 
transport a new molecule. 
 
2.2.2 Multidrug resistance protein 1, breast cancer resistance protein and multidrug 
resistance proteins 2-4 
 
MDR1, BCRP and MRP2-4 were all cloned from human cancer cell lines that showed 
resistance against multiple cancer drugs (Chen et al. 1986; Taniguchi et al. 1996; Kool et 
al. 1997; Doyle et al. 1998). In addition, rat Mrp2 was earlier cloned from rat strain the 
(TR-) that has chronic conjugated hyperbilirubinemia and defective bile excretion of 
organic anions (Paulusma et al. 1996). Multidrug resistant cancer cell lines overexpress 
an efflux transporter or pattern of transporters, which causes multifold resistance to 
certain cancer drug molecules when compared to same cancer cell line without any 
overexpression. Expression of above transporters was found to cause in vitro resistance 
against multiple cancer agents such as doxorubicin, etoposide, vincristine and 
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methotrexate (Gottesman et al. 2002). Because of that, function of these transporters was 
mainly considered only from the perspective of the cause for multidrug resistance in the 
beginning, although MRP2 was known to be involved in excretion of organic anionic 
compounds. However, later their contribution to absorption and disposition of drug 
molecules and their metabolites were recognized (Suzuki and Sugiyama 2000). 
Besides cancer tissues, MDR1, BCRP and MRP2-4 are expressed in important tissues in 
the view of drug metabolism, namely in intestine, liver and kidney (Figure 2). 
Enterocytes, hepatocytes and kidney proximal tubule epithelial cells are polarized cells, 
which form a barrier between two compartments. Transporters could be expressed in 
either side of membrane. Figure 2 presents localization of each of these transporters in 
liver, intestine and kidney tissue. In addition, MRP4 might be localized in the basolateral 
membrane of human enterocytes, because it is was shown to be localized in the basolateral 
membrane of human epithelial colorectal adenocarcinoma cells (Caco-2) (Ming and 
Thakker 2010). MRP3 was shown to be expressed also in the basolateral membranes of 
the distal convoluted tubules in kidney (Scheffer et al. 2002). 
Figure 2. Localization of MDR1, BCRP and MRP2-4 in liver, intestine and kidney cells. 
Localization of MRP3 in enterocytes is based on human colon cells and rat small intestine 
(Rost et al. 2002; Scheffer et al. 2002). Localization of MRP2, BCRP, MDR1, and MRP3 
in other tissues, is based on human samples (Thiebaut et al. 1987; Mayer al. 1995; 
Kartenbeck et al. 1996; König et al. 1999a; Fromm et al. 2000; Maliepaard et al. 2001; 
Scheffer et al. 2002; Van Aubel et al. 2002; Rius et al. 2003; Huls et al. 2008). 
 
In addition to the different localization in plasma membranes, these proteins show also 
different expression patterns and protein levels in tissues (Table 4). MRP2 has the highest 
expression compared to other MRPs in liver but in small intestine its expression is almost 
equal to MRP3 (Drozdzik et al. 2014; Wang et al. 2015). Interestingly, in colon MRP3 is 
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highly expressed compared to MRP2 (Drozdzik et al. 2014). MDR1 and MRP4 show high 
expression in kidney, whereas MRP2 has moderate and MRP3 has minor expression in 
kidney (Hilgendorf et al. 2007). In addition to kidney, MRP4 is highly expressed in 
prostate where it localizes to the basolateral membrane (Rius et al. 2005). Thrombocytes 
also show high expression of MRP4 (Jedlitschky et al. 2004). It is notable that only 
MDR1, BCRP and MRP4 have significant expression in human brain microvessels that 
are present in the blood brain barrier (Shawahna et al. 2011; Uchida et al. 2011). Relative 
expression levels of MDR1, BCRP and MRP2-4 in kidney, small intestine and liver are 
presented in Table 4. 
Table 4. Relative expression of MDR1, BCRP and MRP2-4 in liver, small intestine and 
kidney. Relative expressions are based on protein expression (liver and small intestine) 
or mRNA expression (kidney and MRP4 in small intestine). In addition, expressions in 
selected other tissues is presented. 1Wang et al. 2015, 2Ohtsuki et al. 2012, 3Drozdzik et 
al. 2014 4Hilgendorf et al. 2007, 5Shawahna et al. 2011, 6Uchida et al. 2011, 7Sugawara 
et al. 1998, 8Maliepaard et al. 2001, 9Kool et al. 1997, 10König et al. 1999a, 11Scheffer et 
al. 2002, 12Lee et al. 1998, 13Rius et al. 2005, 14Jedlitschky et al. 2004 
 
2.2.3 In vitro substrate specificity of multidrug resistance protein 1, breast cancer 
resistance protein and multidrug resistance proteins 2-4 
 
MDR1, BCRP and MRP2-4 show quite distinctive substrate specificities even sometimes 
overlapping. MDR1 is mainly involved in transport of lipophilic drug molecules that 
Transporter 
Relative expression 
Other tissues 
Liver 
Small 
Intestine 
Kidney 
MDR1 141, 2 23 High4 
Human brain microvessels5,6, 
colon3, adrenal gland7, 
placenta7 
BCRP 41, 2 13 Low4 
 
Human brain microvessels 5,6, 
colon3,8, placenta8 
MRP2 221, 2 33 High4 
 
Colon3 
 
MRP3 111, 2 23 Low4 
Colon3,9,10,11, pancreas10,11 
adrenal gland10,11 
MRP4 12 Low3, 4 High4 
 
Human brain microvessels 5,6 
Colon3, prostate12,13 
thrombocytes14  
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contain a cationic charge or no charge (Oude Elferink et al. 1995; Seelig 1998; Ambudkar 
et al. 1999; Stouch and Gudmundsson 2002; Ambudkar et al. 2003; Fromm 2004; 
Hoffmann and Kroemer 2004). However, there are some reports that MDR1 might 
transport also anionic drugs including olmesartan and fexofenadine and glucuronide 
conjugates of estradiol and telmisartan (Huang et al. 1998; Cvetkovic et al. 1999; Yamada 
et al. 2007; Ishiguro et al. 2008). MRP2-4 were reported to be mainly transporters of 
anionic drugs, and especially anionic drug conjugates such as glucuronides, sulfates and 
glutathiones (König et al. 1999b; Zamek-Gliszczynski 2006a; Borst et al. 2007; van der 
Schoor et al. 2015). On the other hand, substrate specificity of BCRP seems to be mixed 
between substrate specificity of MRPs and MDR1 (Ni et al. 2010; Szafraniec et al. 2014; 
Mao and Unadkat 2015). BCRP has an overlapping substrate specificity with MDR1 by 
transporting neutral, cationic, lipophilic and aromatic rings containing drug molecules. In 
addition, BCRP is able to transport anionic molecules and even sulfate and glucuronide 
conjugates (Zamek-Gliszczynski 2006a; van de Wetering et al. 2009a; Han et al. 2010; 
Mao and Unadkat 2015). Actually, BCRP prefers sulfate conjugates over glucuronide 
conjugates and it is recognized as a transporter of sulfate conjugates (Suzuki et al. 2003; 
Mizuno et al. 2007; Mao and Unadkat 2015; Mutsaers et al. 2015). Because BCRP, and 
especially MDR1, are not mainly considered as transporters for glucuronide conjugates, 
they are no further discussed here. 
 
2.2.4 Considerations in substrate specificity determination for multidrug resistance 
proteins in vitro 
 
In vitro assays for the identification of substrates for efflux transporters could be classified 
in direct and indirect assays. Direct assays use inside-out oriented membrane vesicles 
prepared from cell lines and tissues overexpressing a transporter of interest (Glavinas et 
al. 2008; Brouwer et al. 2013). In addition, cell lines overexpressing a transporter of 
interest could be used for direct transport assays, if the permeability of a compound is 
high enough (Brouwer et al. 2013). On the other hand, determination of cytotoxicity 
produces indirect evidence of substrates for transporters (Xia et al. 2007). For cytotoxicity 
determinations, a compound is incubated in transporter-transfected and non-transfected 
cell lines and cytotoxicity is compared between these two cell lines. In addition, indirect 
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measurement of transport are also inhibition studies in which a compound is tested to 
modulate transport of a probe substrate by the transporter of interest in inside-out oriented 
membrane vesicles or in cell lines (Brouwer et al. 2013). 
Different assay techniques could yield discrepancies in characterization of the substrate 
specificity of the transporter. For example, cytotoxicity assays do not reveal which 
transporter causes the resistance, because cell lines could overexpress multiple different 
transporters (Kool et al. 1997). In addition, if transport of a radiolabeled compound is 
studied in a cell line overexpressing a single transporter and only total radioactivity is 
measured, it is impossible to draw conclusions if the compound or its metabolites are 
actually transported. Most of the pioneer work in the area of MRPs was done by utilizing 
cytotoxicity assays or using radiolabeled compounds in whole cell based assays without 
proper analytical tools. Especially, most of the neutral lipophilic cancer agents considered 
as substrates for MRPs were investigated in these assays. For example, MRP1 was shown 
to cause resistance against doxorubicin and vincristine, but vesicle transport assays with 
the same compounds did not show active transport by MRP1 (Grant 1994; Jedlitschky et 
al. 1996; Loe et al. 1996). Interestingly, Priebe and coworkers (1998) found that 
glutathione conjugates of doxorubicin and daunorubicin inhibiting transport of 
leukotriene C4 by MRP1, which might indicate that they are the actual substrates, but not 
the parent compounds. In addition, glutathione itself was also identified as a substrate for 
MRP2 but not for MRP3 in whole cell based assays (Kool et al. 1999; Paulusma et al. 
1999; Evers et al. 2000; Wortelboer et al. 2003). However, this could not be shown in 
vesicle studies (Paulusma et al. 1999). 
In addition, it is shown that cell lines used for overexpression of efflux transporters (e.g. 
HeLa, MDCK, LLC-PK1, CHO-K1, COS-7) have also capability for the metabolic 
reactions (Hao et al. 1994; Evers et al. 1998; Ryu et al. 2000; Ji et al. 2002; Ng et al. 2003; 
Imai et al. 2003; Wortelboer et al. 2003; Zamek-Gliszczynski et al. 2006b; Lo et al. 2007). 
These reactions include sulfation, glucuronidation and glutathione transferase activity. 
Because all above disruptive factors, only inside-out oriented membrane vesicle assays 
or cell line assays with modern analytical techniques such as liquid chromatography 
should be considered as the gold standard for in vitro transporter substrate specificity 
determination. 
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2.2.5 Substrates of multidrug resistance proteins 2-3 
 
Table 5 presents substrates and their kinetic constants, if available, for MRP2 and MRP3 
based on literature review. Substrates are further classified in glutathione conjugates, 
glucuronide conjugates, sulfate conjugates, and sulfite or phosphonate or carboxyl 
containing substrates and neutral compounds. Substrate specificity of MRP2 and MRP3 
is quite highly overlapping. In addition, glucuronide conjugates and carboxylic acid 
containing compounds seem to be the major classes of substrates for both transporters. 
Sulfate, sulfite and phosphonate containing compounds are also anionic and partly 
transporterted by MRP2 and MRP3. On the other hand, neutral molecules are not readily 
transporterted by MRP2 or MRP3. Affinity (Km-value) varies also quite much between 
substrates, being over 10 000 fold different between the highest affinity and the lowest 
affinity compounds. However, if the affinity of the compound for both transporters is 
available, differences between them are not high. Selected examples of structures of 
MRP2 and MRP3 substrates are presented in Figure 3. 
Table 5. Substrates for MRP2 and MRP3 and their Km-values if available. + = is a 
substrate, - = is not a substrate, N.A. = not available. 1Smitherman et al. 2004, 2Wortelboer et al. 
2003, 3Evers et al. 1998, 4Zeng et al. 2000, 5Cui et al. 1999, 6Bakos et al. 2000, 7Paumi et al. 2003, 8Ji et al. 
2002, 9Kamisako et al. 1999, 10Lee et al. 2004, 11Krumpochova et al. 2012, 12van de Wetering et al. 2009b, 
13Gerk et al. 2007, 14Chu et al. 2004, 15Zelcer et al. 2001, 16Hirouchi et al. 2009, 17Chu et al. 2009, 18Zelcer 
et al. 2006, 19Leslie et al. 2001, 20van de Wetering et al. 2007, 21Patel et al. 2013, 22Matsunaga et al. 2014, 
23van de Wetering et al. 2009a, 24Vasilyeva et al. 2015, 25Ishiguro et al. 2008, 26Wittgen et al. 2012, 27Zelcer 
et al. 2003 28Kopplow et al. 2005, 29Han et al. 2010, 30Akita et al. 2002, 31Letschert et al. 2005, 32Oleschuk 
et al. 2003, 33Imaoka et al. 2007, 34Ray et al. 2006, 35Cui et al. 2001, 36Pratt et al. 2006, 37Seelheim et al. 
2013, 38de Waart et al. 2012, 39Ferslew et al. 2014, 40Matsushima et al. 2008, 41Zeng et al. 2001, 42Yamada 
et al. 2007, 43Leier et al. 2000, 44de Waart et al. 2006, 45Evers et al. 2000, 46van Aubel et al. 2005, 47Baltes 
et al. 2007, 48Minematsu et al. 2008, 49Li et al. 2008a, 50Marchetti et al. 2008, 51Huisman et al. 2002, 52Tong 
et al. 2014, 53Yu et al. 2013, 54Takusagawa et al. 2013, 55Chu et al. 2007 
SUBSTRATE 
MRP2 MRP3 
Glutathione conjugates 
Chlorambucil 10 µM1 N.A. 
Curcumin +2 N.A. 
Dinitrophenyl 7 µM3 6 µM4 
Ethacrynic acid +3 N.A. 
Leukotriene C4 1 µM5 5 µM4 
N-ethylmaleimide +6 N.A. 
Prostaglandin J2 N.A. 3 µM7 
4-hydroxynonenal +8 N.A. 
Glucuronide conjugates MRP2 MRP3 
Bilirubin (mono- and bis-
glucuronides) 
1 µM9 +10 
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Enterodiol +11 5 µM12 
Enterolactone +11 2 µM12 
Equol N.A. 6 µM12 
Estradiol (3-glucuronide) 130 µM13 N.A. 
Estradiol (17-glucuronide) 7 µM5 26 µM4 
Ethinylestradiol (3-glucuronide) 25 µM14 9 µM14 
Etoposide N.A. 11 µM15 
E3040 (6-hydroxy-5,7-dimethyl-2-
methylamino-4-(3-
pyridymethyl)benzothiazole) 
+16 +16 
Gaboxadol -17 N.A. 
Gemfibrozil +16 +16 
Genistein N.A. 8 µM12 
Glycitein N.A. 14 µM12 
Hyocholate N.A. 40 nM18 
Hyodeoxycholate N.A. 700 nM18 
(methylnitrosamino)-1-(3-pyridyl)-1-
butanol  
+19 N.A. 
Morphine 50 µM20 +20 
Mycophenolic acid (acyl 
glucuronide) 
-21 N.A. 
Mycophenolic acid (phenol 
glucuronide) 
300 µM22 270 µM22 
Resveratrol 22 µM23 14 µM23 
Secoisolariciresinol  +11 6 µM12 
Sorafenib 24 µM24 190 µM24 
Telmisartan +25 N.A. 
Troglitazone +16 +16 
7-hydroxycoumarin -26 190 µM26 
Sulfate conjugates MRP2 MRP3 
Dehydroepiandrosterone -27 46 µM10 
Estrone (3-sulfate) +28 N.A. 
Ethinylestradiol (3-sulfate) -29 -29 
Taurolithocholate (3-sulfate) N.A. +30 
Enterodiol-glucuronide 0.75 µM11 N.A. 
Enterolactone-glucuronide 0.6 µM11 N.A. 
Cholecyctokinin octapeptide (CCK-
8) 
8 µM31 N.A. 
Sulfite containing compounds MRP2 MRP3 
Taurocholate -13 +32 
Tauroursodeoxycholate +13 N.A. 
Phosphonate containing 
compounds 
MRP2 MRP3 
Adefovir  -33 N.A. 
Cidofovir -33 N.A. 
Tenofovir -34 N.A. 
Carboxyl containing 
compounds 
MRP2 MRP3 
Bromosulfophthalein 12 µM35 N.A. 
Carboxydichlorofluorescein 20 µM36 11 µM37 
Cefadroxil +38 2.5 mM38 
Enalaprilat N.A. -39 
Fexofenadine +40 N.A. 
Folic acid N.A. 2 mM41 
Glycocholate N.A. 250 µM4 
Leucovorin N.A. 1.7 mM41 
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Methotrexate 3 mM6 620 µM41 
Mycophenolic acid -21 N.A. 
Olmesartan 15 µM42 N.A. 
Para-aminohippurate 900 µM43 N.A. 
Prostaglandin E2 +44 -44 
Sulfinpyrazone (acidic carbon) +45 N.A. 
Uric acid -46 N.A. 
Valproic acid -47 N.A. 
Zonampanel -48 N.A. 
Neutral compounds MRP2 MRP3 
Belotecan +49 N.A. 
Enalapril N.A. -38 
Erlotinib -50 N.A. 
Gaboxadol -16 N.A. 
Indinavir +51 -51 
Lenalidomide -52 -52 
Liensinine -53 N.A. 
Mirabegron -54 N.A. 
Ritonavir +51 -51 
Saquinavir +51 -51 
Sitagpliptin -55 N.A. 
Topotecan +49 N.A. 
 
 
Leukotriene C4 
 
 
 
Estradiol-17-glucuronide 
 
Carboxydichlorofluorescein 
 
 
Resveratrol-glucuronide 
 
Figure 3. Selected examples of structures of substrates for MRP2 and MRP3. 
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2.3 Integrating glucuronidation and drug efflux tranporters 
 
Drug molecules that undergo extensive metabolism have good permeability and passive 
diffusion plays a key role in the permeation of these compounds into cells (Wu and Benet 
2005; Benet et al. 2011). Substrates for UGTs are generally lipophilic and thus have 
sufficient properties for good cell membrane permeability (Lin and Wong 2002; Smith et 
al. 2003; Rowland et al. 2013). On the other hand, conjugation of drug molecules with 
glucuronic acid leads generally to more hydrophilic compounds that are any more able to 
cross cell membranes by passive diffusion (Jeong et al. 2005; Zamek-Gliszczynski et al. 
2006a; Smith and Dalvie 2012; Shi and Li 2014).  
Glucuronidation takes place in the main drug metabolizing tissues including intestine, 
liver and kidney (Jeong et al. 2005; Rowland et al. 2013; Di 2014). During absorption of 
orally administered drug, it could go through first pass biotransformation in intestine and 
liver (Caldwell et al. 1995). Subsequent distribution phase will expose drug molecules 
for biotransformation in all three main tissues that metabolize drugs, namely in liver, 
intestine and kidney.  
Because glucuronides, and other conjugates, are hydrophilic and could not cross cell 
membrane by passive diffusion, they are actively transported out of cells by efflux 
transporters (Jeong et al. 2005; Zamek-Gliszczynski et al. 2006a; Smith and Dalvie 2012; 
Shi and Li 2014). As is presented in section 2.2.5, glucuronides are good substrates for 
MRP2 and MRP3. Conjugation and subsequent excretion of glucuronides from tissues 
are together regarded as interplay of conjugation and efflux transport (Shi and Li 2014).  
Generally, disposition of lipophilic drugs is dependent on metabolism and especially 
conjugation because they have high reabsorption from renal tubule, bile ducts and 
intestine and thus could not be easily eliminated from the body directly (Fagerholm 2007; 
Fagerholm 2008, Varma et al. 2009 and Varma et al. 2012). On the other hand, 
glucuronidation and subsequent efflux transport mediate excretion of drugs from human 
body via bile to feces or via blood circulation to urine (Jeong et al. 2005).  However, 
questions remain to answer in this interplay (Jeong et al. 2005; Shi and Li 2014; Zamek-
Gliszczynski et al. 2014): 
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1. When will a glucuronide conjugate of a drug eliminated via urine or feces? 
2. Is efflux transport the limiting step of elimination of glucuronide conjugates and 
could it affect bioavailability or toxicity of drugs, or cause drug-drug interactions? 
 
2.3.1 Disposition of glucuronides 
 
MRP2 is highly expressed in liver and small intestine, and to lesser extent in kidney (see 
section 2.2.2). It excretes glucuronides to bile and subsequently to intestinal lumen. In 
intestine, it transports glucuronides into intestinal lumen. In addition, it contributes to the 
excretion of locally formed glucuronides and to vectorial transport and subsequent active 
secretion of glucuronides in kidney. MRP4 has tissue specific localization; it is localized 
in apical membrane of kidney contrary to liver where it is localized in basolateral 
membrane (see section 2.2.2). In addition, it has an expression equal or even higher than 
MRP2 in kidney (Nishimura and Naito 2005; Hilgendorf et al. 2007). Therefore, it 
contributes, as MRP2, to active secretion and vectorial transport of glucuronides in 
kidney.  
Excretion of glucuronides via bile could lead to enterohepatic circulation, which will lead 
to prolonged residence time of drug molecule in the human body (Gregus and Klaassen 
1987; Fagerholm 2008). Enterohepatic circulation means deconjugation of glucuronides, 
excreted to intestine via bile, by intestinal β-glucuronidases and subsequent reabsorption 
of the parent drug molecule. MRP2 might be solely responsible for the biliary excretion 
of glucuronides even BCRP and MDR1 have comparable expression levels and 
localization in liver (see seaction 2.2.2). Beside liver, MRP2 might affect local 
enteroenteric circulation in intestine (Jeong et al. 2004). This means that glucuronides 
formed in intestine are excreted to intestinal lumen, deconjugated and subsequently 
reabsorbed (Wakabayashi et al. 1994; Jeong et al. 2005; Xia et al. 2012; Zhang et al. 
2013).  
MRP3 is localized in basolateral membranes of liver, intestine and kidney. In addition, 
MRP4 is localized in basolateral membrane of liver and probably in basolateral 
membrane of human intestine (see section 2.2.2). However, expression of MRP4 in 
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normal liver is much lower than the expression of MRP3 or MRP2 (Ohtsuki et al. 2012). 
In addition, in small intestine MRP4 is expressed less than MRP3, which is expressed at 
similar level to MRP2 (Hilgendorf et al. 2007). Based on expression levels, it is unknown 
if MRP4 contributes to the transport of glucuronides in liver and/or intestine. On the other 
hand, MRP3 has a high expression level in these tissues and contributes to the efflux of 
glucuronides. However, MRP3 has low expression in kidney and its contribution to 
reabsorption and excretion of glucuronides to blood circulation in kidney is unknown. 
Processes of interplay between glucuronidation and efflux transporters in liver and small 
intestine are summarized in Figure 4.  
 
 
 
 
 
 
Figure 4. Scheme of interplay between glucuronidation and efflux transport in small 
intestine and liver. D = drug and D-G = glucuronide conjugate of drug. 
 
2.3.2 Studying of the interplay between glucuronidation and efflux transport 
 
Lack of specific MRP2-4 inhibitors and difficult bile sampling from humans causes 
difficulties in studies of the interplay between glucuronidation and efflux transport in vivo 
in humans (Gregus and Klaassen 1987; Ghibellini et al. 2006; Brouwer et al. 2013; 
Hillgren et al. 2013). Samples of feces and urine are available for biotransformation 
studies in man, but feces samples represent unabsorbed and unconjugated drug or 
metabolites but not actual metabolites excreted via bile and/or enterocytes. In addition, 
tissue sampling (e.g. kidney and liver) in humans is not routinely possible. Because of 
these limitations, in vivo animal studies and especially several different transporter-
knockout mice models are widely used for studying the interplay between 
glucuronidation and efflux transport in vivo (Xia et al. 2007; Zamek-Gliszczynski et al. 
2013; Zamek-Gliszczynski et al. 2014). 
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There are also several cell lines that express transporters of human origin and thus allow 
studying of efflux and uptake in same cell-based system in in vitro (Xia et al. 2007; 
Brouwer et al. 2013). However, there are only few cell lines reported that co-overexpress 
both metabolizing enzymes and efflux transporters (Fahrmayr et al. 2012; Kwatra et al. 
2012; Neve et al. 2013 Quan et al. 2015). In addition, intestinal and hepatic cell lines 
(such as Caco-2 and hepatocytes) express several metabolizing enzymes, uptake and 
efflux transporters and thus cannot be used for detailed studies, because there are no 
specific inhibitors of transporters or metabolizing enzymes (Xia et al. 2007; Brouwer et 
al. 2013; Hillgren et al. 2013).  
Several rat strains lack functional Mrp2 and thus they could be used as models to study 
the in vivo significance of the transporter (Oude Elferink et al. 1995). These rat strains 
are GY/TR- and Eisai hyperbilirubinemic mutant rats (EHBR). In vivo studies with these 
rat strains have proved the most important in vivo function of Mrp2; biliary excretion of 
conjugated bilirubin, which is almost absent in these strains and leads to highly elevated 
plasma levels of bilirubin glucuronides. However, later more defined animal models have 
become available, namely knockout mice (Xia et al. 2007). The advantage of these 
models is that they are well defined by silencing specifically a gene and allow combining 
different knockout strains. Knockout mice of Mrp2-4 are available including different 
combined strains such as Mrp2-/-/Mrp3-/- and Mrp3-/-/Mrp4-/- (Leggas et al. 2004; Belinsky 
et al. 2005; Chu et al. 2006; van de Wetering et al. 2007). 
Because of species differences, the animal models might not be fully representative for 
the human situation. Two main reasons contribute to discrepancies: differences in 
substrate specificity of transporters and differences in protein expression of transporters 
between species. There are comparative in vitro studies between human and animal 
transporters such as MRP2 and Mrp2 (Ishizuka et al. 1999; Akita et al. 2002; Li et al. 
2008b; Yasunaga et al. 2008; Herédi-Szabó 2009). However, these studies suggest that 
there are no substantially differences in substrate specificities of the same transporters 
between species. On the other hand, protein amounts of transporters in different species 
seem to explain more of variability between species (Ninomiya et al. 2005; Li et al. 2009). 
For example, Mrp2 is highly expressed in livers of rats and mice but less in humans, dogs 
and monkeys (Ninomiya et al. 2005; Kamiie et al. 2008; Li et al. 2009; Wang et al. 2015). 
On the other hand, Mrp3 was hardly detectable in livers of rats, but was expressed quite 
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comparable to human MRP3 in livers of monkey and dogs (Wang et al. 2015). However, 
Mrp3 is highly expressed in mice (Kamiie et al. 2008). In addition to transporters, it is 
important to know that there are interspecies differences in drug metabolizing enzymes 
such as UGTs (Komura and Iwaki 2011). 
There are also reports that dog and rats have lower molecular weight threshold for anionic 
compounds that are excreted to bile compared to humans (Yang et al. 2009; Yang et al. 
2010). This cut-off value was 400 Da for dogs and rats and 475 Da for humans. Therefore, 
prediction of biliary excretion of drugs in humans based on animal studies is not 
straightforward and does not give reliable results (Mahmood 2005; Ghibellini et al. 2006; 
Fagerholm 2008). Nevertheless, knockout animal studies represent good models for 
mechanistic understanding of interplay between glucuronidation and efflux transporters 
even if translating their data to human is challenging (Zamek-Gliszczynski et al. 2013). 
For this purpose, some examples are presented in the next sections. 
 
2.3.3 In vivo contribution of multidrug resistance protein 2-4 to disposition of 
glucuronides in liver 
 
Paracetamol is extensively conjugated with glucuronic acid and subsequently excreted 
via urine in human and mouse (Zamek-Gliszczynski et al. 2006c; McGill and Jaeschke 
2013). Knockout of Mrp2 in mice led to no changes of biliary clearance of paracetamol 
glucuronide (Zamek-Gliszczynski et al. 2006c). Interestingly, basolateral clearance of 
paracetamol glucuronide was three times higher in Mrp2-/- mice. On the other hand, it is 
known that protein levels of basolateral efflux transporters Mrp4 and Mrp3 are elevated 
in Mrp2-/--mice seven and one and half times, respectively (Chu et al. 2006; Nezasa et al. 
2006). This might affect the interpretation of the results, when Mrp2 is absent. However, 
knockout of Mrp3 in mice led to a substantial change of the basolateral excretion and 
intracellular concentration of paracetamol glucuronide (Manautou et al. 2005). 20 times 
more of paracetamol glucuronide accumulated in livers of Mrp3-/- mice compared to 
control mice. At the same time, plasma excretion of paracetamol glucuronide was 
decreased 10 times and cumulative biliary excretion increased 10 times. Zamek-
Gliszczynski and coworkers (2006c) also found that Mrp3-/- mice accumulated six times 
  26  
 
   
more paracetamol glucuronide in liver and had 25 times lower basolateral clearance of it 
compared to control mice. In addition, biliary clearance was not changed but cumulative 
excretion of paracetamol glucuronide in bile was 10 times higher. Mrp4-/- mice was also 
used in the same study, but pharmacokinetics of paracetamol glucuronide stayed similar 
compared to wild type mice. 
Morphine is rapidly metabolized to two glucuronides (M3G and M6G) in humans 
(Hoskin and Hansk 1990). On the other hand, mice are able only to form M3G (Zelcer et 
al. 2005). Mrp3-/- mice had almost abolished urinary excretion of M3G and very low 
plasma concentrations of it compared to wild type mice. In addition, hepatic 
concentrations of M3G were over five times higher and biliary excretion was the main 
route of M3G compared to wild type mice. In summary, knockout of Mrp3 changed the 
predominant excretory route from urine to bile and subsequently to feces compared to 
wild type mice and this was caused mainly by impaired basolateral excretion of morphine-
glucuronide from liver. van de Wetering and coworkers (2007) further characterized 
pharmacokinetics of M3G in Mrp2-/- and Mrp2-/-/Mrp3-/- double knockout mice and found 
that both mouse strains lacked almost fully biliary excretion of M3G, which was around 
30 % in Mrp3-/- and wild type mice. In addition, Mrp2-/- mice had higher plasma 
concentrations of M3G compared to wild type mice. Mrp3-/-/Mrp4-/- mice was also 
compared to Mrp3-/- mice, but there was no difference in plasma concentration of M3G 
between these two strains indicating that Mrp4 does not play role in basolateral efflux of 
morphine glucuronide.  
Etoposide is partly metabolized via glucuronidation in human (D'Incaici et al. 1986). 
Mrp2-/- mice excrete 20 % of administered etoposide to urine compared to less than 5 % 
excreted by wild type mice (Lagas et al. 2010a). In addition, plasma concentration of 
etoposide glucuronide was two times higher when Mrp2 was absent and the intrahepatic 
concentration was slightly decreased. Interestingly, absence of Mrp3 did not change 
plasma or intrahepatic levels of etoposide glucuronide but Mrp2-/-/Mrp3-/- mice had 
substantially higher intrahepatic concentrations but no change in plasma concentrations 
of etoposide glucuronide. Based on these results, it seems that in some cases Mrp2 and 
Mrp3 could compensate each other when one is absent, but when both are absent the 
glucuronide will accumulate inside the tissue where it is formed. In addition, upregulation 
of Mrp3 in Mrp2-/- mice might complicate interpretation of results. 
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Sorafenib is partly metabolized via glucuronidation (Zimmerman et al. 2012). 
Pharmacokinetics of sorafenib-glucuronide was studied in Mrp2-/-, Mrp3-/-, Mrp4-/- and 
Mrp3-/-/Mrp4-/- mice and compared to wild type mice (Vasilyeva et al. 2015). Absence of 
Mrp2 resulted in 350 fold higher plasma levels and three times higher liver concentrations 
of sorafenib-glucuronide compared to wild type mice. However, urinary excretion of 
sorafenib-glucuronide was practically unchanged but biliary excretion decreased 12 fold 
compared to wild type. Interestingly, when Mrp3-/-, Mrp4-/- and Mrp3-/-/Mrp4-/- mice were 
compared to wild type, no differences in liver accumulation or plasma levels of sorafenib-
glucuronide was seen. These results indicate that Mrp2 excretes efficiently sorafenib-
glucuronide to bile and Mrp3-/- and Mrp4-/- can compensate the absence of Mrp2. 
However, when Mrp2 is present, the absence of Mrp3-/- and Mrp4-/- does not affect 
pharmacokinetics of sorafenib-glucuronide, but there has to be other transporter(s) for 
basolateral efflux because knockout of Mrp3 and Mrp4 did not decrease basal levels of 
sorafenib-glucuronide in plasma. 
 
2.3.4 In vivo contribution of multidrug resistance protein 2-4 to disposition of 
glucuronides in small intestine 
 
4-methylumbelliferone (4-MU) is extensively conjugated with glucuronide acid (Nagy et 
al. 2015). Zamek-Gliszczynski and coworkers (2006c) showed that the glucuronide of 4-
MU accumulated three times more in livers of Mrp3-/- mice, but not in livers of   Mrp4-/- 
mice, compared to wild type mice. In addition, basolateral clearance was five times lower 
and biliary clearance two times higher in Mrp3-/- mice compared to wild type mice. When 
4-MU was administered orally to Mrp3-/- and wild type mice, the wild type mice had four 
times lower plasma levels of 4-MU-glucuronide (Hirouchi et al. 2009). Perfused 
segments of small intestine from Mrp3-/- and wild type mice revealed that along the whole 
small intestine, basolateral efflux of 4-MU-glucuronide was 2-4 lower in the absence of 
Mrp3 (Kitamura et al. 2010). However, apical efflux or intracellular concentrations of 4-
MU-glucuronide did not change.  
Resveratrol is highly glucuronidated (Walle et al. 2004). When resveratrol was 
administered orally to Mrp3-/- and wild type mice, the knockout mice had 10 times lower 
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plasma levels of resveratrol glucuronide compared to wild type mice (van de Wetering et 
al. 2009). In addition, urinary excretion of resveratrol glucuronide was markedly reduced 
but accumulation in liver was only minor affected when Mrp3 was absent. The excretion 
pathway of total resveratrol changed from urine to feces in Mrp3-/- mice compared to wild 
type mice.  
Zamek-Gliszczynski and coworkers (2011) studied the effect of Mrp2 knockout in mice 
on plasma concentrations of ethinylestradiol-glucuronide. When ethinylestradiol was 
administered orally, 46 times higher exposure of ethinylestradiol-glucuronide was 
detected in the absence of Mrp2.  
Diclofenac was administered orally to Mrp2-/- and wild type mice and plasma levels of 
diclofenac-glucuronide were measured (Lagas et al. 2010b). In the absence of Mrp2, 
plasma levels of diclofenac-glucuronide were eight times higher compared to wild type 
mice. Biliary excretion was decreased two fold but no change in hepatic concentrations 
was seen. In addition, the effect of single and double knockout mice, Mrp3-/- and Mrp2-/-
/Mrp3-/-, was studied after parenteral administration of diclofenac. Plasma levels of 
diclofenac-glucuronide were only minorly decreased in both strains compared to wild 
type mice, but no change was seen in intrahepatic concentration. However, when 15 times 
higher diclofenac dosage was administered in another study to Mrp3-/- mice, a nine fold 
decrease in diclofenac-glucuronide plasma level was found compared to wild type mice 
(Scialis et al. 2015). However, biliary excretion or intrahepatic concentrations were not 
increased. These results indicate that Mrp2 transports diclofenac-glucuronide to the 
intestinal lumen and into bile. In addition, Mrp3 compensates the absence of Mrp2, when 
a high amount of glucuronide is produced. However, in both studies basal levels of 
basolateral and apical excretion of diclofenac-glucuronide was found, although Mrp3 
or/and Mrp2 were absent. This indicates that there are other transporters capable to 
transport diclofenac-glucuronide. 
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2.3.5 Summary of in vivo animal studies of interplay between glucuronidation and efflux 
transport 
 
Based on in vivo mice studies (2.3.3 and 2.3.4), it is quite clear that Mrp2 and Mrp3 
contribute significantly to apical and basolateral efflux of glucuronides, respectively. 
Together Mrp2 and Mrp3 restrict the accumulation of glucuronides in drug metabolizing 
tissues, namely in liver and intestine. In addition, they can compensate for each other, 
when one is absent or if high intracellular glucuronide levels are present. However, 
contribution of Mrp4 to excretion of glucuronides seems to be currently unclear.  
 
2.4 Background and aims of this study 
 
UGTs and MRPs play key roles in the detoxification and disposition of various 
endogenous and exogenous compounds, and drugs. Because they work together and form 
interplay, it is important to study them in the same system. However, best tools at present 
to study this interplay are only tools to study both individual processes in vitro or have a 
mechanistic understanding of the interplay in vivo. These include in vitro glucuronidation 
and transport assays with human originated material or recombinant material. On the 
other hand, in vivo studies are conducted only in preclinical animals and are mainly 
restricted to transporter knockout models of mice. 
However, there are only few reported in vitro based systems for studying the 
glucuronidation-efflux transport interplay. Quan and coworkers (2015) established 
transfected HeLa-cells with UGT1A1 and studied excretion of chrysin-glucuronide in the 
presence of MRP and BCRP inhibitors or by knocking down BCRP, MRP1, MRP3 or 
MRP4 with short hairpin RNA. However, because there are not specific inhibitors for 
these transporters and knocking down with short hairpin RNA does not fully silence 
expression of transporters, this system does not allow for specific determination of 
transporters contributing to glucuronide efflux. HeLa-cells also do not express MRP2 and 
expression levels of other transporters might differ substantially compared to liver or 
intestine tissues. In addition, difference in basolateral and apical efflux is not possible to 
study in this system because HeLa-cells do not form polarized monolayers. 
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Fahrmayr and coworkers (2012) established more advanced systems based on triple-
transfected MDCK-cells expressing OATP1B1, UGT1A1 and MRP2. This cell line was 
used to study vectorial transport of ezetimibe. Interestingly, increased amount of 
ezetimibe-glucuronide was transported to the apical compartment, when MRP2 was 
present in the cell lines compared to control cell line expressing only OATP1B1 and 
UGT1A1. However, these cell models do not allow studying basolateral efflux of 
glucuronides. In addition, these cell lines express uptake-transporter that complicates the 
handling of the cell lines and usually highly metabolized drugs have high passive 
permeability. Actually, in that study the expression of OATP1B1 did not affect the 
accumulation of ezetimibe inside cells. 
Prediction of biotransformation reactions of drugs and subsequent metabolites in humans 
is routinely done in drug development and is based on in vitro assays (Vermeir et al. 2005; 
Ruiz-Garcia et al. 2008; Di 2014). However, understanding of disposition of metabolites 
is still poor and better tools are needed, especially for the prediction and understanding 
of human circulating metabolites (Anderson et al. 2009; Dalvie et al. 2009; Smith and 
Dalvie 2012; Loi et al. 2013). In addition, preclinical animal in vivo models are not 
sufficient to predict human metabolism (Lavé et al. 2009; Pellegatti 2012; Zamek-
Gliszczynski et al. 2013). Futhermore, European Medicines Agency (EMA) and U.S. 
Food and Drug Administration (FDA) demand preclinical toxicological studies for all 
metabolites that are present in humans but not in preclinical animals or human exposure 
of metabolites exceeds significantly animal exposure (FDA 2008; EMA 2009). Because 
of these factors, better tools are needed to understand and predict systemic and tissues 
exposure and excretory routes for drug metabolites. 
The main objective of this study was to establish cell lines expressing human UGT1A1 
or UGT2B7 and both MRP2 and MRP3, because these enzymes and transporters play a 
key role in glucuronidation of drugs and excretion of glucuronides from intestine or liver 
to blood circulation or to bile and intestinal lumen (see sections 2.1-2.3). The MDCK-cell 
line was chosen to express human proteins because this cell line is well established in 
drug metabolism studies and it forms polarized monolayer that allows studying vectorial 
transport of drug molecules (Fahrmayr et al. 2012; Brouwer et al. 2013). Newly 
established cell lines would allow studying glucuronidation of drugs and subsequent 
disposition of glucuronides. In addition, it could allow a better prediction of human 
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metabolism of drugs that are metabolized by UGT1A1 or UGT2B7. These cell lines could 
also be used to identify inhibitors of UGT1A1, UGT2B7, MRP2 and MPR3 and study the 
effect of inhibitors to glucuronidation-efflux transport interplay.  
For this purpose, the following aims were set: 
 Clone the UGT2B7 cDNA, construct a mammalian expression vector of the 
UGT2B7 cDNA and express UGT2B7 in MDCK cells expressing MRP2 or 
MRP3. 
 
 Clone the ABCC3 cDNA encoding MRP3, construct a mammalian expression 
vector of this cDNA and express MRP3 in MDCK cells expressing UGT2B7 or 
UGT1A1 and MRP2. 
 
 Establish MDCK-UGT1A1 and MDCK-UGT1A1-MRP2 cell lines. 
 
 Characterize newly established cell lines regarding the level of mRNA and protein 
expression of UGT1A1, UGT2B7 and MRP3. 
 
 
3.  MATERIALS AND METHODS 
 
All materials and devices used in this study are presented in this section. In addition, all 
methods are described in detail. Solutions and buffers are described in detail in 
Appendices 1 and 2. 
 
3.1 Materials 
 
All commercially acquired reagents and materials used in this study are presented in Table 
6 (Cell culturing) and Table 7 (Molecular biology). All materials used for molecular 
biology applications or cell culturing were used sterile (provided by manufacturer or 
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autoclaved in-house). Water used for all reactions was molecular biology quality (Table 
7). Ion exchanged and 0.2 µm -filtered water was used only for preparation of solutions 
and buffers (see Appendices 1 and 2 for recipes). In addition, certain materials are not 
presented here (for example pipette tips and glass pipettes), but they were from 
commercial origins and were autoclaved in-house before use. 
 
Table 6. Cell culturing materials and reagents. A = Greiner-Bio-One GmbH (Frickenhausen, 
Germany); B = Carl Roth GmbH + Co. KG (Karlsruhe, Germany); C = Sarstedt AG & Co (Nümbrecht, 
Germany); D = Life Technologies GmbH (Darmstadt, Germany); E = Merck KGaA (Darmstadt, Germany); 
F = Becton, Dickinson and Company (NJ, USA); G = QIAGEN GmbH (Hilden, Germany) 
MATERIAL 
CATALOGUE NUMBER 
OF THE SUPPLIER 
SUPPLIER 
Cell culture flask, 25 cm2 83.3910.002 C 
Cell culture flask, 75 cm2 83.3911.002 C 
Cell culture multiwell plate, 24 wells 662160 A 
Cell culture dish, 10 cm  664160 A 
DMSO 4720.2 B 
DPBS 14190-094 D 
FBS 10270-106 D 
G418 sulfate 11811-031 D 
MEM 31095-029 D 
Penicillin (10 000 U/ml) – Streptomycin 
(10 000 µg/ml) solution  
15140-122 D 
Serological pipettes: 2 ml  
                                  5 ml  
                                  10 ml  
                                  25 ml  
                                  50 ml 
86.1252.001  
86.1253.001  
86.1254.001  
86.1685.001  
86.1689.001 
C 
C 
C 
C 
C 
Sodium butyrate 8.17500.0100 E 
Sterile syringe filter, 0.2 µm pore size 83.1826.001 C 
Syringe, 20 ml 300296 F 
Tube, 2 ml,  cryogenic 5000-0020 D 
Tube, 15 ml 62.554.502 C 
Tube, 50 ml 62.547.254 C 
Transfection reagent, Effectene 301425 G 
Trypsin (0.05 %)-EDTA (0.5 mM),  
phenol red solution 
25300-062 D 
Zeocin, 100 mg/ml solution R250-01 D 
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Table 7. Molecular biology materials and reagents. A = Greiner-Bio-One GmbH (Frickenhausen, 
Germany); B = Carl Roth GmbH + Co. KG (Karlsruhe, Germany); C = Sarstedt AG & Co (Nümbrecht, 
Germany); D = Life Technologies GmbH (Darmstadt, Germany); E = Merck KGaA, Darmstadt, Germany; 
F = Becton, Dickinson and Company ( NJ, USA); G = QIAGEN GmbH (Hilden, Germany); H = New 
England Biolabs GmbH (Frankfurt, Germany); I = Agilent Technologies Sales & Services GmbH & Co.KG 
(Waldbronn, Germany); J = Bio-Rad Laboratories GmbH (München, Germany); K = Promega GmbH 
(Mannheim, Germany); L = Roche Diagnostics GmbH (Mannheim, Germany); M = Genaxxon BioScience 
GmbH (Ulm, Germany); N = Sigma-Aldrich Chemie GmbH (Schelldorf, Germany); O  = Abcam plc 
(Cambridge, UK); P = Dianova GmbH (Hamburg, Germany); Q = GE Healthcare Life Sciences 
(Buckinghamshire, UK); R = A. Hartenstein GmbH (Würzburg, Germany); S = Medicell Membranes Ltd 
(London, UK); T = VWR International GmbH (Erlangen, Germany); U = Clontech Laboratories, Inc. (CA, 
USA); V = MACHEREY-NAGEL GmbH & Co. KG, (Düren, Germany); W = AppliChem GmbH 
(Darmstadt, Germany); X = Institute of Experimental and Clinical Pharmacology and Toxicology, 
Friedrich-Alexander-Universität Erlangen-Nürnberg (Erlangen, Germany) 
MATERIAL 
CATALOGUE NUMBER 
OF SUPPLIER 
SUPPLIER 
Acetic Acid 3738.1 B 
Acrylamide/bis-acrylamide solution,  
30 %, 2,7 % cross-linker 
161-0158 J  
Agarose, genetic technology quality 6352.2 B 
Agarose, LE M3044.0500 M 
Ampicillin, sodium salt K029.2 B 
Antibody, Anti-β-actin,  
mouse monoclonal 
A5441 N 
Antibody, Anti-UGT1A1,  
rabbit polyclonal 
Ab62600-100 O 
Antibody, Goat Anti-Mouse IgG  
-Horseradish Peroxidase conjugated, 
polyclonal 
115-035-062 P 
Antibody, Goat Anti-Rabbit IgG  
-Horseradish Peroxidase conjugated 
RPN4301 Q 
Ammonium peroxydisulfate 9178.1 B 
Blotting paper, 0.35 mm thickness GB58 R 
Bromophenol blue B0126 N 
cDNA, liver In-house synthesis X 
cDNA synthesis kit, iScript 170-8891 J  
Cell culture dishes 100x20 mm 664160 A 
Cell scraper 83.1830 C 
Chemiluminescent detection reagent, 
Amersham ECL Western Blotting 
Detection Reagent 
RPN2209 Q 
Competent cells, One Shot TOP10 C404003 D 
Competent cells,  
XL10-Gold ultracompetent 
200315 I  
Competent cells,  
XL1-Blue supercompetent 
200519-4 (mutagenesis kit)/ 
200236 
I  
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Cuvette, semi-micro acrylic 67.740 C 
Dialysis tubing, molecular weight cut off 
12-14 000 Da 
DTV.12000.02.30 S 
Dimethylformamide T921.1 B 
DNA ladder, 1 kb, 0.5 mg/ml 25-2030 T 
DNA ladder, 2-log, 1 mg/ml N3200S H  
DNA ladder, 2-log, tridye, 100 µg/ml N3270S H 
DNA ligase T4, 400 u/µl M0202S H 
DNA ligase T4 reaction buffer, 10X B0202S H  
DNA quick ligase T4, 2 000 u/µl M2200S H  
DNA quick ligase T4 reaction buffer, 2X B2200S H  
DNA polymerase, Advantange cDNA 
polymerase mix 
639105 U 
DNA polymerase, iTaq 170-8870 J  
DPBS, powder 21600-044 D 
DTT 6908.2 B 
EDTA, disodium salt dihydrate 8043.3 B 
Ethanol 9065.4 B 
Ethidium bromide 7870.2 B 
Gel loading dye, Blue, 6X B7021S H  
Gel loading dye, Purple, 6X B7024S H 
Glycerin 3783.1 B 
Glycin 3908.3 B 
Hydrochloric acid, 32 % P074.1 B 
Isopropanol 6752.4 B 
LB-Agar, (Luria/Miller) X969.1 B 
LB-Medium, (Luria/Miller) X968.1 B 
LightCycler Capillaries, 20 µl 04929292001   L 
LightCycler reaction mix 03515885001   L 
Lysozyme, 20 000 u/mg 8259.1 B 
Methanol 8388.6 B 
Milk powder T145.2 B 
Mutagenesis kit,  
QuickChange II site-directed 
200523-5 I 
Mutagenesis kit,  
QuickChange multi-site-directed 
200515-5 I 
N,N,N',N'-Tetramethylethylendiamin A1148.0025 W 
Nucleotides for PCR: 
dATP, dCTP, dGTP, dTTP  
N0440S, N0441S, N0442S, 
N0443S 
H 
Petri dishes 632180 A 
Phosphatase, Antarctic, 5 u/µl M0289S H  
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Phosphatase reaction buffer, 10X B0289S H  
Plasmid Miniprep System, PureYield A1222 K 
Ponceau S 5938.1 B 
Protease inhibitor cocktail tablets, 
Complete Mini 
04693124001 L 
Protein Assay Kit, BCA Pierce 23225 D 
Protein ladder, 10 to 250 kDa PageRuler 
Plus Prestained 
26619 D 
Restriction enzyme, ApaI, 50 u/µl R0114S H 
Restriction enzyme, BamHI-HF, 
20 U/µl 
R3136S H  
Restriction enzyme, BstXI, 10 u/µl R0113S H  
Restriction enzyme, EcoRI-HF RE-Mix, 
10X 
R5101S H  
Restriction enzyme, KpnI, 10 u/µl R0142S H 
Restriction enzyme, NotI-HF, 20 u/µl R3189S H  
Restriction enzyme, PstI, 20 u/µl R0140S H  
Restriction enzyme reaction buffer, 
CutSmart Buffer, 10X 
B7204S H  
Restriction enzyme reaction buffer, 
NEBuffer 1, 10X 
B7001S H  
Restriction enzyme reaction buffer, 
NEBuffer 2, 10X 
B7002S H  
Restriction enzyme reaction buffer, 
NEBuffer 3, 10X 
B7003S H 
Restriction enzyme reaction buffer, 
NEBuffer 4, 10X 
B7004S H 
Restriction enzyme reaction BSA, 10 
mg/ml, 100X 
B9001S H 
Reverse transcriptase, M-MLV, RNase 
H Minus + 5x reaction buffer 
M368B K  
Ribonuclease A, 90 u/mg 7156.1 B 
RNA, liver and kidney, Human Total 
RNA Master Panel II 
636643 U 
RNase inhibitor, 40 u/µl N251B H 
RNA isolation kit, NucleoSpin RNA 
Plus 
740984.50 V 
Saccharose 1.07653.1000 E 
SDS  2326.2  B 
S.O.C. Medium 15544-034 D 
Sodium Acetate trihydrate 6779.2 B 
Stripping reagent for western blot 21059 D 
Topo TA Cloning Kit 450641 D 
Transfer membrane NC02 R 
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TRIS-Base 4855.3 B 
TRIS-HCl 9090.2 B 
Triton X 100 3051.2 B 
Tube, 13 ml 62.515.006 C 
Tube, PCR, 0.2 ml 82-0620-A T 
Tube, micro, 1.5 ml 72.690.001 C 
Tube, micro, 1.5 ml with assembled cap 72.692.005 C 
Tube, micro, 2 ml 72.695.500 C 
Trichloroacetic acid 8789.1 B 
Tween 20 9127.1 B 
Water, for molecular biology T143.3 B 
X-β-Gal 2315.2 B 
 
3.1.1 Devices 
 
Devices used in this study for cell culturing work or molecular biology work are presented 
in Table 8 and Table 9, respectively. 
Table 8. Devices used in cell culturing work. 
DEVICE MODEL MANUFACTURER 
Biosafety cabinet, class II Biowizard KR-130 Kojair Tech Oy (Vilppula, 
Finland) 
Cell counting chamber, 
0.100 mm depth, 0.0025 
mm2 
Neubauer Paul Marienfeld GmbH & 
Co. KG (Lauda-
Königshofen, Germany) 
Centrifuge Z400 HERMLE Labortechnik 
GmbH (Wehingen, 
Germany) 
Freezing container 5100-0001 Thermo Fisher Scientific 
Inc. (MA, USA) 
Incubator Heracell 150 Thermo Fisher Scientific 
Inc. (MA, USA) 
Microscope CKX41 Olympus Co. (Tokyo, Japan) 
Water bath 1004 GFL - Gesellschaft für 
Labortechnik GmbH 
(Burgwedel, Germany) 
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Table 9. Devices used in molecular biology work. 
DEVICE MODEL MANUFACTURER 
Autoclave 2540 EL Systec GmbH (Linden, 
Germany) 
Centrifuge, microtube 5424 Eppendorf AG (Hamburg, 
Germany) 
Centrifuge, cooling  5810R with rotor F45-30-
11 (microtubes) or with 
rotor A-4-62 (15 ml 
tubes) 
Eppendorf AG (Hamburg, 
Germany) 
Electrophoresis system 
with 1 mm glass and 10 
well comb 
Mini-PROTEAN 3 Cell Bio-Rad Laboratories (CA, 
USA) 
Electrophoresis power 
supply 
PowerPac 1000 Bio-Rad Laboratories (CA, 
USA) 
Gel electrophoresis cell, 
large 
Sub-Cell GT Bio-Rad Laboratories (CA, 
USA) 
Gel electrophoresis cell, 
small 
Mini-Sub Cell GT Bio-Rad Laboratories (CA, 
USA) 
Gel electrophoresis power 
supply 
PowerPac Basic Bio-Rad Laboratories (CA, 
USA) 
Heating block MC-01N UniEquip Laborgerätebau- 
und Vertriebs GmbH, 
(Planegg, Germany) 
Incubator IH50 Incutec GmbH (Mössingen, 
Germany)  
Lightcycler 2.0 Roche Diagnostics GmbH, 
(Mannheim, Germany) 
Lightcycler centrifuge 
adapters 
1909312 Roche Diagnostics GmbH, 
(Mannheim, Germany) 
Microcentrifuge 1Rotilabo Carl Roth GmbH + Co. KG 
(Karlsruhe, Germany) 
Mixer, rotating  RM 5-40 Ingenieurbüro CAT M. 
Zipperer GmbH (Staufen, 
Germany) 
Molecular Imager ChemiDoc XRS System Bio-Rad Laboratories (CA, 
USA) 
pH-meter CyberScan pH310 Thermo Fisher Scientific 
Inc. (MA, USA) 
Protein blotting system Mini Trans-Blot Cell Bio-Rad Laboratories (CA, 
USA) 
Scale, 0.01-120 g TB-124A Sartorius Corporation (NY, 
USA 
Scale, 0.5-2200 g TB-2202A Sartorius Corporation, NY, 
USA) 
Shaker K15-500 Incutec GmbH (Mössingen, 
Germany)  
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Spectrophotometer Genesys 10S UV-Vis Thermo Fisher Scientific 
Inc. (MA, USA) 
Spectrophotometer cell, 
quartz, 10 mm path 
- Bio-Rad Laboratories (CA, 
USA) 
Thermocycler Labcycler 48 Sensoquest GmbH 
(Göttingen, Germany) 
UV imaginer Intas UV systeme INTAS Science Imaging 
Instruments GmbH 
(Göttingen, German)y 
Vacuum manifold Vac-Man Laboratory 
Vacuum Manifold, 20 
sample capacity 
Promega Corporation (WI, 
USA) 
Vacuum pump for 
manifold 
2522C-02 Welch (IL, USA) 
Vortex mixer ZX3 VELP Scientifica (Usmate, 
Italy) 
Water bath 1004 GFL - Gesellschaft für 
Labortechnik GmbH 
(Burgwedel, Germany) 
Water purification with 0.2 
µm filter  
TKA GenPure UF/UV,           
08.2204 
Thermo Fisher Scientific 
Inc. (MA, USA) 
 
3.1.2 Primers 
 
All primers used in this study and their applications are presented in Table 10. 
Oligo(dT)18, oMRP3-RT-F, oMRP3-RT-R, oUGT2B7-seq1, oUGT2B7-seq2, 
oUGT2B7-R, oUGT1A1-seq1, oUGT1A1-RT-F and oUGT1A1-RT-R primers were 
ordered from Sigma-Aldrich Chemie GmbH (Schnelldorf, Germany). All the other 
primers were from biomers.net GmbH (Ulm, Germany). Primers used for mutagenesis 
reactions were acquired as high-pressure liquid chromatography (HPLC) purified from 
the manufacturer. Other primers were standard quality provided by manufacturer without 
additional purifications. 
Table 10. Primers used in this study and their DNA sequence. Added restriction site is 
indicated by bold letters. 
NAME OF THE 
PRIMER 
USED FOR DNA SEQUENCE 
T7-promoter Sequencing 5’-taatacgactcactataggg-3’ 
BGH-reverse Sequencing 5’-tagaaggcacagtcgagg-3’ 
M13-reverse Sequencing 5’-caggaaacagctatgac-3’ 
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Oligo(dT)18 cDNA synthesis 5’-tttttttttttttttttt-3’ 
oβ-actin-F qPCR, PCR 5’-tgacggggtcacccacactgtgcccatcta-3’ 
oβ-actin-R qPCR, PCR 5’-ctagaagcatttgcggtggacgatggaggg-3’ 
oMRP3-F Cloning PCR 5’-gcctcggccccatggacg-3’ 
oMRP3-R Cloning PCR 5’-ggccaggaggaaatctcagg-3’ 
oMRP3-XbaI-F Cloning PCR 5’-tctagacgcgcctcggccc-3’ 
oMRP3-Clone-R Cloning PCR 5’-ggccccgatgacgtggtcaaa-3’ 
oMRP3-Clone-F Cloning PCR 5’-ccaagcgctaccagcagact-3’ 
oMRP3-Clone-R2 Cloning PCR 5’-ccaggaaaggccaggaggaaatctc-3’ 
oMRP3-Clone-F2 Cloning PCR 5’-gctagctgacctggagatgctgcctg-3’ 
oMRP3-RT-F qPCR, PCR 5’-ggaccctgcgcatgaacctg-3’ 
oMRP3-RT-R Cloning PCR, 
qPCR, PCR 
5’-aggcaagtccagcatctctgg-3’ 
oMRP3-seq1 Sequencing 5’-ccacagctgctcagcatcct-3’ 
oMRP3-seq2 Sequencing 5’-ggtgagctccagctgctgc-3’ 
oMRP3-seq3 Sequencing 5’-cgctcgccacagtccttctt-3’ 
oMRP2-RT-F qPCR 5’-cttcggaaatccaagatcctgg-3’ 
oMRP2-RT-R qPCR 5’-tagaattttgtgctgttcacattct-3’ 
oUGT2B7-F Cloning PCR 5’-caccaggatgtctgtgaaatgg-3’ 
oUGT2B7-R Cloning PCR 5’-actgaatgagtctcacctatcag-3’ 
oUGT2B7-Clone-R Cloning PCR 5’-ccagcttcaaatctcagatataac-3’ 
oUGT2B7-seq1 Sequencing 5’-tgaagttctaggaagacccact-3’ 
oUGT2B7-seq2 Sequencing 5’-ttcaacacaatgtcgagtacaga-3’ 
oUGT2B7-Mut-F Mutagenesis 5’-
caactgtgatatttatcgtcacaaaatgttgtctgttttgtt 
tctgg-3’ 
oUGT2B7-Mut-R Mutagenesis 5’-ccagaaacaaaacagacaacattttgtgacgat 
aaatatcacagttg-3’ 
oUGT1A1-seq1 Sequencing 5’-gcagcgggtgaagaacatgc-3’ 
oUGT1A1-RT-F qPCR 5’-gttacaaggagaacatcatgcg-3’ 
oUGT1A1-RT-R qPCR 5’-cccacccacttctcaatggg-3’ 
 
3.1.3 Plasmids 
 
Plasmids used in this study were from either commercial origin or in-house established 
(Table 11). In addition, Table 11 presents plasmids generated within this study. Charts of 
the plasmids are presented in Appendix 3. Charts include restrictions sites used in this 
study, primer binding sites and sites of antibiotic resistance genes, the cytomegalovirus 
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promoter and the insert. 
Table 11. Plasmids used in this study and their origin of source and literature reference if 
available. 
NAME OF THE PLASMID 
CATALOGUE NUMBER OF THE 
MANUFACTURER OR THE 
LITERATURE REFERENCE AND 
ORIGIN OF SOURCE  
pcDNA3.1/Hygro(-) V875-20, Life Technologies GmbH (Darmstadt, 
Germany) 
pcDNA3.1/Zeo(-) V86520, Life Technologies GmbH (Darmstadt, 
Germany) 
pCR2.1-TOPO 450641, Life Technologies GmbH (Darmstadt, 
Germany) 
pcDNA3.1/Zeo(-)-UGT1A1 Institute of Experimental and Clinical 
Pharmacology and Toxicology, Friedrich-
Alexander-Universität Erlangen-Nürnberg 
(Erlangen, Germany), (Fahrmayr et al. 2012) 
pcDNA3.1/Zeo(-)-
UGT2B7(1575T) 
Institute of Experimental and Clinical 
Pharmacology and Toxicology, Friedrich-
Alexander-Universität Erlangen-Nürnberg 
(Erlangen, Germany) 
pcDNA3.1/Hygro(-)-MRP3 This study 
pMA-MRP3 Dr. Markus Keiser, University of Greifswald 
(Greifswald, Germany), (Commercially 
produced by Life Technologies GmbH, 
Darmstadt, Germany) 
pGEM-T-UGT2B7(802C) Institute of Experimental and Clinical 
Pharmacology and Toxicology, Friedrich-
Alexander-Universität Erlangen-Nürnberg 
(Erlangen, Germany) 
pCR2.1-TOPO-MRP3-part Institute of Experimental and Clinical 
Pharmacology and Toxicology, Friedrich-
Alexander-Universität Erlangen-Nürnberg 
(Erlangen, Germany) 
pCR2.1-TOPO-MRP3 This study 
pCR2.1-TOPO-MRP3-3‘-part This study 
 
3.1.4 Cell lines 
 
Table 12 describes all cell lines used in this study. MDCK-VC cell line is transfected with 
the empty pcDNA3.1/G418(-)-vector and does not overexpress any protein. This cell line 
was used as control for immunoblot analysis. 
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Table 12. Cell lines used in this study, their origin of source and literature reference if 
available. 
NAME OF THE CELL LINE 
CATALOGUE NUMBER OF THE 
MANUFACTURER OR THE 
LITERATURE REFERENCE AND 
ORIGIN OF SOURCE 
MDCK-II parental cell line  LGC Standards (Teddington, UK), CRL-
2936 
MDCK-MRP2 Institute of Experimental and Clinical 
Pharmacology and Toxicology, Friedrich-
Alexander-Universität Erlangen-Nürnberg 
(Erlangen, Germany), (Cui et al. 1999) 
MDCK-VC G418 (transfected with the 
empty pcDNA3.1/G418) 
Institute of Experimental and Clinical 
Pharmacology and Toxicology, Friedrich-
Alexander-Universität Erlangen-Nürnberg 
(Erlangen, Germany), (Cui et al. 1999) 
MDCK-UGT1A1 This study 
 
3.2 Methods 
 
All methods used in this study are described below. Reagents used in methods are 
presented in Table 6 and Table 7. In addition, description of solutions and buffers are 
presented in Appendices 1 and 2. 
 
3.2.1 Cell culturing 
 
MDCK-cells were cultured in MEM-medium supplemented with 1 % penicillin, 1% 
streptomycin and 10 % heat-inactivated FBS and were incubated under moisture 
atmosphere containing 5 % of CO2. Cells were grown as monolayers in 25 cm
2 cell culture 
flasks containing 8 ml appropriate media. Depending on cell line, the medium was 
supplemented with additional 0.8 mg/ml G418 (MDCK-VC and MDCK-MRP2), 0.5 
mg/ml zeocin (MDCK-UGT1A1) or both 1 mg/ml zeocin and 0.8 mg/ml G418 (MDCK-
UGT1A1-MRP2). Detailed recipes for media are presented in Appendix 1. 
Cells were split and subcultured two times a week. During day 3-4 of post-splitting, cells 
reached confluence in 25 cm2 flasks. Splitting was conducted according to following 
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protocol: Medium was aspirated and cell monolayer was washed with 2 ml DPBS. 
Subsequently, 1.5 ml trypsin-solution was applied to cell monolayer and the flask was 
incubated 15-30 minutes at 37 °C in the cell incubator. After cells were detached from 
the surface, cell suspension was transferred with 5 ml of appropriate media to 15 ml tubes 
and centrifuged for 3 minutes at 500 g. Supernatant was removed and the cell pellet was 
suspended in 5 ml appropriate media and 0.4-0.8 ml of this suspension, corresponding a 
subdilution of 1:13 or 1:6, was subcultured as described above. 
All media, DPBS and trypsin solution applied to cells were warmed to 37 °C before use 
in any cell culture method. 
 
3.2.2 Transfection of MDCK-cells 
 
1x106 parental MDCK or MDCK-MRP2 cells were cultured in 10 cm cell culture dishes 
containing 10 ml of appropriate medium for 24 hours before the stable transfection with 
the vector containing UGT1A1 cDNA (pcDNA3.1/Zeo(-)-UGT1A1). Cells reached 
approximately 40 % confluency before the transfection. Transfection was done according 
to protocol of the manufacturer of the transfection reagent. Briefly, 2 µg of the plasmid 
DNA was mixed with Buffer EC in a total volume of 300 µl. Furthermore, 16 µl of 
Enhancer-solution was added to the mixture and it was vortexed for one second followed 
by incubation for 5 minutes at room temperature. Following incubation, 60 µl of 
Effectene-solution was added to the mixture, vortexed for 15 seconds and further 
incubated 10 minutes at room temperature. Before applying the transfection mixture to 
the cells, medium was aspirated from the cell culturing dish, cells were washed with 5 ml 
DPBS and supplemented with 8 ml of the appropriate medium. After 10 minutes 
incubation of the transfection reagent mixture, it was first mixed with 2 ml of the 
appropriate medium and then transferred to the cells and mixed gently by shaking the 
dish. 
After 24 hours of transfection, the medium was aspirated, cells were washed with 5 ml of 
DPBS and 10 ml fresh pre-warmed medium was added. 48 hours after transfection, 
medium was aspirated, cells were washed with 5 ml DPBS and trypsinized with 1 ml 
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trypsin solution for 20 minutes at 37 ˚C. After the cells were detached, they were 
transferred with 5 ml of appropriate media to 15 ml tubes and centrifuged 3 minutes at 
500 g. The supernatant was aspirated and the pellet was suspended with 10 ml of 
appropriate media containing the selection antibiotic zeocin. This suspension was 
transferred in dilutions of 1:5, 1:10 and 1:20 to cell culture dishes in a total volume of 10 
ml of appropriate media containing 0.5 mg/ml of zeocin to give the first passage of 
MDCK-UGT1A1 or MDCK-UGT1A1-MRP2 cells. 
The media were changed two times a week. Subsequent passages were done according to 
same protocol as above. Instead of dilutions used for the first passage, higher dilutions 
were used for the subsequent passages; 1.25-200 µl of 5 ml cell suspension was 
subcultured. Dilution factors and number of the passages are presented in the Results 
section. In addition, zeocin concentration was changed from 0.5 mg/ml to 1 mg/ml in the 
case of MDCK-UGT1A1-MRP2 cells after the first passage. 
Single colonies were isolated by using blotting paper size of approximately 0.25 cm2. 
First, media were aspirated and cells were washed with 5 ml DBPS. A piece of blotting 
paper was drowned in trypsin solution and subsequently pressed onto a colony and 
transferred into a well of 24 well plate containing 1 ml media. The plate was incubated at 
37 °C in cell incubator and medium was changed two times a week until cells reached 
50-80 % confluency. Finally, cells from one well were transferred to a 25 cm2 cell culture 
flask. For the transfer, medium was aspirated, cells were washed with 1 ml DPBS and 
300 µl trypsin was applied to the cells. Trypsinization was carried out for 30-60 minutes 
in 37 °C incubator, after which the suspension was diluted with 1 ml appropriate medium 
and transferred to 25 cm2 cell culture flask containing 7 ml of the same medium to give 
the first passage for a clone. Cells were cultured 3-11 days and the medium was changed 
two times a week. After cells reached 80-100 % confluency, they were split, as described 
in 3.2.1, and subcultured.  
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3.2.3 Storage cell culture 
 
MKDC-UGT1A1 clones 4 and 7 were grown to 100 % confluence in two 75 cm2 cell 
culture flasks during 4 days after 2:5 subdilution from 25 cm2 cell culture flasks. After 
reaching confluence, cells were washed with 3 ml DPBS, trypsinized with 2 ml trypsin 
solution for 30 minutes, transferred to 15 ml tubes with 5 ml MEM-PS-Zeo-medium and 
centrifuged 3 minutes at 500 g. Supernatants were removed and both pellets were 
suspended and combined in a total volume of 7.2 ml MEM-PS-Zeo medium. This 
suspension was divided into 0.9 ml aliquots in 2 ml cryogenic tubes. Tubes were filled 
with 0.9 ml media containing 20 % DMSO, 40 % FBS and 40 % MEM-PS-Zeo-medium 
to a total volume of 1.8 ml. Tubes were frozen in freezing container at -80 °C for 24 hours, 
after which they were stored in liquid nitrogen. 
 
3.2.4 RNA isolation 
 
MDCK-UGT1A1 and MDCK-UGT1A1-MRP2 cells were cultured in a cell culture dish 
with a dilution of 1:5-3:5 from 25 cm2 flask, in a total volume of 8 ml appropriate medium. 
After culturing for 72 hours, medium was changed to fresh medium containing 10 mM 
sodium butyrate to induce protein expression (Cui et al. 1999). After 24 hours of the 
induction, RNA was isolated by NucleoSpin RNA Plus kit according to the procedure of 
the manufacturer. Briefly, medium was aspirated from the cell culture dish and 350 µl 
lysis buffer was applied, spread over the entire surface and incubated for a couple of 
minutes at room temperature. The cell suspension was harvested with cell scraper, 
homogenized with pipette and centrifuged through the first column of the kit. 100 µl of 
binding solution was added to the filtrate and mixed with a pipette. The entire solution 
was centrifuged through the second column of the kit. This column was further washed 
with 200 µl wash buffer 1 and 600 µl and 250 µl wash buffer 2. RNA was eluted two 
times with 30 µl water provided by the kit. 
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3.2.5 sscDNA synthesis using total RNA of MDCK cells  
 
sscDNA was synthesized using total RNA of MDCK cells using the iScript cDNA 
synthesis kit according to the protocol of the manufacturer. Briefly, the reaction contained 
1 µg of total RNA, 4 µl iScript reaction mix, 1 µl reverse transcriptase and water, provided 
by the kit, added to a total reaction volume of 20 µl. Reaction was prepared in a PCR-
tube and run in the thermocycler according to the parameters in Table 13. 
Table 13. Thermocycler parameters for sscDNA synthesis using total RNA of MDCK-
cells. 
TEMPERATURE TIME 
25 ˚C 5 minutes 
42 ˚C 30 minutes 
85 ˚C 5 minutes 
  4 ˚C Until sample was analyzed 
 
sscDNA synthesis was evaluated by PCR amplification of a 660 base pair fragment of β-
actin using iTaq DNA polymerase according to the protocol provided by the 
manufacturer. Briefly, reaction was prepared in a PCR tube and contained 2 µl 10X PCR 
buffer, 1.5 mM magnesium chloride, 200 µM of each nucleotide (dATP, dCTP, dGTP 
and dTTP), 0.5 U DNA polymerase, 1 µl of cDNA preparation, 0.4 µM oβ-actin-F and 
oβ-actin-R and water added to a final volume of 20 µl. Reaction was run in the 
thermocycler according to the parameters in Table 14. 
Table 14. Thermocycler parameters for amplification of a 660 base pair fragment of β-
actin for analysis of sscDNA synthesis. 
TEMPERATURE TIME  
95 ˚C 3 minutes  
95 ˚C 30 seconds  
40X 62 ˚C 30 seconds 
72 ˚C 1 minute 
72 ˚C 10 minutes  
  4 ˚C Until sample was analyzed  
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3.2.6 Quantitative PCR (Lightcycler) 
 
LightCycler was used for qPCR-analysis of UGT1A1, ABCC2 and β-actin mRNA 
expression. Reactions were prepared in LightCycler 20 µl capillaries on precooled 
LightCycler centrifuge adapters according to the protocol provided by the manufacturer 
with slight modifications. Briefly, reactions were prepared in volumes of 10 µl containing 
1 µM reverse primer, 1 µM forward primer, 1 µl sscDNA template and 2 µl DNA 
polymerase, reaction buffer and fluorescence dye mixture diluted with water to a total 
volume. Capillaries were centrifuged briefly and qPCR was run in LightCycler according 
to the parameters in Table 15. Primers used for specific amplifications of cDNA fragment 
are presented in Table 16. 
Table 15. LightCycler parameters for qPCR amplification of ssCDNA fragments. 
TEMPERATURE TIME  
95 ˚C 10 minutes  
95 ˚C 10 seconds 
45 cycles 64 ˚C 10 seconds 
72 ˚C 30 seconds 
95 ˚C 10 seconds  
60 ˚C 10 seconds 0.1˚C/min 
95 ˚C - 
25 ˚C Until sample was analyzed  
 
Table 16. Primers used for amplification of cDNA fragments in qPCR. 
ANALYZED cDNA FORWARD PRIMER REVERSE PRIMER 
UGT1A1 oUGT1A1-RT-F oUGT1A1-RT-R 
ABCC2 oMRP2-RT-F oMRP2-RT-R 
β-actin oβ-actin-F oβ-actin-R 
 
3.2.7 Protein isolation and determination of protein concentration for immunoblotting 
 
MDCK-UGT1A1 cells were cultured on a cell culture dish by dilution of 2:5 from a 25 
cm2 culture flask in a total volume of 8 ml. Cells were incubated at 37 °C in the cell 
incubator for 24 hours after the medium was changed to medium containing 10 mM 
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sodium butyrate to induce protein expression (Cui et al. 1999). After 24 hours incubation, 
medium was aspirated and cells were washed with 5 ml DPBS. 10 ml DPBS was added 
to the dish and cells were incubated for 5 minutes at 37 °C. After the incubation, cells 
were harvested with a cell scraper, transferred to a 15 ml tube and centrifuged 10 minutes 
at 400 g and 4 °C. The supernatant was removed and the pellet was suspended in 100 µl 
cold 0.2 % SDS solution containing protease inhibitors (one tablet dissolved in 7 ml 0.2 
% SDS). This suspension was stored for 24 hours at             -20 °C. 
Protein concentrations of protein homogenates were measured by commercially available 
BCA Protein Assay Kit according to the protocol of the manufacturer. Briefly, all the 
samples were diluted by a factor of 1:5 with 0.2 % SDS solution to a total volume of 25 
µl in 1.5 ml micro tubes. 500 µl mixture containing 49 parts of solution A and 1 part of 
solution B, was mixed with the samples. In addition, standards were prepared by the same 
procedure using 0.2 % SDS stock solutions of standards containing 0, 100, 250, 500 and 
1000 µg/ml BSA (diluted from BSA provided by the kit). Samples were incubated 30 
minutes at 37 °C in water bath and subsequently the absorbance was measured at 560 nm 
wavelength in the spectrophotometer. The protein concentration of samples were 
calculated based on absorbance of the standard samples. 
 
3.2.8 Protein electrophoresis, blotting and immunostaining 
 
A two segment gel was used for protein electrophoresis. This gel was casted in two 
phases: Firstly, a 10 % running gel was casted between isopropanol rinsed glass plates 
and covered finally by isopropanol after the casting. Secondly, after 45 minutes 
incubation of the running gel at room temperature, 1 cm of 4 % stacking gel was casted 
and a 10 well comb was installed at the head of the glass plate. The gel was stored over 
night between wet paper towels and packed inside aluminium folio.  
For the protein electrophoresis, 15 µg of total protein of every sample was diluted with 5 
µl of 4X loading buffer and water to a total volume of 20 µl. Samples were incubated 5 
minutes at 95 °C and subsequently cooled down on ice. The entire volume of the samples 
were applied into the wells of the gel. In addition, 8 µl of the protein ladder was applied 
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(see Figure 5 for protein bands in the ladder). The gel was run in running buffer for 90 
minutes using 130 V.  
After separation of the proteins, the gel was blotted onto transfer 
membrane (nitrocellulose) between three blotting papers on each side 
in blotting buffer for 90 minutes at 100 V. The system was cooled 
with ice during the entire blotting procedure. After the blotting, the 
membrane was stained with protein staining solution for 5 minutes, 
washed once with water and photographed under visible light to 
ensure proper protein separation.  
The membrane was further washed with PBST solution for 10 
minutes. After PBST washing, the membrane was blocked with 5 % 
milk for 1 hour. Primary antibody staining was done overnight at 4 
°C by placing the membrane inside a 50 ml tube containing 5 ml of 
1:400 UGT1A1-antibody dilution in 0.5 % milk. On the next day, the 
membrane was washed twice for 10 minutes with PBST. Secondary 
antibody staining was done for 45 minutes at room temperature by 
placing the membrane inside a 50 ml tube containing 5 ml of 1:10 
000 Anti-rabbit-antibody dilution in 5 % milk. The staining was 
followed by four washes of the membrane with PBST, each for 15 minutes. Luminescence 
reaction was induced by staining the membrane for approximately 2 minutes with 4 ml 
of a mixture containing 1:1 dilution of solutions 1 and 2 provided by chemiluminescent 
detection reagent kit. The membrane was photographed under visible light and 
luminescence was detected by exposing the membrane five times for 20 seconds. The 
final picture was merged from all five pictures and the visible light picture. 
For β-actin immunostaining, the membrane was stripped of the previous antibodies by 
incubating it 15 minutes at 37 °C with 10 ml stripping reagent. The membrane was 
subsequently washed two times for 10 minutes with PBST. Primary antibody staining 
was done by placing the membrane inside a 50 ml tube containing 5 ml of 1:15 000 
dilution of β-actin-antibody in 5 % milk. This reaction was incubated 90 minutes at room 
temperature. After the incubation, membrane was handled as described above, but instead 
of the Anti-rabbit-antibody, Anti-mouse-antibody was used in a 1:2 000 dilution.  
 
 
 
 
 
 
 
 
 
 
Figure 5. Sizes 
of marker 
proteins in the 
protein ladder 
used in this 
study (www. 
thermoscientific
.de). 
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A vertical mixer was used for all washing steps and protein stainings. For primary and 
secondary antibody stainings, a roll mixer was used. In addition, all antibodies and their 
dilutions are presented in Table 17. 
Table 17. Antibodies used in this study, their dilutions, incubation temperatures and time. 
PRIMARY ANTIBODY SECONDARY ANTIBODY 
Anti-UGT1A1, 1:400 in 0.5 % milk, 
incubated at 4 °C for overnight 
Goat Anti-rabbit IgG, 1:10 000 in 5 % 
milk incubated at RT for 45 minutes 
Anti-β-actin, 1:15 000 in 5 % milk, 
incubated at RT for 90 minutes 
Goat Anti-mouse IgG, 1:2000 in 5 % milk 
incubated at RT for 45 minutes 
 
3.2.9 sscDNA synthesis using total RNA of liver or kidney  
 
For the synthesis of liver and kidney sscDNA, 1 µg of total RNA of liver or kidney was 
supplemented with 14 U RNase inhibitor and 1 µg of Oligo(dT)18 in a total volume of 14 
µl in a PCR-tube. This reaction was incubated at 70 °C for five minutes in the 
thermocycler and subsequently cooled down on ice for 5 minutes. After this incubation, 
5 µl 5X reaction buffer, 1 µl (200 U) reverse transcriptase and final concentration of 500 
µM of each nucleotide (dATP, dCTP, dGTP and dTTP) were added. Water was added to 
a total volume of 25 µl. The reaction was incubated in the thermocycler for 10 minutes at 
40 °C, 50 minutes at 55 °C and finally cooled down on ice. 
 
3.2.10 PCR for cloning of cDNA fragments 
 
PCR for cloning of ABCC3 and UGT2B7 cDNAs and cDNA fragments is described here. 
The Advantage cDNA polymerase mix was used for amplification reactions according to 
instructions of the manufacturer. Briefly, 5 µl 10X reaction buffer, 2 µl liver or kidney 
sscDNA, 1 µl DNA polymerase mixture, 0.4 µM final concentration of both forward and 
reverse primers and 200 µM final concentration of each nucleotide (dATP, dCTP, dGTP 
and dTTP) were mixed in a PCR-tube. Water was added to final volume of 50 µl and the 
reaction was carried out as presented in Table 18. When pGEM-T-UGT2B7(802C) or 
non-linearized pMA-MRP3 -plasmids were used as the templates, 4 pg of the plasmid 
was used for amplification reaction. In the case of NotI linearized pMA-MRP3, 20 pg of 
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the plasmid was used for amplification reaction. Control reactions were carried out as 
cloning reactions, but the reaction volume was reduced to a volume of 20 µl. Table 19 
presents primers used for all cloning PCR amplifications in this study. 
Table 18. Thermocycler parameters for PCR amplifications of ABCC3 and UGT2B7 
cDNAs and cDNA fragments. Panel A describes conditions for all other PCR 
amplifications but two-step PCR for ABCC3 cDNA amplification is described in panel 
B. 
A        B    
TEMPE- 
RATURE 
TIME  TEMPE- 
RATURE 
TIME  
94 ˚C 60 seconds  94 ˚C 60 seconds  
94 ˚C 30 seconds 
 
 
40-45 
cycles 
94 ˚C 30 seconds 30-40 
cycles 60-64 ˚C 30 seconds 68 ˚C 3 minutes 
72 ˚C 60 seconds/ 
1 kilobase of the 
target sequence 
68 ˚C 
 
4 ˚C 
3 minutes 
 
Until sample was 
 
72 ˚C 10 minutes   analyzed  
4 ˚C 
 
Until sample was 
analyzed 
 
 
   
 
 
 
Table 19. Primers used for PCR amplification of cDNA fragments. 
cDNA fragment FORWARD PRIMER REVERSE PRIMER 
UGT2B7 oUGT2B7-F 
oUGT2B7-R (sscDNA)/ 
oUGT2B7-Clone-R (for 
pGEM-T-UGT2B7(802C)) 
UGT2B7 control oUGT2B7-seq2 oUGT2B7-R 
ABCC3 oMRP3-F oMRP3-R 
ABCC3 (pMA-MRP3) oMRP3-F oMRP3-RT 
ABCC3 3’-part oMRP3-XbaI-F oMRP3-Clone-R 
ABCC3 5’-part oMRP3-Clone-F oMRP3-R 
ABCC3 5’-part (two step 
PCR) 
oMRP3-Clone-F2 oMRP3-Clone-R2 
ABCC3 control oMRP3-RT-F oMRP3-RT-R 
β-actin oβ-actin-F oβ-actin-R 
 
3.2.11 Cloning of PCR amplified fragments 
 
PCR amplified cDNA fragments were cloned into the pCR2.1-TOPO-vector using both 
PCR reaction and gel electrophoresis purified cDNA fragments. The Topo TA Cloning 
  51  
 
   
Kit was used for this purpose according to the instructions of manufacturer. Briefly, 4 µl 
of a PCR-reaction or 4 µl of a gel purified cDNA fragment was mixed with 1 µl salt-
solution and 1 µl pCR2.1-TOPO in a 2 ml micro tube. Reaction was incubated 5-30 
minutes at room temperature. 3 µl of the reaction was transformed in One Shot TOP10 -
cells as described in 3.2.15. White colonies were further analysed by isolation and 
restriction analysis of plasmids (see 3.2.12 and 3.2.19). 
 
3.2.12 Plasmid restrictions 
 
Plasmid restrictions were used for three different purposes in this study: For subcloning 
of the UGT2B7 cDNA or the ABCC3 cDNA into expression vectors  pcDNA3.1/Hygro(-
)- or pcDNA3.1/Zeo(-), for restriction analysis of subclonings of the UGT2B7 cDNA and 
the ABCC3 cDNA and restriction analysis of cloning of PCR amplified fragments. In 
addition, pMA-MRP3 was restricted to aid PCR amplification of the full-length ABCC3 
cDNA.  
For the restriction of pMA-MRP3, 1 µg of pMA-MRP3 was incubated with 20 U of NotI 
in a reaction containing 5 µl of 10X SmartCut buffer and water added to a total volume 
of 50 µl. This reaction was incubated 80 minutes at 37 °C.  
Reactions that were set up for subcloning of the UGT2B7 cDNA into pcDNA3.1/Hygro(-
)-vector, contained 4-9 µg of vectors pGEM-T-UGT2B7(802C) or pcDNA3.1/Hygro(-), 
100-150 U of ApaI or 30 U of BstXI or 20-40 U of NotI and 5 µl 10X CutSmart buffer 
for ApaI and NotI or 5 µl 10X NEBuffer 3 supplemented with 5 µg of BSA for BstXI. 
Total volume of reactions were 50 µl and they were incubated overnight at 37 °C for 
BstXI and NotI or at 25 °C for ApaI reactions.  
Reactions that were set up for subcloning of the UGT2B7 cDNA into pcDNA3.1/Zeo(-)-
vector, contained 3-7 µg of vectors pGEM-T-UGT2B7(802C) or pcDNA3.1/Hygro(-)-
vector, 50-250 U of ApaI or 20-100 U of PstI and 5 µl 10X CutSmart buffer for ApaI or 
5 µl 10X NEBuffer 3 supplemented with 5 µg of BSA for PstI in a total volume of 50 µl. 
Reactions were incubated 9 hours or overnight at 37 °C. 
For subcloning of ABCC3 cDNA, 3.5 µg of pcDNA3.1/Hygro(-) was restricted with 40 
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U of NotI and 45 U of KpnI for 4.5 hours at 37 °C. NotI restriction contained 5 µl 10X 
CutSmart buffer and KpnI restriction contained 5 µl 10X NEBuffer 1 supplemented with 
5 µg of BSA. 5 µg of pCR2.1-TOPO-MRP3 was restricted with 5 U of NotI, 15 U of KpnI 
and 5 µl 10X NEBuffer 2 supplemented with 5 µg of BSA. This reaction was incubated 
for 6 hours at 37 °C. Reaction volumes were 50 µl in both cases. 
For the analysis of clonings of PCR amplifications, 9 µl of plasmid isolation was 
restricted with 1 µl of 10X EcoRI-HF Re-Mix in a total volume of 10 µl at 37 °C for 30-
90 minutes.  
All other restriction analysises were performed with 1-2 µg of plasmid DNA in a reaction 
with either EcoRI or BamHI. 1-2 µl of EcoRI-HF RE-Mix was used for EcoRI restrictions 
in a total volume of 10-20 µl. BamHI restrictions were supplemented with 10-20 U of the 
enzyme and 1-2.5 µl 10X SmartCut buffer in a total volume of 10-25 µl. 
 
3.2.13 DNA dephosphorylation 
 
To avoid religations in subcloning reaction of the UGT2B7 cDNA into NotI restricted 
pcDNA3.1/Hygro(-)-vector, the vector was dephosphorylated. The dephosphorylation 
reaction was conducted by addition of 6 µl 10 X Antarctic phosphatase reaction buffer 
and 5-20 U of Antarctic phosphatase directly to the NotI restriction of the vector. The 
reaction was incubated 15-20 minutes at 37 °C and the phosphatase was heat-inactivated 
subsequently for 5 minutes at 65 °C. 
 
3.2.14 DNA ligation 
 
Before ligation, gel-purified cDNA fragments and the respective expression vectors were 
analysed by agarose gel electrophoresis and concentrations of both were estimated. In all 
ligation reactions, the concentration of the vector and the insert cDNA varied between 
20-60 ng and 20-100 ng, respectively. Total concentration of DNA in ligation reactions 
varied between 40-120 ng of DNA. Ratios between expression vector and insert were 1:2-
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1:4 and 1:2-1:9 for the ABCC3 cDNA and the UGT2B7 cDNA ligation reactions, 
respectively. In addition, control ligation reactions were occasionally added by excluding 
insert from the ligations reaction to check religations. 
Two different ligation methods were used in this study: T4 DNA quick ligase and T4 
DNA ligase. Ligations with T4 DNA quick ligase were conducted in the reaction volume 
of 20 µl containing 10 µl 2X of quick ligase reaction buffer, appropriate amount of DNA 
diluted with water in a volume of 10 µl and 1 µl quick T4 ligase corresponding to 2 000 
U. Ligations were incubated 5-10 minutes at 25 °C and after the incubation, the reactions 
were cooled down on ice. T4 DNA ligase reactions contained 2 µl 10X reaction buffer, 
appropriate amount of DNA diluted with water to a total volume of 18 µl and 1 µl of T4 
DNA ligase corresponding to 400 U. Reactions were incubated overnight at 16 °C and 
subsequently heat-inactivated for 10-15 minutes at 65 °C and cooled down on ice. 
Ligation reactions for ABCC3 cDNA into pcDNA3.1/Hygro(-) or for UGT2B7 cDNA 
into pcDNA3.1/Zeo(-) were transformed to XL-1 Blue supercompetents cells (see 
3.2.15). All the other ligation reactions were transformed to XL-10-Gold ultracompetent 
cells (see 3.2.15). 
 
3.2.15 Plasmid transformation 
 
Three different competent cells were used in this study: One Shot TOP10, XL-10-Gold 
ultracompetent and XL-1 Blue supercompetent. The TOP10 cells were used only for 
transformations of PCR amplifications cloned into the pCR2.1-TOPO-vector. The other 
two competent cells were used for transformations of mutagenesis and ligation reactions. 
PCR amplifications cloned in the pCR2.1-TOPO-vector were transformed into One Shot 
TOP10 cells according to the instructions of the manufacturer. Briefly, 3 µl of the cloning 
reaction was transferred to tube containing 50 µl of competent cells that were thawed on 
ice. Transformation reaction was incubated 30 minutes on ice and heat-shocked for 30 
seconds at 42 °C in water-bath. After the heat-shock, the transformation was cooled down 
for 2 minutes on ice and subsequently 250 µl of S.O.C.-medium (room temperature) was 
added into the tube. The transformation reaction was further incubated 1 hour at   37 °C. 
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A 100 µl aliquot and the rest of the transformation reaction was plated onto agar plates 
supplemented with 100 µg/ml ampicillin and pre-warmed to 37 °C. In addition, plates 
were spread beforehand with 40 µl of 40 mg/ml X-β-Gal DMF-solution, corresponding 
to 1.6 mg of X-β-Gal per plate, for α-complementation test. Plates were incubated at 37 
°C for 20-24 hours. 
Transformations into XL-10-Gold ultracompetent cells were done according to the 
instructions of the manufacturer with slight modifications. Briefly, 50 µl of the cells were 
thawed on ice and transferred to a 13 ml pre-cooled tube. 2 µl of the β-mercaptoethanol 
mixture was transferred to the cells and tubes were gently shaked every two minutes for 
10 minutes during incubation on ice. 2 µl of the ligation or 1.5 µl of the mutagenesis 
reaction was transferred to the cells, shaked gently and incubated 30 minutes on ice. 
Transformation reaction was subsequently heat-shocked 30 seconds at 42 °C in water-
bath, cooled down on ice for 2 minutes and 450 µl of preheated (42 °C) S.O.C.-medium 
was applied to the cells. Transformation reaction was incubated 1 hour at 37 °C. A 100 
µl aliquot and the rest of the transformation reaction was plated onto 37 °C pre-warmed 
agar plates supplemented with 100 µg/ml ampicillin. Plates were incubated for 16-20 
hours at 37 °C. 
Tranformations into XL-1 Blue supercompetent cells were done according to the 
instructions of the manufacturer with slight modifications. Briefly, 50 µl of the cells were 
thawed on ice and transferred to a 13 ml pre-cooled tube on ice. 0.85 µl of the β-
mercaptoethanol mixture was transferred to the cells and tubes were gently shaked every 
two minutes for 10 minutes during incubation on ice. 5 µl of ligation reaction was 
transferred to the cells, shaked gently and incubated further 30 minutes on ice. 
Transformation reaction was heat-shocked 45 seconds at 42 °C in water-bath, cooled 
down on ice for 2 minutes and 450 µl of preheated (42 °C) S.O.C.-medium was applied 
to the cells. Transformation reaction was incubated 1 hour at 37 °C. A 100 µl aliquot and 
the rest of the transformation reaction was plated onto 37 °C pre-warmed agar plates 
supplemented with 100 µg/ml ampicillin. Plates were incubated for 20-24 hours at 37 °C. 
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3.2.16 Site-directed mutagenesis 
 
For the correction of base pair exchange in the vector pcDNA3.1/Zeo(-)-
UGT2B7(1575T), two commercial mutagenesis kits were used: QuickChange multi-site-
directed kit with XL-10-Gold ultracompetent cells (Kit I) and QuickChange II site-
directed kit with XL-1 Blue supercompetent cells (Kit II). Three reactions (I-III) were 
conducted with Kit I and nine reactions (I-IX) and one control reaction with Kit II. 
Mutagenesis reactions with Kit I were prepared according to instructions of the 
manufacturer. Three different experimental setups were carried out with Kit I. Reactions 
I and II consisted of 100 ng of the pcDNA3.1/Zeo(-)-UGT2B7(1575T)-vector, 100 ng of 
oUGT2B7-Mut-F-primer, 2.5 µl 10 X QuickChange Multi reaction buffer, 0.5 µl 
QuickSolution, 1 µl deoxynucleotide mix, 1 µl QuickChange Multi enzyme blend and 
water added to total reaction volume of 25 µl in a PCR-tube. Reaction III was same as 
reactions I and II, but consisted of 50 ng of the pcDNA3.1/Zeo(-)-UGT2B7(1575T)-
vector, 150 ng of oUGT2B7-Mut-F-primer and DMSO was added to final concentration 
of 10 %. Reactions were run in the thermocycler as described in Table 20. After the 
thermocycler reaction, 1 µl of DpnI was added to the reactions and reaction I and II were 
incubated for 1 hour and the reaction III for 1.5 hours at 37 °C. 1.5 µl of every reaction 
was transformed into XL-10-Gold ultracompetent cells as described in 3.2.15. 100 µl and 
250 µl aliquots of the transformation reaction were plated onto agar plates supplemented 
with 100 µg/ml ampicillin. 
Table 20. Thermocycler parameters for mutagenesis reactions with Kit I. Panel A 
describes parameters for reactions I and II and panel B describes parameters for reaction 
III. 
A         B    
TEMPERATURE TIME  TEMPERATURE TIME  
95 ˚C 60 seconds  98 ˚C 90 
seconds 
 
95 ˚C 60 seconds 
30 
cycles 
98 ˚C 90 
seconds 30 
cycles 55 ˚C 60 seconds 65 ˚C 15 
minutes 
65 ˚C 14 minutes 65 ˚C 5 
minutes 
 
65 ˚C 
 
5 minutes 
 
  
 
 
 
 
  56  
 
   
4 ˚C 
 
Until 
sample  
was 
analyzed 
4 ˚C Until 
sample 
was 
analyzed 
      
Mutagenesis reactions with Kit II were prepared according to instructions of the 
manufacturer. Briefly, reactions consisted of 5 µl of 10X reaction buffer, 5-150 ng of 
pcDNA3.1/Zeo(-)-UGT2B7(1575T)-vector, 125-200 ng of both oUGT2B7-Mut-F- and 
oUGT2B7-Mut-R-primers, 1 µl deoxynucleotide mix, 1 µl PfuUltra High-Fidelity DNA 
polymerase and water was added to a final reaction volume of 50 µl in a PCR-tube. 
Together nine different reactions were performed (Table 21). Reaction conditions for 
each reaction are described in Table 21. Reactions were run in the termocycler according 
to parameters in Table 22. After the thermocycler reaction, reactions were incubated with 
1 µl DpnI for 1 hour or 1.5 hours (reactions VII and IX) at 37 °C. Reactions were 
transformed into XL-1 Blue supercompetent cells as described in 3.2.15 and Table 21. 
Transformations of reactions I-VII were not incubated for 10 minutes with β-
mercaptoethanol mixture, because this step was not included in the mutagenesis protocol 
provided by the manufacturer. 100-500 µl aliquots of the transformation reactions were 
plated onto agar plates supplemented with 100 µg/ml of ampicillin. 
The control reaction was performed according to instructions of the manufacturer. 
Table 21. Reaction setups for Kit II –mutagenesis reactions. 
*Reaction was precipitated according to 3.2.21 before the transformation. #Reaction was 
transformed in XL-10-Gold ultracompetent cells according to 3.2.15. 
REACTION I II III IV V VI VII VIII IX 
Amount of the 
template 
5 ng 20 ng 
150 
ng 
5 ng 
25 
ng 
50 
ng 
50 ng 25 ng 
25 
ng 
Amount of 
each primer 
125 
ng 
125 
ng 
125 
ng 
125 
ng 
125 
ng 
125 
ng 
125 
ng 
150 
ng 
200 
ng 
Final 
concentration 
of DMSO 
0 % 0 % 0 % 0 % 0 % 0 % 5 % 10 % 10 % 
Amount of 
transformed 
1 µl 
and 
30 
µl* 
1 µl 
and 
30 
µl* 
3 µl, 
4 µl 
and 36 
µl* 
1 µl 1 µl 
4 µl 
and 
36 
µl* 
4 µl 
and 
45 
µl# 
50 
µl* 
50 
µl* 
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Table 22. Thermocycler parameters for mutagenesis reactions with Kit II. Panel A 
describes parameters for reactions I-VI and panel B describes parameters for reaction VII-
IX. *In reaction IX 45 seconds and 16 cycles was used instead of 30 seconds and 12 
cycles. 
A        B    
TEMPERATURE TIME  TEMPERATURE TIME  
95 ˚C 30 seconds  98 ˚C 30 
second
s* 
 
95 ˚C 30 seconds 
12 
cycles 
98 ˚C 45 
second
s 12* 
cycles 55 ˚C 60 seconds 68 ˚C 8 
minute
s 
68 ˚C 7 minutes 4 ˚C Until 
sample 
was 
analyze
d 
 
4 ˚C 
 
Until sample 
was 
analyzed 
   
 
3.2.17 Bacterial cultures 
 
For preparation of plasmids, a single colony was picked with a pipette tip from agar plates 
and transferred to 13 ml tubes containing 5 ml LB-medium supplemented with 50 µg/ml 
ampicillin. The culture was incubated overnight at 37 °C with shaking. In the case of over 
day incubation, 2 ml of the respective media were used instead of 5 ml and incubation 
was carried out for 6-8 hours. 
 
3.2.18 Permanent bacterial culture 
 
For permanent bacterial cultures, a fresh overnight bacterial culture was established by 
transferring approximately 10 µl of an appropriate bacterial culture to 5 ml of fresh LB-
medium supplemented with 50 µg/ml ampicillin. The culture was incubated overnight at 
37 °C. After the incubation, 600 µl of culture was supplemented with 400 µl of sterile 
glycerol in 1.5 ml micro tube with assembled cap, vortex mixed and stored at -80 °C. 
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3.2.19 Plasmid isolation 
 
Two different plasmid isolation procedures were used in this study; a commercially 
available plasmid extraction kit (PureYield Plasmid Miniprep System) and the plasmid 
extraction method described by Holmes and Quigley (1981). The former was used when 
plasmid was prepared for sequencing, transfection or cloning reactions. The latter was 
used for analysis of cloning reactions or mutagenesis.  
The PureYield Plasmid Miniprep System plasmid extraction kit was used according to 
instructions of the manufacturer. Briefly, 3 ml (in two 1.5 ml aliquots) of overnight 
bacterial culture was centrifuged at 20 000 g for 30 seconds in 1.5 ml micro tube. The 
supernatant was removed and the pellet suspended in 600 µl of water. 100 µl of lysis 
buffer was added to the suspension and mixed gently turning up and down the tube three 
times. This was followed by addition of 350 µl of neutralization solution and inverting 
the tube 6-10 times. The tube was centrifuged at 20 000 g for 3 minutes and the resulting 
supernatant was loaded onto column and eluted in vacuum manifold. The column was 
washed with 200 µl of endotoxin removal solution and 400 µl of wash solution. This was 
followed by 1 minute centrifugation of the column at 20 000 g. DNA was eluted with 32 
µl of water by incubating 1 minute at room temperature and 15 seconds centrifugation at 
20 000 g. 
For plasmid isolations according to Holmes and Quigley (1981), 1.5 ml of overnight 
culture was centrifuged 5 minutes at 2 000 g in 1.5 ml micro tube. The supernatant was 
removed and the pellet was suspended in 200 µl of STETL-solution. The tube was 
incubated in boiling water for 35 seconds and centrifuged 10 minutes at 16 000 g. The 
resulting cell debris was removed by a toothpick and 200 µl of isopropanol was added to 
precipitate plasmid DNA. The precipitation was centrifuged at 4 °C and at 18 000 g for 
30 minutes. After the centrifugation, the supernatant was removed, the pellet was airdried 
at room temperature for 10-20 minutes and dissolved in 50 µl of water containing 1.8 
U/ml of ribonuclease A. 
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3.2.20 DNA and RNA concentration measurement 
 
2 µl of DNA or RNA was diluted by a factor of 40 with water into a total volume of 80 
µl. This solution was transferred to quartz cuvette and UV absorbance was measured at 
260 nm and 280 nm in spectrophotometer. Water was used as a blank sample for all 
measurements. Concentration of DNA or RNA was based on the absorbance at 260 nm. 
Purity of DNA or RNA was evaluated based on ratio of absorbance at 260 nm and 280 
nm. 
 
3.2.21 DNA purification 
 
DNA-fragment purification was performed after gel electrophoresis of PCR amplified 
cDNA fragments or restriction reactions. In addition, when sequential restrictions were 
done and one buffer was not compatible for both reactions, DNA-fragments were 
purified.  
cDNA fragments or restricted plasmids of interest were cut out of the agarose gel with a 
scalpel and transferred into dialysis tubing and filled with 200-600 µl of 1X TAE-buffer. 
Tubing was sealed at both ends and placed in the gel electrophoresis cell containing 1X 
TAE. The gel inside the tube was placed at the edge near the cathode of the 
electrophoresis cell to aid transfer of DNA out of the gel into buffer. Dialysis was run for 
60 minutes at 60 V. After the run, the solution was transferred to 1.5 ml micro tube and 
DNA was precipitated by adding 1/10 of total volume of 3 M sodium acetate pH 4.8 and 
absolute ethanol 3 times of a total volume. The precipitation was incubated at least 30 
minutes at -20 °C but also incubations over night or over weekend were conducted. The 
incubation was followed by 21 000 g centrifugation at 0 °C for 30 minutes. Finally, the 
supernatant was removed, the pellet was washed by up and down pipetting 200 µl of 70 
% ethanol and dried at room temperature. The pellet was dissolved in appropriate volume 
of water before use for next reaction. 
 
  60  
 
   
3.2.22 DNA sequencing 
 
Samples for DNA sequencing were prepared in 1.5 ml microtubes and contained 800 ng 
of the plasmid of interest, 1.4 µM final concentration of the primer used for sequencing 
and water added to total volume of 14 µl. Samples were sequenced by LGC Genomics 
GmbH (Berlin, Germany). 
 
3.2.23 Agarose gel electrophoresis 
 
Gel electrophoresis analysis of DNA fragments was performed in 0.8 % or 1.5 % agarose 
gels. 1.5 % agarose gels were used only for the analysis of qPCR-reactions. A typical 
sample volume loaded onto gel was 12 µl per well and it contained appropriate amount 
of DNA (typically 400-600 ng), a restriction or  a plasmid isolation and 2 µl 6X gel 
loading dye. In the case of DNA purifications, larger volumes were loaded onto the gel. 
These volumes were in the range of 15-30 µl and contained 1/6 of a total volume 6X gel 
loading dye. In addition, 10 µl DNA marker, corresponding to 1 µg of DNA, was loaded 
onto every gel. The length of bands and amount of DNA per band in DNA markers are 
presented in Figure 6. Gels were run in electrophoresis chamber filled with 1X TAE-
buffer for 40-100 minutes at 100 V, or at 120 V in the case of larger gel. After the run, 
gel was stained for 3-4 minutes with ethidium bromide water solution. Staining was 
followed by one brief and a second 6-10 minutes wash with tap water. Gels were 
visualized under UV-light of 312 nm and digitally photographed. 
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Figure 6. Length and amount of DNA fragments of 2-log (A) and 1 kb (B) DNA ladder 
(www.neb.com; www.peqlab.de).  
 
 
4.  RESULTS 
 
4.1 Cloning of the human UGT2B7 cDNA 
 
To establish a stable expression of a human protein in mammalian cells, an expression 
vector containing the cDNA encoding the protein of interest has to be generated. For 
this purpose, the cDNA has to be cloned, sequenced (and corrected if it contains base 
pair exchanges) and subsequently subcloned into expression vector. Here, mammalian 
expression vectors pcDNA3.1/Hygro(-) and pcDNA3.1/Zeo(-) were chosen for the 
expression of UGT2B7 cDNA. For the amplification of the UGT2B7 cDNA, kidney and 
liver sscDNAs were used (4.1.1). In addition, in-house generated vectors pGEM-T-
UGT2B7(802C) and pcDNA3.1/Zeo(-)-UGT2B7(1575T) were available. However, 
both vectors contained a base pair exchange compared to reference sequence of 
UGT2B7. Because of that, they had to be corrected before using them for the expression 
bases          ng ng     kilobases   
A B 
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of UGT2B7 (4.1.5). In addition, pGEM-T-UGT2B7(802C) is a subcloning vector and is 
suitable only as a source for the UGT2B7 cDNA that has to be cloned in one of the 
expression vectors before transfecting mammalian cells (4.1.3-4). However, UGT2B7 
cDNA could be amplified using pGEM-T-UGT2B7(802C) as the template and 
subsequently subcloned into another cloning vector such as the pCR2.1-TOPO, which 
would allow to use multiple different cloning strategies compared to pGEM-T-
UGT2B7(802C)-vector (4.1.2).  
 
4.1.1 Amplification of the UGT2B7 cDNA using liver or kidney sscDNA as the 
template 
 
UGT2B7 is expressed in intestine, liver 
and kidney (Sato et al. 2014). Therefore, 
total RNA of all these tissues could be 
used as a template for the amplification 
of the 1690 bp protein coding sequence 
of the UGT2B7 cDNA. Attempts to 
amplify the UGT2B7 cDNA from liver 
sscDNA did not succeed, although the β-
actin control reaction gave an 
amplification product (results not 
shown). However, the amplification of 
the UGT2B7 cDNA fragment was 
successful when using kidney sscDNA 
(Figure 7). In addition, two control 
reactions were included in the same experiment; amplification of the β-actin cDNA 
fragment (661 bp) and amplification of the 393 bp control fragment of the UGT2B7 
cDNA (Figure 7). The amplified 1600 bp cDNA fragment of UGT2B7 was subcloned 
into the pCR2.1-TOPO-vector and 32 transformants were analyzed after the 
transformation (results not shown). Restriction analysis was further conducted with 
BamHI and EcoRI for two transformants.  
 
 
 
 
 
 
 
 
 
Figure 7. Amplification of the UGT2B7 
cDNA fragments and the β-actin cDNA 
fragment using kidney sscDNA as the 
template. The amplified cDNA fragments 
are the control fragment of UGT2B7 (lanes 
1-3), the UGT2B7 (lanes 4-7) and the β-
actin fragment (lanes 8-9). 
 500 bp > 
1 4 8 
1 500 bp > 
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The UGT2B7 cDNA contains an internal restriction site for both enzymes (Appendix 3). 
In addition, pCR2.1-TOPO contains an internal BamHI restriction site and two internal 
EcoRI restriction sites at the both ends of the cloned PCR fragment. Restriction analysis 
of pCR2.1-TOPO-UGT2B7 with BamHI should result in 1210 bp and 4370 bp fragments. 
On the other hand, EcoRI digestion of the plasmid should result in 309 bp, 1360 bp and 
3910 bp fragments.  
The results of the restriction analysis are 
shown in Figure 8. BamHI digestions of 
both transformants resulted in a 6000 bp 
fragment and EcoRI digestions resulted 
in 4000 bp and 1500 bp fragments. These 
results are not in agreement with the 
expected fragment lengths (see above). In 
addition, both transformants were 
sequenced (T7-promoter-primer) 
including sequencing of transformant 1 
also with oUGT2B7-seq1-primer. No 
sequence could be detected for the 
sequencing with the oUGT2B7-seq1, 
which indicates absence of the UGT2B7 
cDNA. Even though two other sequencing analyses gave same results, no UGT2B7 cDNA 
was observed in this sequence. An alignment of the sequence corresponded with the 
sequence between bp 922-1989 in the expression vectors pcDNA3.1/Zeo(-) and 
pcDNA3.1/Hygro(-). Cloning was repeated and 20 additional transformants were 
analyzed. Similar results were obtained with the restriction analysis and no positive 
clones could be generated (results not shown) 
 
 
 
 
 
 
 
 
 
 
Figure 8. Restriction analysis of pCR2.1-
TOPO-UGT2B7 transformants 1 and 2. 
The UGT2B7 cDNA was cloned using 
kidney sscDNA as the template. Lane 1 and 
2 are BamHI restriction analyses of 
transformant 1 and 2, respectively. Lane 3 
and 4 are EcoRI restriction analyses of 
transformant 1 and 2, respectively. Lanes 5 
and 6 are unrestricted plasmids 1 and 2, 
respectively. 
1 500 bp > 
1 2 3 4 5 6 
6 000 bp > 
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4.1.2  Amplification of the UGT2B7 cDNA using pGEM-T-UGT2B7(802C) as the 
template 
 
Because the amplification of the UGT2B7 cDNA 
was not successful when using liver or kidney 
sscDNA as the template, attempts were made to 
amplify it using in-house available pGEM-T-
UGT2B7(802C)-vector as the template. Although 
this cDNA contains a base pair exchange 
compared to reference sequence, it could be 
corrected when the cDNA is subcloned into the 
expression vector.  
The amplification was successful only in one 
experiment (Figure 9). The amplified fragment 
was subsequently cloned into pCR2.1-TOPO and 
10 transformants were analyzed with EcoRI restriction analysis (Figure 10).  
 
The UGT2B7 cDNA contains an internal EcoRI restriction site and two EcoRI restriction 
sites are located at the both ends of the cloned cDNA fragment in the pCR2.1-TOPO-
plasmid (Appendix 3). Therefore, EcoRI digestion of pCR2.1-TOPO-UGT2B7 is 
expected to result in 309, 1360 and 3910 bp fragments. Even the shortest fragment was 
not visible in the restriction analysis, longer fragments showed the correct lengths in the 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Amplification of the 
UGT2B7 cDNA using pGEM-T-
UGT2B7(802C)-plasmid as the 
template. 1700 bp bands 
correspond to the length of the 
UGT2B7 cDNA. 
 
 
 
 
 
 
 
 
 
Figure 10. EcoRI restriction analysis of transformant from the cloning of PCR 
amplified UGT2B7 cDNA. Lanes 1-10 and Lanes 11-20 are EcoRI restriction analyzed 
and unrestricted transformants, respectively. Lanes 1 and 11 and lanes 2 and 12 are 
transformants 1 and 2, respectively. 
1 500 bp > 
1 2 11 12 10 20 
1 500 bp > 
4 000 bp > 
500 bp > 
5 15 
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case of three transformants (lanes 1, 2 and 5 in Figure 10). Transformants 1 and 2 were 
sequenced using T7-promoter-primer. Interestingly, both sequences were same and 
identical with sequences obtained using kidney sscDNA as the template (see 4.1.1).   
 
4.1.3 Cloning of the UGT2B7 cDNA from the pGEM-T-UGT2B7(802C) into 
expression vector pcDNA3.1(-)-Hygro 
 
After unsuccessful amplifications of the UGT2B7 cDNA, the cloning strategy was 
changed to restrict UGT2B7 cDNA from the vector pGEM-T-UGT2B7(802C), ligate it 
into expression vector pcDNA3.1 and correct the base pair exchange. For the first 
strategy, the expression vector pcDNA3.1(-)-Hygro was used, which contains same 
unique restrictions sites as pGEM-T-UGT2B7(802C) (Appendix 3). These restriction 
sites, ApaI and BstXI, allow ligation of the UGT2B7 cDNA in the right orientation into 
expression vector, when both vectors are restricted with them. 
 
Figure 11 shows ApaI and BstXI restrictions of the vectors pcDNA3.1(-)-Hygro and 
pGEM-T-UGT2B7(802C). The correct length band, 1630 bp, corresponding to the 
UGT2B7 cDNA was obtained (the arrow in Figure 11B). In addition, the restriction of 
pcDNA3.1(-)-Hygro showed the correct length of the vector, 5600 bp. Both DNA 
fragments were purified and ligated. Subsequent 100 transformants of the cloning 
 
 
 
 
 
 
 
 
 
Figure 11. ApaI and BstXI restrictions of the vectors pcDNA3.1(-)-Hygro (panel A) 
and  pGEM-T-UGT2B7(802C) (panel B). Lanes 1 and 2-4 are unrestricted and 
restricted vectors, respectively. The arrow indicates the 1600 bp cDNA fragment of 
the UGT2B7. 
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reaction were analysed by plasmid isolation and agarose gel electrophoresis analysis of 
plasmids. A representative analysis is shown in Figure 12. None of the analysed 
transformants showed significantly longer plasmids than the empty pcDNA3.1(-)-Hygro-
vector. The cloning reaction was repeated and additional 60 transformants were analysed 
with the similar result (results not shown).  
 
As the second strategy, pGEM-T-UGT2B7(802C) and pcDNA3.1(-)-Hygro vectors were 
restricted with NotI that is not a unique restriction site for them. Because of that, the 
ligation reaction could result in two different orientations of the UGT2B7 cDNA in 
pcDNA3.1(-)-Hygro and thus is less favorable than the first strategy with ApaI and BstXI 
restrictions. A representative agarose gel electrophoresis analysis of transformants from 
the cloning reaction of NotI restricted UGT2B7 cDNA into NotI restricted pcDNA3.1(-)-
Hygro-vector  is presented in Figure 13. This cloning reaction was repeated four times 
and all together 350 transformants were analysed. Interestingly, seven transformants 
showed similar length as transformant 11 and were longer in length than the empty vector 
pcDNA3.1/Hygro(-) (Figure 13). Because this cloning strategy could lead in two different 
orientations of the UGT2B7 cDNA in the expression vector, restriction analysis was 
conducted. All the seven transformants were analysed with restriction analysis using 
EcoRI and BamHI. In the correct orientation, the start codon of the UGT2B7 cDNA 
locates after the cytomegalovirus promoter and the restriction analysis should result in 
fragments of 297, 1360 and 4170 bp, and 534 and 6730 bp for EcoRI and BamHI 
restrictions, respectively (Appendix 3). On the other hand, if the orientation of the 
UGT2B7 cDNA in the expression vector is the wrong, the restriction analysis with EcoRI 
 
 
 
 
 
 
 
 
Figure 12. Agarose gel electrophoresis analysis of 20 transformants isolated from the 
cloning of the UGT2B7 cDNA into pcDNA3.1(-)-Hygro. Lanes 1 and 12 are the empty 
vector pcDNA3.1(-)-Hygro.  
12 1 
3 000 bp > 
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should result in the same fragments but BamHI restriction should result in fragments of 
1240 and 6030 bp. 
 
 
 
 
 
 
 
 
 
Figure 13.  Agarose gel electrophoresis analysis of 20 transformants isolated from the 
cloning of the UGT2B7 cDNA into pcDNA3.1(-)-Hygro using NotI restriction. Lanes 1 
and 12 are the empty pcDNA3.1/Hygro(-)-vectors. 
 
A representative agarose gel 
electrophoresis analysis of BamHI and 
EcoRI restriction analysed 
transformant 11 and the empty vector 
pcDNA3.1/Hygro(-) is presented in 
Figure 14. EcoRI restriction linearized 
transformant 11 and did not show 1360 
bp length fragment (lane 2 in Figure 
14). However, the 1360 bp fragment 
was released when the empty vector 
pcDNA3.1(-)-Hygro was restricted 
with EcoRI (lane 5 in Figure 14). This 
result indicates that the transformant did not contain either pcDNA3.1(-)-Hygro-vector or 
the UGT2B7 cDNA. Finally, two transformants were sequenced with T7-promoter-
primer but in both cases, no clear DNA sequence could be detected. The fluorograms 
showed overlay of different sequences (results not shown). 
 
 
 
 
 
 
 
 
 
Figure 14. Restriction analysis of the empty 
pcDNA3.1(-)-Hygro-vector and transformant 
11 (see Figure 13). Lanes 1-3 are, BamHI, 
EcoRI and unrestricted transformant 11, 
respectively. Lanes 3-6 are BamHI, EcoRI and 
unrestricted empty vector pcDNA3.1(-)-
Hygro, respectively. 
1 12 
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11 
1 000 bp > 
1 
1 500 bp > 
4 2 3 5 6 
8 000 bp > 
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4.1.4 Cloning of the UGT2B7 cDNA from the pGEM-T-UGT2B7(802C) into 
expression vector pcDNA3.1(-)-Zeo 
 
Because the subcloning of the UGT2B7 cDNA into vector pcDNA3.1(-)-Hygro was not 
successful, another expression vector was chosen for the next attempt. pcDNA3.1(-)-Zeo 
contains unique restriction sites for ApaI and PstI, which were not available in the vector 
pcDNA3.1(-)-Hygro (Appendix 3). In addition, the same restrictions sites are in the 
vector pGEM-T-UGT2B7(802C) and thus could be used for the subcloning of the 
UGT2B7 cDNA into pcDNA3.1(-)-Zeo. 
Figures 15 presents ApaI and PstI 
restricted vectors pGEM-T-
UGT2B7(802C) and the 
pcDNA3.1/Zeo(-). Restriction of the 
pGEM-T-UGT2B7(802C) resulted 
in 1700 bp fragment corresponding to 
the length of the UGT2B7 cDNA 
(lanes 2-5 in Figure 15). In addition, 
ApaI and PstI restriction of the 
pcDNA3.1/Zeo(-)-vector resulted in 
a 5000 bp fragment corresponding to 
the length of the vector (Lanes 7-10 
in Figure 15). The DNA fragments 
were purified and subsequently 
ligated. Figure 16 shows a representative agarose gel electrophoresis analysis of 20 
transformants isolated from the transformation. Altogether, 200 transformants were 
analyzed after all cloning attempts. All analyzed plasmids were of the same length as the 
empty pcDNA3.1/Zeo(-)-vector, but one transformant showed an insert in the vector 
(Lane 6 in Figure 16). This transformant was further analyzed with restriction analysis 
and sequencing.  
Figure 17 presents restriction analysis of transformant 6 and the empty  pcDNA3.1/Zeo(-
)-vector with EcoRI and BamHI. EcoRI and BamHI restrictions of pcDNA3.1/Zeo(-)-
UGT2B7 should result in fragments of 5010, 1360 and 277 bp, and 6170 and 480 bp, 
 
 
 
 
 
 
 
 
Figure 15. ApaI and PstI restricted vectors 
pGEM-T-UGT2B7(802C) and 
pcDNA3.1/Zeo(-). Lane 1 and 6 are unrestricted 
pGEM-T-UGT2B7(802C) and 
pcDNA3.1/Zeo(-), respectively. Lanes 2-5 and 
lanes 7-10 are restricted pGEM-T-
UGT2B7(802C) and pcDNA3.1/Zeo(-), 
respectively. 
6 000 bp > 
3 000 bp > 
1 500 bp > 
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respectively (Appendix 3). On the other hand, BamHI and EcoRI are unique restriction 
sites of the empty pcDNA3.1/Zeo(-)-vector and the restrictions with them linearizes the 
vector and subsequently result in a 5000 bp fragment.  
BamHI and 
EcoRI restriction 
analysis of 
transformant 6 
did not 
correspond to the 
expected 
fragments (lanes 
2 and 3 in Figure 
17). In addition, 
sequencing of 
transformant 6 
with T7-promoter 
and BGH-reverse primers resulted in no 
UGT2B7 cDNA sequence but a sequence 
that aligned with genomic E.coli DNA 
(http://blast.ncbi.nlm.nih.gov, results not 
shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Agarose gel electrophoresis analysis of 20 transformants 
isolated from the cloning of the UGT2B7 cDNA into pcDNA3.1(-
)-Zeo. Lane 1 is the empty pcDNA3.1/Zeo(-) and lanes 2-21 are 
transformants. 
 
 
 
 
 
 
 
 
 
Figure 17. Restriction analysis of 
transformant 6 (see Figure 16) and the 
empty pcDNA3.1/Zeo(-)-vector. Lanes 1-
3 are unrestricted, BamHI and EcoRI 
restricted transformant 6, respectively. 
Lanes 4-6 are unrestricted, BamHI and 
EcoRI restricted empty vector 
pcDNA3.1/Zeo(-), respectively. 
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4.1.5 Site-directed mutagenesis of the vector pcDNA3.1/Zeo(-)-UGT2B7(1575T) 
 
After unsuccessful amplifications (4.1.1 and 4.1.2) and subclonings (4.1.3 and 4.1.4) of 
the UGT2B7 cDNA, the final strategy was to use the in-house available vector 
pcDNA3.1/Zeo(-)-UGT2B7(1575T). This vector contained a single base pair exchange 
(A to T)  at site 1575 resulting in a premature stop codon of the UGT2B7 cDNA sequence 
compared to the reference sequence (Genbank accession NM_001074.2). To achieve the 
correct sequence, a site-directed mutagenesis reaction was conducted for the vector. For 
this purpose, two different commercially available mutagenesis kits were used. 
 Three reactions 
were conducted 
with QuickChange 
multi-site-directed 
mutagenesis kit. 
Reactions with 
three-step 
thermocycler 
protocol and 
without additional 
DMSO 
supplement in the 
reaction resulted in 
hundreds of 
colonies on the plates after the transformation of the mutagenesis reaction. On the other 
hand, reactions with the two-step thermocycler protocol and 10 % DMSO supplemented 
reaction, only dozens of colonies were detected after the transformation. Together 22 
transformants were sequenced from all reactions with QuickChange multi-site-directed 
mutagenesis kit and none of them showed the correct T1575A exchange but only the 
original uncorrect (1575A) sequence. 
Another mutagenesis kit, QuickChange II site-directed, was also used from the same 
manufacturer. Together nine reactions were conducted with this kit. These reactions 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Restriction analysis of selected transformants from the 
base pair exchange reaction for the pcDNA3.1/Zeo(-)-
UGT2B7(1575T). Panel A presents BamHI restrictions and panel 
B EcoRI restrictions. Lane 1 is the template pcDNA3.1/Zeo(-)-
UGT2B7(1575T)-vector and lanes 2-14 are transformants from 
the mutagenesis reaction. 
4 000 bp > 
6 000 bp > 
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resulted in less than 10 colonies on the plates after the transformation. Due to that, 
subsequent reactions were purified before the transformation and the whole reactions 
were transformed to achieve higher amount of the colonies. This method resulted in a 
couple of tens of colonies. However, all sequenced transformants showed no the correct 
base pair exchange (14 samples) or showed the correct base pair exchange (3 samples) 
but also a deletion of the coding sequence of the UGT2B7 cDNA after or before the  
mutagenesis primer binding sites. In addition, EcoRI and BamHI restriction analysis was 
conducted for 13 transformants from the base pair exchange reactions (Figure 18). 
Restriction analysis of the pcDNA3.1/Zeo(-)UGT2B7(1575T/A) with EcoRI and BamHI 
should result in fragments of 5010, 1360 and 277 bp, and 6170 and 480 bp, respectively 
(Appendix 3). However, EcoRI restriction analysis resulted in no fragment of 277 bp or 
a shorter fragment in half of the analysed transformants (lanes 3, 4, 6, 9, 10 and 14 in 
Figure 18). In addition, BamHI restriction analysis gave similar results; no 480 bp 
fragment or shorter fragment. These results are in agreement with the sequencing results 
that showed a deletion of the UGT2B7 cDNA coding sequence. 
 
4.2 Cloning of the ABCC3 cDNA encoding the human MRP3 
 
MRP3 is expressed in liver and thus total RNA of this tissue could be used as the source 
of the ABCC3 cDNA encoding MRP3 (König et al. 1999a). In addition, later during the 
study, the pMA-MRP3-plasmid that contains the ABCC3 cDNA, was available. 
Amplification of the ABCC3 cDNA was tried using liver sscDNA or the pMA-MRP3-
plasmid as the templates. To coexpress MRP3 with UGT2B7 or UGT1A1 and MRP2, the 
pcDNA3.1/Hygro(-)-vector was chosen for the expression of the ABCC3 cDNA. To 
establish a double- or triple-transfected cell line, all the cDNAs of interest should be 
cloned in different expression vectors containing different antibiotic resistance genes for 
the selection of transfected cell lines. The UGT1A1 cDNA was cloned into 
pcDNA3.1/Hygro(-)-vector and MRP2 expressing cell line contains G418 resistance.  
 
 
5 
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4.2.1 Cloning of the ABCC3 cDNA using liver sscDNA as the template 
 
Amplification of the full-
length ABCC3 cDNA 
should result in cDNA 
fragment of 4620 bp in 
length. However, several 
experiments using liver 
sscDNA resulted in no 
product (panel A in 
Figure 19). 
Amplification of the 661 
bp fragment of β-actin 
cDNA was included as a 
control reaction. In 
addition, a 450 bp fragment of 3’-end of the ABCC3 cDNA was also included as a control 
fragment to the amplification reaction using liver sscDNA and a plasmid that includes 
this cDNA fragment (panel B in Figure 19). Both control reactions resulted in an 
amplification product.  
Because the amplification of the 
full length ABCC3 cDNA did not 
result in a correct amplification 
product, a two fragment 
amplification strategy was 
attempted. Primers were designed 
for amplification of the 5‘-part and 
the 3‘-part fragments of the ABCC3 
cDNA corresponding to length of 
2470 bp and 2460 bp, respectively. 
However, the amplification of the 
both fragments using liver sscDNA resulted in no correct length fragments (Figure 20). 
The amplification of the control β-actin cDNA fragment resulted in the correct 
 
 
 
 
 
 
 
 
 
Figure 19. Amplification of the full-length ABCC3 cDNA 
(panel A, lanes 3-6) and a β-actin fragment (panel A, lanes 
1-2) using liver sscDNA as the template. Amplification the 
ABCC3 cDNA control fragment using liver sscDNA (panel 
B, lane 1) or pCR2.1-TOPO-MRP3-part-plasmid (panel B, 
lane 2). 
 
 
 
 
 
 
 
 
Figure 20. Amplification of 5’-part (lanes 1-3) 
and 3‘-part (lanes 4-6) fragments of the ABCC3 
cDNA using liver sscDNA. Lane 7 represents 
amplification of the β-actin cDNA fragment. 
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amplification product. In addition to the standard PCR conditions, 3 % DMSO was 
included into the reaction but it did not have any effect on the amplification (results not 
shown). Futhermore, amplification of the 3’-part fragment was further tried using two-
step PCR conditions and with a liver sscDNA prepared in-house from total RNA isolated 
from a cryopreserved liver tissue. No amplification was achieved in the presence of 3 % 
DMSO or without DMSO (results not shown). 
 
4.2.2 Amplification of the ABCC3 cDNA using pMA-MRP3-plasmid as the template 
 
Because no amplification of the ABCC3 cDNA was achieved when liver sscDNA was 
used as the template, another strategy was applied. For this purpose pMA-MRP3-plasmid 
containing ABCC3 cDNA was used. However, no amplification of the full-length ABCC3 
cDNA or 5’-part fragment of ABCC3 cDNA was achieved when pMA-MRP3-plasmid 
was used as the template (results not shown). However, amplification of the 3’-part 
fragment was achieved (panel A in Figure 21) and it was successfully cloned into pCR2.1-
TOPO, sequenced and a storage culture was prepared (results not shown).  
The pMA-MRP3-
plasmid contains a 
unique NotI 
restriction site right 
before the start of 
the ABCC3 cDNA. 
Therefore, the 
plasmid was 
restricted with NotI 
to simplify the 
amplification of 
the full-length 
ABCC3 cDNA. Using the NotI restricted pMA-MRP3-plasmid as the template, the 
amplification of the full-length ABCC3 cDNA was achieved (panel B in Figure 21). The 
cDNA fragment was cloned into pCR2.1-TOPO-plasmid.  
 
 
 
 
 
 
 
Figure 21. Amplification of the 3’part fragment of the ABCC3 
cDNA (panel A) and the full length ABCC3 cDNA (panel B) using 
pMA-MRP3-plasmid or NotI-restricted pMA-MRP3-plasmid as 
the template, respectively. 
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14 transformants from the transformation of cloned ABCC3 cDNA were analyzed by 
BamHI restriction analysis. The pCR2.1-TOPO-plasmid contains a unique BamHI 
restriction site before the cloning site of the plasmid. In addition, the ABCC3 cDNA 
contains two internal BamHI restriction sites (Appendix 3). Depending of the orientation 
of the ABCC3 cDNA in the pCR2.1-TOPO-plasmid, restriction analysis with BamHI 
should result in fragments of 294 bp, 2524 bp and 5706 bp (orientation 2) or in fragments 
of 294 bp, 1855 bp and 6375 bp (orientation 1). Restriction analysis results are shown in 
Figure 22. All the restrictions resulted in 300 bp and 5700 bp fragments. In addition, 
restictions resulted in 2500 bp fragments in the case of 10 transformants (lanes 1-10 in 
Figure 22) and in 1900 bp fragments in the case of 3 transformants (lanes 11-13 in Figure 
22). The results are in agreement with expected fragments (see above). Transformant 9 
was further sequenced with T7-promoter and M13-reverse primers. The sequencing 
resulted in the correct sequences of the ABCC3 cDNA. 
 
 
 
 
 
 
 
 
4.2.3 Construction of the pcDNA3.1/Hygro(-)-MRP3 
 
For cloning the ABCC3 cDNA into the expression vector pcDNA3.1/Hygro(-), the 
expression vector and the pCR2.1-TOPO-MRP3-vector (orientation 2) were restricted 
with NotI and KpnI. These restriction sites are unique in both vectors and will cut out the 
ABCC3 cDNA from the pCR2.1-TOPO-MRP3-plasmid (orientation 2) and allow ligation 
of the fragment into pcDNA3.1/Hygro(-) (Appendix 3). The restricted fragments were 
 
 
 
 
 
 
 
Figure 22. Restriction analysis of the pCR2.1-TOPO-MRP3 
transformants Lanes 1-13 are BamHI restricted and lanes 14-27 are 
respective unrestricted plasmids. 
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purified and analyzed by agarose gel electrophoresis before the ligation (panel A in Figure 
23). Figure 23 (panel A) presents the restricted vector and the ABCC3 cDNA. The lengths 
of the fragments correspond to correct length of the empty vector pcDNA3.1/Hygro(-) 
(5600 bp) and the ABCC3 cDNA (4700 bp). The ABCC3 cDNA fragment was ligated 
into the pcDNA3.1/Hygro(-)-vector. Almost all analyzed transformants from the ligation 
reaction showed an insert compared to the empty pcDNA3.1/Hygro(-) (results not 
shown). Five of transformants were further analyzed by restriction analysis with BamHI 
(panel B in Figure 23). The ABCC3 cDNA contains two internal BamHI restriction site 
and the pcDNA3.1/Hygro(-) contains one (Appendix 3). Restriction analysis should result 
in the fragments of 7397 bp, 2524 bp and 294 bp in length. Restriction analysis of all five 
transformant resulted in the correct length fragments (panel B in Figure 23). 
The transformant 3 was further sequenced with T7-promoter, oMRP3-Clone-F, oMRP3-
seq1, oMRP3-seq2, oMRP3-seq3 and BGH-reverse primers. The sequencing covered the 
entire MRP3 coding sequence and no base pair exchange was found compared to 
published reference sequence (Genbank accession NM_003786).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. NotI and KpnI restricted empty pcDNA3.1/Hygro(-)-
vector (panel A, lane 1) and the ABCC3 cDNA (panel A, lane 2). 
BamHI restriction analysed empty pcDNA3.1/Hygro(-) (panel B, 
lane 1),  BamHI restriction analysed pcDNA3.1/Hygro(-)-MRP3 
transformants (panel B, lanes 2-6) and the respective unrestricted 
plasmids (panel B, lanes 7-11).  
A 
6 000 bp > 
4 000 bp > 
1 2 B 
6 000 bp > 
1 
3 000 bp > 
300 bp > 
10 5 
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4.3 Establishing MDCK-UGT1A1 and MDCK-UGT1A1-MRP2 cell lines 
 
The UGT1A1 cDNA was previously cloned into pcDNA3.1/Zeo(-) expression vector in-
house and thus there was  no need for the cloning of the UGT1A1 cDNA in this study 
(Fahrmayr et al. 2012). This vector was used to express UGT1A1 in MDCK and MDCK-
MRP2 cells. The newly established MDCK-UGT1A1 and MDCK-UGT1A1-MRP2 
could be further used for the transfection of the ABCC3 cDNA. 
 
4.3.1 Transfection of parental MDCK and MDCK-MRP2 cell with the UGT1A1 cDNA 
 
The pcDNA3.1/Zeo(-)-UGT1A1-vector was isolated from 
the storage culture and  a restriction analysis was carried 
out. The UGT1A1 cDNA contains an EcoRI restriction site 
and the pcDNA3.1/Zeo(-)-vector two EcoRI restriction 
sites at both ends of the cloned cDNA fragment (Appendix 
3). The restriction analysis should result in fragments of 
5100 bp, 920 bp and 730 bp in length. The restriction 
analysis corresponded to the expected fragments of the 
pcDNA3.1/Zeo(-)-UGT1A1-vector (Figure 24). The vector 
was further sequenced with T7-promoter and oUGT1A1-
seq1 primers. The sequencing verified the correctness of 
the entire UGT1A1 cDNA sequence compared to the 
reference sequence (GenBank accession NM_000463.2).  
The pcDNA3.1/Zeo(-)-vector includes the zeocin 
resistance gene that allows selection of the stable 
transfected cells from non-transfected cells using this 
antibiotic. After the transfection of parental MDCK and 
MDCK-MRP2 cells with the pcDNA3.1/Zeo(-)-UGT1A1, 
cells were passaged and cultured in various dilutions in 
media containing 500 µg/ml of zeocin (Table 23 and 24). This concentration was selected 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Restriction 
analysis of 
pcDNA3.1/Zeo(-)-
UGT1A1 with EcoRI. 
Lane 1 is EcoRI 
restricted 
pcDNA3.1/Zeo(-)-
UGT1A1 and lane 2 is 
unrestricted respective 
vector. 
3 000 bp > 
500 bp > 
1 2 
5 000 bp > 
1 000 bp > 
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based on the previously established MDCK-OATP1B1-UGT1A1 cell line transfected 
with the same vector (Fahrmayr et al. 2012). No cytotoxicity of zeocin to parental MDCK 
or MDCK-MRP2 cells was determined. No cytotoxicity of the transfection reagent was 
observed at any stage of the transfection.  
Zeocin did not have the desired effect on MDCK-MRP2 cells after the transfection with 
UGT1A1 cDNA because all transfection plates of the first passage grew confluent in 6 
days. To isolate single colonies of the cells, new passages and very high dilutions were 
carried out. In addition, zeocin concentration was increased to 1 mg/ml. Number of 
passages after the transfection and subdilution factors are presented in Table 23. Together 
93 colonies were isolated and 20 of them grew enough to produce a clone when MDCK-
MRP2 cells were transfected with the UGT1A1 cDNA. 
Table 23. Number of passages and factor of subdilutions for each passage after the 
transfection of MDCK-MRP2 with the UGT1A1 cDNA. In addition, number of colonies 
isolated from transfection plates and number of clones are presented.  
Number of the passage (the 
subdilution plate of the 
previous passage used for the 
new passage) 
Factor of 
the 
subdilution 
Colonies 
isolated 
Clones 
Days after the 
transfection 
to isolation of 
colonies 
1 (transfection) 1:5 0 0 - 
1 (transfection) 1:10 0 0 - 
1 (transfection) 1:20 0 0 - 
2 (1:10) 1:1000 12 3 16 
2 (1:10) 1:250 0 0  
3 (1:250) 1:100 
36 7 26-34 
3 (1:250) 1:25 
3 (1:1000) 1:50 0 0 - 
4 (1:50) 1:1000 
12 1 30 
4 (1:50) 1:500 
4 (1:100) 1:1000 
33 9 47-58 
4 (1:100) 1:250 
 
Zeocin had stronger effect to MDCK cells transfected with the UGT1A1 cDNA compared 
to transfected MDCK-MRP2 cells. The effect was strong enough to allow isolation of 
single colonies from the highest dilution of the first passage (Table 24). However, 
subsequent passages were done in higher dilutions to isolate more colonies and have 
higher probability to have a clone with sufficient expression of UGT1A1 mRNA. 
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Together 39 single colonies were isolated and 13 of them grew to produce a clone when 
parental MDCK cells were transfected with UGT1A1. 
Table 24. Number of passages and factor of subdilutions for each passage after the 
transfection of parental MDCK cells with UGT1A1 cDNA. In addition, number of 
colonies isolated and number of clones are presented. 
Number of the passage (the 
subdilution plate of the  
previous passaged used for 
the new passage) 
Factor of  
the 
subdilution 
Colonies 
isolated 
Clones  
Days after 
the 
transfection 
to isolation 
of colonies 
1 (transfection) 1:5 0 0 - 
1 (transfection) 1:10 0 0 - 
1 (transfection) 1:20 6 4 16 
2 (1:10) 1:500 0 0 - 
3 (1:500) 1:2000 10 7 30 
3 (1:500) 1:4000 14 0 36 
4 (1:1000) 1:1000 9 2 42 
 
4.3.2 UGT1A1 mRNA expression characterization in MDCK-UGT1A1 and MDCK-
UGT1A1-MRP2 cell lines 
 
Total RNA of each clone was isolated and reverse 
transcripted to sscDNA. The cDNA synthesis was 
evaluated with PCR amplification of the 661 bp 
fragment of β-actin cDNA. Representative 
amplification of β-actin cDNA fragments is 
presented in Figure 25. Analysis of UGT1A1 
mRNA expression was conducted only if the 
amplification of the β-actin cDNA fragment was 
successful. 
For the analysis of UGT1A1 mRNA expression, 
quantitative PCR was used to amplify a 311 bp 
fragment of the UGT1A1 cDNA. In addition, the 
β-actin cDNA fragment was amplified in each 
analysis. Linearity of the analysis was ensured by including four samples of 
 
 
 
 
 
 
 
 
 
Figure 25. Amplification of the 
661 bp fragment of β-actin cDNA 
from sscDNAs of MDCK-
UGT1A1#7 (lane 1), -#11 (lane 2), 
-#12 (lane 3), MDCK-UGT1A1-
MRP2#11 (lane 4) and -#12 (lane 
5). 
3 4 
1 000 bp > 
500 bp >  
1 2 5 
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pcDNA3.1/Zeo(-)-UGT1A1-vector in the range of 1-1000 pg in each run. Correlation 
coefficient of linearity was 1 in each analysis. In addition, the amount of amplified β-
actin cDNA fragments and, if expression of UGT1A1 cDNA was observed, the amount 
of the UGT1A1 cDNA fragments was ensured to be in the linear range. Melting curve and 
agarose gel analysis was also conducted for all amplified UGT1A1 cDNA fragments. 
Analysis showed in each case identical melting curve and migration in agarose gel 
electrophoresis compared to standard samples. Representative agarose gel electrophoresis 
analysis of qPCR amplified cDNAs is shown in Figure 26.  
Together 13 clones of MDCK-UGT1A1 and 20 clones of MDCK-UGT1A1-MRP2 cell 
lines were analysed with qPCR. Four clones of MDCK-UGT1A1 showed significant 
expression of UGT1A1 cDNA (>1%) when normalized to expression of β-actin cDNA. 
Expression of UGT1A1 mRNA in these clones is summarized in Table 25. Expression of 
UGT1A1 mRNA was observed in none of clones of MDCK-UGT1A1-MRP2, in MDCK-
VC (empty vector transfected) or in parental MDCK cells. In addition, a 284 bp fragment 
of ABCC2 mRNA was amplified in a couple of analysis of MDCK-UGT1A1-MRP2 cell 
line clones. Expression of ABCC2 cDNA in MDCK-MRP2 cells and in four analysed 
clones of MDCK-UGT1A1-MRP2 were 83 % and 79-89 % of the expression of β-actin 
cDNA, respectively. In addition, no ABCC2 cDNA expression was observed in MDCK-
VC cells. 
 
 
 
 
 
 
 
 
 
 
Figure 26. A representative agarose gel analysis of qPCR amplified UGT1A1, ABCC2 
and β-actin cDNA fragments from sscDNAs of UGT1A1 clones. Lanes 1-4 are 1000-
1 pg standards of the vector pcDNA3.1/Zeo(-)-UGT1A1. Lanes 5-10, 11-16 and 17-22 
are amplification of fragments of UGT1A1 (311 bp), ABCC2 (284 bp) and β-actin (661 
bp) cDNA from MDCK-UGT1A1#7, -#11, -12#, UGT1A1-MRP2#11, -#12 and 
control (water) samples, respectively. 
1 000 bp > 
600 bp > 
1 5 11 17 
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Table 25. Expression of UGT1A1 mRNA in MDCK-UGT1A1 clones 2, 4, 7 and 8. The 
expression of UGT1A1 mRNA is normalized to expression of β-actin mRNA. 
Clone 
mRNA expression of 
UGT1A1/β-actin 
Relative mRNA expression of 
UGT1A1 
MDCK-UGT1A1#2 2 % 0.01 
MDCK-UGT1A1#4 307 % 2.05 
MDCK-UGT1A1#7 150 % 1 
MDCK-UGT1A1#8 3 % 0.02 
 
4.3.3 Immunoblot analysis of UGT1A1 protein expression in the MDCK-UGT1A1#4 
and MDCK-UGT1A1#7 cell lines 
 
 Two clones with the highest 
expression of UGT1A1 mRNA were 
further characterized at the protein 
expression level by immunoblot 
analysis. UGT1A1 was detected in 
both analysed clones but not in the 
control cells (Figure 27). In addition, 
UGT1A1 showed the correct, 
approximately 55 kDa molecular 
weight (Lévesque et al. 2007). 
 The same membrane was used for the 
analysis of β-actin expression after 
stripping off the previous antibodies (Figure 28).  
In addition, intensities of UGT1A1 bands and β-actin bands were measured. Relative β-
actin expressions were 1.10, 1.00 and 1.13 in MDCK-UGT1A1#4, MDCK-UGT1A1#7 
and MDCK-VC cells, respectively. Relative UGT1A1 expressions were 1.89 and 1.00 in 
MDCK-UGT1A1#4 and MDCK-UGT1A1#7 cells, respectively. There were no 
significant differences in the β-actin expression levels between three analysed samples. 
In addition, the expression of UGT1A1 protein was quite comparable to mRNA 
expression levels of UGT1A1 in both clones (Table 25). 
 
 
 
 
 
 
 
 
Figure 27. Immunoblot analysis of UGT1A1 
in SDS-polyacrylamide gel electrophoresis 
separated and membrane transferred protein 
homogenates. Lane 1 is MDCK-UGT1A1#4, 
lane 2 is MDCK-UGT1A1#7 and lane 3 is 
MDCK-VC. 
2 3 1 
35 kDa > 
55 kDa > UGT1A1 
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5.  DISCUSSION 
 
5.1 Cloning of the human UGT2B7 cDNA 
 
For the establishment of UGT2B7 expressing cell lines, first the UGT2B7 cDNA has to 
be cloned. Several methods were tried, but none of the methods were successful and no 
cloning of this cDNA was achieved. Several research groups have already cloned the 
human UGT2B7 cDNA earlier, and thus this process should be repeatable with our 
methods (Ritter et al. 1990; Jin et al. 1993; Coffman et al. 1997; Kurkela et al. 2003). In 
addition, the UGT2B7 mRNA is highly and equally expressed in both human kidney and 
liver (Court et al. 2012). Thus, it was expected that amplification of this cDNA from total 
kidney sscDNA would result in the correct length amplification (Figure 7). However, it 
was quite unexpected that several attempts for amplification of this cDNA from total liver 
sscDNA did not result in any successful amplification. One explanation for unsuccessful 
amplifications, when using total liver sscDNA as template, could be the quality of the 
RNA that was used as the template for sscDNA synthesis. In this study, the liver sscDNA 
was synthesized by using commercially available total liver RNA as the template. 
However, storage and handling of RNA could have resulted in degradation and loss of 
 
 
 
 
 
 
 
 
Figure 28. Immunoblot analysis of β-actin in 
the same membrane as in Figure 27 after 
stripping of UGT1A1 antibody. Lane 1 is 
MDCK-UGT1A1#4, lane 2 is MDCK-
UGT1A1#7 and lane 3 is MDCK-VC. 
2 3 1 
35 kDa > 
55 kDa > 
β-actin 
  82  
 
   
integrity of the RNA and subsequently poor quality of the total liver sscDNA (Holland et 
al. 2003). 
Although, no amplification of the UGT2B7 cDNA was achieved using liver sscDNA as 
the template, an amplification product using kidney sscDNA as template was achieved 
(Figure 7). However, when this cDNA fragment was subcloned and a pair of 
transformants was sequenced, no UGT2B7 sequence was found. Instead, a sequence that 
gave a full correct alignment with a part of the pcDNA3.1-expression vector was found. 
This strange finding could be a result of contamination of the cloning reactions, or 
reaction components, with pcDNA3.1-vector. Even if very low DNA amounts, such as 
ten femtograms are present, plasmid DNA could be transformed into competent cells 
(Hanahan 1983). 
In addition to liver and kidney sscDNA, the UGT2B7 cDNA was tried to amplified using 
in-house available pGEM-T-UGT2B7(802C)-vector as the template. This was not used 
as the first option, because this vector contains a base pair exchange (T802C) in the 
UGT2B7 cDNA, which results in an amino acid change compared to the reference 
sequence. However, despite several attempts, only one successful amplification was 
achieved although the used template was well defined. Because the template vector for 
the amplification was circular plasmid DNA, it is possible that this supercoiled 
conformation of the vector inhibited the amplification reaction and caused unsuccessful 
amplifications (see also 5.4). Therefore, linearization of the pGEM-T-UGT2B7(802C)-
vector with a single cutting enzyme, outside of the UGT2B7 cDNA, could have aided the 
amplification. However, despite difficulties in amplification of the UGT2B7 cDNA using 
the vector pGEM-T-UGT2B7(802C), a successful amplification was achieved and the 
cDNA fragment was cloned (Figure 9). Subcloning was followed by a sequencing of a 
pair of transformants. The results of sequencing corresponded to sequencing results from 
the cloning reaction of the amplified kidney sscDNA amplified fragment (4.1.1). This 
suggests that this cloning reaction was also contaminated with pcDNA3.1-expression 
vector (see above). 
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5.2 Construction of the expression vector containing the UGT2B7 cDNA 
 
Because all attempts to amplify UGT2B7 cDNA were unsuccessful, ligation and 
restriction based cloning of the UGT2B7 cDNA fragment was attempted by utilizing the 
in-house available vector pGEM-T-UGT2B7(802C) and using unique restriction sites in 
this vector and in the expression vector pcDNA3.1. For the first strategy, 
pcDNA3.1/Hygro(-) was chosen for the expression of the UGT2B7 cDNA because this 
vector contains a different antibiotic selection gene than the expression vector containing 
the ABCC2 cDNA encoding MRP2. This strategy would allow construction of MRP2 and 
UGT2B7 double-transfected cell lines. However, the subcloning was possible only with 
one pair of single cutting restriction enzymes, ApaI and BstXI. Despite several attempts, 
no correct construct of the expression vector containing the UGT2B7 cDNA was achieved 
(4.1.3). A possible explanation for the unsuccessful subclonings could be that BstXI 
recognizes discontinuous palindromic target sequence (CCANNNNNNTGG, N = A or 
C). This target sequence is CCAACGCGTTGG in the vector pGEM-T-UGT2B7(802C) 
and CCACCACACTGG in the vector pcDNA3.1/Hygro(-). This strongly suggests that 
the restriction did not result in fully compatible sticky ends, which could explain 
unsuccessful subcloning reactions. 
It was also possible to use NotI restriction sites for the subcloning of the UGT2B7 cDNA 
into pcDNA3.1/Hygro(-). One restriction site is located in the multiple cloning site of the 
expression vector pcDNA3.1/Hygro(-). However, NotI is not a unique restriction site in 
the vector pGEM-T-UGT2B7(802C) but it is located at both ends of the UGT2B7 cDNA 
and restriction with it will release UGT2B7 cDNA fragment ready for subcloning. 
Ligation reaction of the above DNA fragment would result in two possibilities of the 
orientation of the cDNA fragment in the expression vector. In addition, this cloning 
strategy demands a dephosphorylation reaction for the vector as an additional step before 
the ligation reaction. Religations of the expression vector would prevent the desired 
ligation if no dephosphorylation of the free phosphate ends of the restricted expression 
vector were conducted. However, this did not cause any difficulties because even the 
amount of potential religations were higher than when using the other cloning strategy, it 
was not still dominating among analysed transformants (Figure 13). Unfortunately, this 
cloning strategy did not lead to any correct constructs of pcDNA3.1/Hygro(-)-UGT2B7. 
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All potential transformants were analysed by restriction analysis and some of them were 
sequenced, but the outcome was that they did contain neither the expression vector 
pcDNA3.1/Hygro(-) not the UGT2B7 cDNA. The identity of these transformants stayed 
unknown.  
The final strategy for subcloning of the UGT2B7 cDNA was to use the expression vector 
pcDNA3.1/Zeo(-). This expression vector contains a different antibiotic resistance gene 
than pcDNA3.1/Hygro(-), but it is also different than in the expression vector containing 
ABCC2 cDNA encoding MRP2. This would allow not only the construction of UGT1A1 
and MRP2 double-transfected cell lines but also of a triple-transfected cell line with 
MRP3, if the ABCC3 cDNA encoding MRP3 is cloned into pcDNA3.1/Hygro(-) 
expression vector (4.2.3). Nevertheless, subcloning of the UGT2B7 cDNA into 
pcDNA3.1/Zeo(-) was attempted with ApaI and PstI restrictions of the vectors pGEM-T-
UGT2B7(802C) and pcDNA3.1/Zeo(-) and subsequently ligating the restricted DNA 
fragments. These restriction sites are unique for both vectors and allow subcloning of the 
UGT2B7 cDNA in the correct orientation into the expression vector. However, almost all 
analysed transformants showed the same length as the empty expression vector. This 
indicates that the expression vector religated with itself and no UGT2B7 cDNA was 
ligated into the cloning site. Although two different restriction enzymes were used for the 
subcloning and no religation should happen. Possibly, one of the restriction enzymes did 
not work properly and resulted in only single restricted expression vector. This could be 
caused for example by old stock of the enzyme. A defective enzyme would lead in high 
amount of religated expression vectors and suppress the desired ligation. However, one 
transformant showed promising length compared to the empty expression vector, when 
using this cloning strategy. The sequencing of this transformant resulted only in genomic 
E.coli DNA, which suggests that a recombination event took place in the competent cells, 
and no correct construct of the UGT2B7 cDNA in the expression vector was present. 
For all above mentioned subcloning strategies, restriction and ligation based cloning 
methods were used. However, restriction free cloning technique is also available (e.g. van 
den Ent and Löwe 2006 and Unger et al. 2010). Briefly, in this method the cDNA of 
interest is PCR amplified with specific primers and subsequently ligated into circular 
vector via a second PCR reaction. Finally, the empty vector is digested and the correct 
construct is transformed into bacterial cells. This cloning strategy could be used in future 
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attempts for the construction of the expression vector containing UGT2B7 cDNA. 
 
5.3 Site-directed mutagenesis of the vector pcDNA3.1/Zeo(-)-UGT2B7(1575T) 
 
UGT2B7 cDNA was already cloned earlier in-house into the expression vector 
pcDNA3.1/Zeo(-). However, this vector contained a base pair exchange (A1575T) 
resulting in a premature stop codon compared to the reference sequence of the UGT2B7 
cDNA (Genbank accession NM_001074.2) and thus was not employed as the first option. 
A site-directed mutagenesis reaction is quite easily conducted with commercially 
available kits that implement standardized methods (Ling and Robinson 1997). However, 
despite multiple attempts with two different commercially kits, no correct site-directed 
mutagenesis of the plasmid was achieved. The main problem with the QuickChange 
multi-site-directed mutagenesis kit was the high amount of colonies after the 
transformation of the reaction. This could be a result of unsuccessful restriction of the 
template vector pcDNA3.1/Zeo(-)-UGT2B7(1575T) after the PCR. This could hindered 
the detection of the desired transformants, because of high amount of the unrestricted 
template among all transformants. However, the restriction enzyme was tested in a 
separate reaction and it worked properly (results not shown). Interestingly, site-directed 
mutagenesis reactions with the QuickChange II site-directed mutagenesis kit resulted in 
almost no colonies after the transformation of the reactions. When the reaction conditions 
were modified, higher amount of colonies were achieved and some of them showed the 
correct base pair exchange but also major deletions after of before the mutagenesis primer 
binding sites. This observation strongly suggests that the major problem in the site-
directed mutagenesis reactions were strong interactions between the two DNA strands in 
the vector, which resulted in poor binding of the primers and DNA-polymerase. Poor 
binding could result in no amplification or partial amplification resulting in deletion of 
parts of the vector. In addition, we contacted the manufacturer of the mutagenesis kits 
(Agilent) regarding the difficulties of the site-directed mutagenesis reaction. Their answer 
was that other customers had also difficulties, when conducting mutagenesis reaction for 
pcDNA3.1-vectors indicating that the difficulties were caused by strong interactions 
between DNA strands in the vector. Further optimization of the site-directed mutagenesis 
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reaction variables such as concentration of DMSO and PCR conditions could possibly 
result in successful reaction (Ling and Robinson 1997). In addition, several other 
commercially site-directed mutagenesis kits are available and could be used for the 
correction of the base pair exchange. 
 
5.4 Cloning of the human ABCC3 cDNA encoding MRP3 
 
The first step for establishment of MRP3 expressing cell lines is cloning of the ABCC3 
cDNA that encodes MRP3. Earlier several groups have cloned the ABCC3 cDNA 
encoding MRP3 using liver sscDNA as the template (Kiuchi et al. 1998; Kool 1999; 
König et al. 1999a; Paumi et al. 2003). Therefore, the amplification of the full-length 
ABCC3 cDNA using liver sscDNA as the template was also attempted in this study. 
However, no success was achieved despite multiple reactions (Figure 19). As second 
strategy, ABCC3 cDNA was attempted to be amplified in two cDNA fragment, which is 
easier than the amplification of the full length 4600 bp cDNA. No correct amplifications 
were achieved either with this strategy (Figure 20). As discussed in the case of UGT2B7 
cDNA amplification, the quality of the sscDNA is important for correct amplification of 
the cDNA of interest. However, in the case of ABCC3 cDNA, the amount of G and C-
bases (GC-content) could also be a significant factor affecting the amplification. The GC-
content of the ABCC3 cDNA is 58 % whereas it is 41 % for the UGT2B7 cDNA. Average 
GC-content of the human genome is 41 %, so the ABCC3 cDNA could be considered as 
a GC-rich fragment (Lander et al. 2001). PCR amplifications of GC-rich templates could 
need optimization of PCR conditions, but also additives such as glycerol, DMSO or 
betaine (Varadaraj and Skinner 1994; Jensen et al. 2010). In this study 3 % DMSO was 
tried as additive in the amplification reaction without any success. However, even 10-15 
% DMSO concentrations were previously used in PCR reactions (Varadaraj and Skinner 
1994). 
Finally, ABCC3 cDNA was successfully amplified using a well-defined template, the 
plasmid pMA-MRP3 (from Dr. Markus Keiser, University of Greifswald, Germany). 
However, amplification of the full-length cDNA fragment was achieved only when the 
plasmid was first linearized with a restriction enzyme. When the non-linearized plasmid 
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was used as template for the amplification, only the 3’-part of the ABCC3 cDNA was 
amplified successfully. This supports the idea that GC-richness causes strong interactions 
between two DNA strands of the ABCC3 cDNA and the interactions are especially strong 
at the start of the cDNA. For example, if the first 40 base pairs starting from the first base 
of the oMRP3-F binding site are analysed, the GC-content is as high as 75 %. 
The amplification of the ABCC3 cDNA was finally achieved and it was successfully 
cloned into the expression vector pcDNA3.1/Hygro(-) and the correctness of the sequence 
was verified by sequencing and it corresponded to the reference sequence (Genbank 
accession NM_003786). This successful cloning strongly suggests that materials and 
methods used for all cloning reactions during this study in principle were proper and 
worked well. This also indicated that the difficulties with sscDNA clonings of UGT2B7 
and ABCC3 cDNAs were associated more with the template and/or with the sequence 
itself. In addition, subcloning issues of the UGT2B7 cDNA could be associated mainly 
with the cDNA itself, because the ABCC3 cDNA was cloned in the same expression 
vector as the UGT2B7 cDNA was attempted to be cloned and also the same DNA ligation 
and purification methods were used. However, in the case of UGT2B7 cDNA, restriction 
reactions and enzymes might also have been the cause for difficulties (see 5.2). 
 
5.5 Establishing MDCK-UGT1A1 and MDCK-UGT1A1-MRP2 cell lines 
 
For the establishment of single- and double-transfected UGT1A1 cell lines, the already 
established expression vector containing the UGT1A1 cDNA was used (Fahmayr et al. 
2012). In this study, the same expression vector and methods were used to establish 
MDCK-UGT1A1 and MDCK-UGT1A1-MRP2 cell lines as in the previous study for 
MDCK-OATP1B1-UGT1A1-MRP2 cell line. However, unexpected difficulties were 
faced with double-transfected cells, because the selection antibiotic zeocin did not 
properly inhibit the growth of the transfected cells when MRP2 was present, even if the 
concentration of zeocin was the same as in the previous study (Fahrmayr et al. 2012). 
Subsequently, the concentration of zeocin was increased from 0.5 mg/ml to 1 mg/ml for 
MDCK-UGT1A1-MRP2 transfected cells, which resulted in better selection of single 
colonies. Despite concentration increment, no cell clones expressing UGT1A1 mRNA 
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were achieved for double-transfected cells. Proper expression of UGT1A1 was achieved 
for two clones of single transfected cells. 
An explanation for this unsuccessful transfection of MDCK-MRP2 cells with the 
UGT1A1 cDNA could be the expression of efflux transporter MRP2. It could be that 
MRP2 transports zeocin out of the cells and thus it decreases antibiotic effect. This should 
be investigated with further studies by determinating the concentration dependent 
cytotoxicity of zeocin to parental and MRP2 transfected MDCK cells. However, this does 
not explain why Fahrmayr and coworkers (2012) were able to establish MDCK-
OATP1B1-UGT1A1-MRP2 cell line. On the other hand, they were not able to establish 
MDCK-OATP1B3-UGT1A1-MRP2 cell line because exactly the same difficulties with 
zeocin as in this study (unpublished observation by Christina Fahrmayr 2012). It could 
be speculated that OATP1B1 contributes to transport of zeocin and concentrates it into 
cells even if MRP2 transports it out of cells. However, this has to be clarified. In the 
future, the MDCK-UGT1A1-MRP2 cell line could be attempted to establish by 
transfection of MDCK-UGT1A1 cell line, which was established in this study, with the 
expression vector containing ABCC2 cDNA encoding MRP2 and G418 resistance gene. 
On the other hand, establishment of MDCK-UGT1A1-MRP2 cell line was recently 
published using hygromycin as the selection antibiotic in the expression vector containing 
the UGT1A1 cDNA (Ge et al. 2015). However, characterization of this cell line was not 
published in the study and no further conclusions of the expression of UGT1A1 in it could 
be drawn. 
Establishment of MDCK-UGT1A1 cell line in this study was successful and protein and 
mRNA expression level of UGT1A1 were characterized. In the studies of Fahrmayr and 
co-workers (2012 and 2013), mRNA expression level of UGT1A1 was reported to be 
approximately 50 %, 250 % and 180 % of β-actin mRNA expression level in MDCK-
OATP1B1-UGT1A1, MDCK-OATP1B1-UGT1A1-MRP2 and MDCK-OATP1B1-
CYP3A4-UGT1A1-MRP2 cell lines, respectively. The expression levels of UGT1A1 
mRNA found in this study, 150 % and 300 % of β-actin mRNA expressions, are in the 
same range as in the previous study. However, none of the MDCK-UGT1A1-MRP2 
clones and most of the MDCK-UGT1A1 clones did not express sufficient amounts of 
UGT1A1 mRNA although they were resistant to zeocin. In addition to the possible 
contribution of MRP2 to zeocin resistance (see above), integration of the transfected 
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cDNA into the genome of cells plays a role key for obtaining sufficient expression of the 
cDNA of interest after the transfection (Büssow et al. 2015). Because the integration is 
unpredictable and could be of low frequency, it might be one of the reasons for 
insufficient expression of UGT1A1 mRNA in most of the clones analysed in this study. 
 
5.6 Future prospects  
 
Multi-transfected cell lines expressing drug transporters and metabolizing enzymes are 
recognized as valuable tools for in vitro evaluation of drug transport and metabolism 
(Brouwer et al. 2013; Zamek-Gliszczynski et al. 2014). The most advanced models 
available at the moment are double-transfected cell lines MDCK-OATP1B1/3-MRP2, 
triple-transfected cell lines MDCK-OATP1B1-MRP2-MRP3, MDCK-OATP1B1-
MRP2-MRP4 and MDCK-OATP1B1-UGT1A1-MRP2, and quadruble-transfected cell 
lines MDCK-OATP1B1-CYP3A4-UGT1A1-MRP2 and MDCK-OATP1B1-OATP1B3-
OATP2B1-MRP2 (Cui et al. 2001; Fehrenbach et al. 2003; Kopplow et al. 2005; Hirouchi 
et al. 2009; Fahrmayr et al. 2012 and Fahrmayr et al. 2013). However, there are no reports 
of cell lines expressing both basolaterally localized MRP3 and any UGT or any cell lines 
co-expressing UGT2B7 with a transporter. The expression vector containing ABCC3 
cDNA encoding MRP3 was established in this study. In addition, MDCK-UGT1A1 cell 
line was established. Both of these could be used in the future for the establishment of a 
MDCK-UGT1A1-MRP3 cell line and further for the establishment of a MDCK-
UGT1A1-MRP2-MRP3 cell line. This cell line could be a valuable tool for understanding 
the interplay between glucuronidation and basolateral efflux transport and to identify 
substrates and inhibitors for both efflux transporters MRP2 and MRP3 and for the drug 
metabolizing enzyme UGT1A1. Although, no expression vector containing UGT2B7 
cDNA could be established in this study, despite several different strategies and attempts, 
there are still several methods available for the construction of the expression vector and 
subsequent expression of UGT2B7 in MDCK cells. 
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6.  CONCLUSIONS 
 
Cloning of the UGT2B7 cDNA and construction a mammalian expression vector 
containing this cDNA for the subsequent expression of UGT2B7 in MDCK cells for drug 
metabolism studies were attempt in this study without success. ABCC3 cDNA encoding 
the efflux transporter MRP3 was successfully cloned into mammalian expression vector 
that could be used in future experiments for the expression of MRP3 in MDCK cells or 
other mammalian cells for drug metabolism studies. In addition, a novel cell line MDCK-
UGT1A1 was established and it could be used for drug metabolism studies and more 
importantly, for the coexpression of drug efflux transporters such as MRP3 and MRP2. 
These cell lines could be used for studying the interplay between glucuronidation and 
efflux transport of drug molecules and drug candidates. 
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APPENDIX 1  
Recipes and concentrations of the reagent solutions. 
 
Final concentration of the reagents are presented in the parenthesis. All the reagents and 
materials used here are presented in MATERIALS AND METHODS. 
 
Agarose gel 0.8 % 
1.6 g  Agarose       (0.8 %) 
Ad. 200 ml 1X TAE-buffer 
Boil the agarose solution in the microwave oven, cool it down to approximately 50 °C 
and cast the gel. 
 
Agarose gel 1.5 % 
3 g  Agarose       (1.5 %) 
Ad. 200 ml 1X TAE-buffer 
Boil the agarose solution in the microwave oven, cool it down to approximately 40 °C 
and cast the gel. 
 
1X TAE-buffer 
242 g  TRIS-Base       (40 mM) 
57.1 g  Acetic Acid       (19 mM) 
18.61 g EDTA disodium salt dehydrate    (1 mM) 
Ad. 1 l  Water 
Adjust pH to 8 with 32 % hydrochloric acid. 
Dilute in the multiple of 50 with water before use to give 1X TAE. 
 
STET  
8 g   Saccharose        (8 %) 
5 g   Triton X 100       (5 %) 
5 ml   500 mM TRIS-HCl water solution pH 8.0   (25 mM)  
5 ml   500 mM EDTA water solution pH 8.0   (25 mM)  
Ad. 100 ml Water 
    
STETL 
5 ml  STET solution 
50 µl  50 mg/ml (1 000 000 U/ml) lysozyme water solution  (10 000 U/ml) 
 
10 % Running gel 
50 µl  10 % SDS water solution     (0.1 %) 
25 µl  10 % APS water solution     (0.05 %) 
2.5 µl  TEMED       (0.05 %) 
1.25 ml 1.5 M TRIS-HCl water solution pH 8.8   (370 mM) 
1.65 ml 30 % Acrylamide/Bis-acrylamide solution   (10 %) 
2.05 ml Water 
 
4 % Stacking gel 
25 µl  10 % SDS water solution     (0.1 %) 
25 µl  10 % APS water solution     (0.1 %) 
2.5 µl  TEMED       (0.1 %) 
0.625 ml 500 mM TRIS-HCl water solution pH 6.8   (125 µM)  
0.325 ml 30 % Acrylamide/Bis-acrylamide solution   (4 %) 
1.525 ml Water   
 
Transfer buffer 
3.034 g TRIS-Base       (25 mM) 
14.42 g Glycin        (190 mM) 
200 ml  Methanol       (20 %) 
Ad. 1000 ml Water 
 
1X Running buffer 
30.25 g TRIS-Base       (25 mM) 
144 g  Glycin        (190 mM) 
10 g  SDS        (0.1 %)  
Ad. 1000 ml Water 
    
Dilute 10 times with water before use. 
 
6X Lämmli buffer 
3.0 g  SDS        (12 %) 
15 g  Glycerol       (60 %) 
3.0 ml  500 mM TRIS-HCl water solution pH 6.8   (60 mM) 
100 mg Bromophenol blue      (0.4 %) 
Ad. 25 ml Water 
 
4X Loading buffer 
80 µl  5 X Lämmli buffer      (4X) 
20 µl  2 M DTT water solution     (400 mM)  
 
PBST 
100 ml  10X PBS water solution prepared using commercial PBS powder  
          (1X) 
1 ml  Tween 20       (0.1 %) 
Ad. 1000 ml Water 
 
5 % Milk 
5 g  Milk powder       (5 %) 
Ad. 100 ml PBST 
 
Protein staining solution 
0.2 g  Ponceau S       (0.2 %) 
3 g  Trichloroacetic acid      (3 %) 
Ad. 100 ml Water 
 
 
 
 
    
APPENDIX 2  
Recipes and concentrations of the cell and bacterial media and related solutions. 
 
Final concentration of the reagents are presented in the parenthesis. All the reagents and 
materials used here are presented in MATERIALS AND METHODS. 
 
Agar Plates with 100 µg/ml ampicillin 
40 g  LB-Agar       (4 %) 
Ad. 1 l  Water 
Autoclave and add 2 ml of 50 mg/ml ampicillin water solution when agar solution is 
cooled down to approximately 40 °C and pour to petri plates immediately. 
 
LB-media with 50 µg/ml ampicillin 
25 g  LB-medium       (2.5 %) 
Ad. 1 l  Water 
Autoclave and add 1 ml of 50 mg/ml ampicillin water solution just before use.  
 
500 mM sodium butyrate solution 
2.75 g  Sodium butyrate      (500 mM) 
Ad. 50 ml DPBS 
Sterile filter with 0.2 µm syringe filter. 
 
G418 solution 
5 g  G418        (0.1 g/ml) 
Ad. 50 ml DPBS 
Sterile filter with 0.2 µm syringe filter. 
 
FBS 
500 ml of FBS is thawed in room temperature, heat inactivated for 30 minutes at 56˚C 
water bath and divided in aliquots which are stored at -20 °C. 
 
 
    
Cell culture media for parental MDCK cells (MEM-PS) 
500 ml  MEM 
55 ml  FBS        (10 %)  
5.7 ml  Penicillin (10 000 U/ml) and Streptomycin (10 mg/ml) solution in PBS 
           (1 %) 
 
Cell culture media for MDCK-MRP2 and MDCK-VC cells (MEM-PS-G418) 
500 ml  MEM 
55 ml  FBS         (10 %) 
5.7 ml  Penicillin (10 000 U/ml) and Streptomycin (10 mg/ml) solution in PBS  
          (1 %) 
4.6 ml  G418 0.1 g/ml       (0.8 mg/ml) 
 
Cell culture media for MDCK UGT1A1 cells (MEM-PS-Zeocin) 
500 ml  MEM 
55 ml  FBS         (10 %) 
5.7 ml  Penicillin (10 000 U/ml) and Streptomycin (10 mg/ml) solution in PBS  
          (1 %) 
2.85 ml Zeocin 100 mg/ml in water       (0.5 mg/ml) 
 
Cell culture media for MDCK-MRP2-UGT1A1 cells (MEM-PS-G418-Zeocin) 
500 ml  MEM 
55 ml  FBS         (10 %) 
5.7 ml  Penicillin (10 000 U/ml) and Streptomycin (10 mg/ml) solution in PBS 
          (1 %) 
4.6 ml  G418 0.1 g/ml       (0.8 mg/ml) 
5.7 ml  Zeocin 100 mg/ml in water       (1 mg/ml) 
 
 
 
 
    
APPENDIX 3  
Charts of the plasmids used in the study including selected restriction enzymes, primer 
binding sites and sizes of the plasmids 
 
Charts of the plasmids pCR2.1-TOPO-UGT2B7, pGEM-T-UGT2B7, 
pcDNA3.1/Hygro(-), pcDNA3.1/Hygro(-)-UGT2B7 (correct orientation), 
pcDNA3.1/Hygro(-)-UGT2B7 (wrong orientation), pcDNA3.1/Zeo(-), pcDNA3.1/Zeo(-
)-UGT2B7, pCR2.1-TOPO-MRP3 (orientation 1), pCR2.1-TOPO-MRP3 (orientation 2), 
pcDNA3.1/Hygro(-)-MRP3 and pcDNA3.1/Zeo(-)-UGT1A1 are presented in Figures 1-
11, respectively. Table 1-11 present location of the restriction sites and binding sites of 
the primers in the respective plasmids. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chart of the plasmid pCR2.1-TOPO-UGT2B7. Restriction sites used in this 
study are indicated. In addition, position of the UGT2B7 cDNA, ampicillin resistance 
gene (AmpR) and primer binding sites are indicated (created in www.benchling.com). 
Table 1. Selected restriction sites and primer binding sites in the plasmid pCR2.1-TOPO-
UGT2B7. 
 
 
 
 
 
Restriction site Start site Primer Start site 
BamHI 253 oUGT2B7-F 315 
BamHI 1461 oUGT2B7-seq1 1032 
EcoRI 284 oUGT2B7-R 1919 
EcoRI 1641 T7-promoter 2012 
EcoRI 1950   
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Chart of the plasmid pGEM-T-UGT2B7(802C). Restriction sites used in this 
study are indicated. In addition, position of the UGT2B7 cDNA, ampicillin resistance 
gene (AmpR) and primer binding sites are indicated (created in www.benchling.com). 
Table 2. Selected restriction sites and primer binding sites in the plasmid pGEM-T-
UGT2B7(802C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Restriction site Start site Primer Start site 
ApaI 15 T7-promoter 3 
BstXI 1754 oUGT2B7-F 83 
NotI 44 oUGT2B7-seq1 800 
NotI 1713 oUGT2B7-seq2 1339 
PstI 1724 oUGT2B7-Clone-R 1658 
    
Figure 3. Chart of the vector pcDNA3.1/Hygro(-). Restriction sites used in this study are 
indicated. In addition, positions of ampicillin resistance gene (AmpR), hygromycin 
resistance gene (HygroR) and cytomegalovirus promoter (CMVp) are indicated (created 
in www.benchling.com). 
Table 3. Selected restriction sites sites in the vector pcDNA3.1/Hygro(-). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Chart of the vector pcDNA3.1/Hygro(-)-UGT2B7 (correct orientation). 
Restriction sites used in this study are indicated. In addition, positions of ampicillin 
resistance gene (AmpR), hygromycin resistance gene (HygroR), cytomegalovirus 
promoter (CMVp) and T7-promoter primer are indicated (created in 
www.benchling.com). 
Table 4. Selected restriction sites and primer binding sites in the vector 
pcDNA3.1/Hygro(-)-UGT2B7 (correct orientation). 
 
 
Restriction site Start site Restriction site Start site 
ApaI 914 EcoRI 955 
BamHI 978 EcoRI 2361 
BstXI 941 KpnI 994 
BstXI 967 NotI 928 
Restriction site Start site Restriction site/Primer Start site 
BamHI 2113 EcoRI 2624 
BamHI 2647 EcoRI 4030 
EcoRI 937 NotI 928 
EcoRI 2293 NotI 2597 
EcoRI 2590 T7-promoter 882 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Chart of the vector pcDNA3.1/Hygro(-)-UGT2B7 (wrong orientation). 
Restriction sites used in this study are indicated. In addition, positions of ampicillin 
resistance gene (AmpR), hygromycin resistance gene (HygroR), cytomegalovirus 
promoter (CMVp) and T7-promoter primer are indicated (created in 
www.benchling.com). 
Table 5. Selected restriction sites and primer binding sites in the vector 
pcDNA3.1/Hygro(-)-UGT2B7 (wrong orientation). 
 
 
 
 
 
 
 
 
Restriction site Start site Restriction site/Primer Start site 
BamHI 1412 EcoRI 2624 
BamHI 2647 EcoRI 4030 
EcoRI 937 NotI 928 
EcoRI 1232 NotI 2597 
EcoRI 2590 T7-promoter 882 
    
  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Chart of the vector pcDNA3.1/Zeo(-). Restriction sites used in this study are 
indicated. In addition, positions of ampicillin resistance gene (AmpR), zeocin resistance 
gene (ZeoR) and cytomegalovirus promoter (CMVp) are indicated (created in 
www.benchling.com). 
Table 6. Selected restriction site sites in pcDNA3.1/Zeo(-). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Restriction site Start site 
ApaI 914 
BamHI 978 
EcoRI 955 
PstI 954 
    
Figure 7. Chart of the vector pcDNA3.1/Zeo(-)-UGT2B7. Restriction sites used in this 
study are indicated. In addition, positions of ampicillin resistance gene (AmpR), zeocin 
resistance gene (ZeoR), cytomegalovirus promoter (CMVp) and primers are indicated 
(created in www.benchling.com). 
 
Table 7. Selected restriction sites and primer binding sites in pcDNA3.1/Zeo(-)-UGT2B7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Chart of the plasmid pCR2.1-TOPO-MRP3 (orientation 1). Restriction sites 
used in this study are indicated. In addition, positions of ampicillin resistance gene 
(AmpR) and primers are indicated (created in www.benchling.com). 
Table 8 Selected restriction sites and primer binding sites in the plasmid  pCR2.1-TOPO-
MRP3 (orientation 1). 
 
Restriction site Start site Restriction site/Primer Start site 
ApaI 914 EcoRI 2595 
BamHI 2133 PstI 2594 
BamHI 2618 T7-promoter 882 
EcoRI 950 oUGT2B7-seq2 2243 
EcoRI 2313 oUGT2B7-Mut-F 2477 
  oUGT2B7-Mut-R 2523 
Restriction site Start site Restriction site/Primer Start site 
BamHI 253 NotI 4922 
BamHI 2108 M13-reverse 221 
BamHI 2402 oMRP3-F 312 
KpnI 245 oMRP3-RT-R 4867 
  T7-promoter 4957 
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Chart of the plasmid pCR2.1-TOPO-MRP3 (orientation 2). Restriction sites 
used in this study are indicated. In addition, positions of ampicillin resistance gene 
(AmpR) and primers are indicated (created in www.benchling.com). 
Table 9. Selected restriction sites and primer binding sites in the plasmid pCR2.1-TOPO-
MRP3 (orientation 1). 
 
 
 
 
 
 
 
 
 
 
 
Restriction site Start site Restriction site/Primer Start site 
BamHI 253 NotI 4922 
BamHI 2777 M13-reverse 221 
BamHI 3071 oMRP3-F 4870 
KpnI 245 oMRP3-RT-R 315 
  T7-promoter 4957 
    
Figure 10. Chart of the vector pcDNA3.1/Hygro(-)-MRP3. Restriction sites used in this 
study are indicated. In addition, positions of ampicillin resistance gene (AmpR), 
hygromycin resistance gene (HygroR), cytomegalovirus promoter (CMVp) and primers 
are indicated (created in www.benchling.com). 
Table 10. Restriction site and primer binding sites in the vector pcDNA3.1/Hygro (-)-
MRP3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Chart of the vector pcDNA3.1/Zeo(-)-UGT1A1. Restriction sites used in this 
study are indicated. In addition, positions of ampicillin resistance gene (AmpR), zeocin 
resistance gene (ZeoR), cytomegalovirus promoter (CMVp) and primers are indicated 
(created in www.benchling.com). 
Table 11. Restriction site and primer binding sites in pcDNA3.1/Zeo(-)-UGT1A1. 
 
 
 
Restriction site/Primer Start site Primer Start site 
BamHI 2779 oMRP3-seq2 2552 
BamHI 3073 oMRP3-Clone-F 3145 
BamHI 5597 oMRP3-Clone-F2 3188 
KpnI 5613 oMRP3-Clone-R 3344 
NotI 928 oMRP3-seq3 4155 
T7-promoter 882 oMRP3-RT-F 5128 
oMRP3-XbaI-F 975 oMRP3-RT-R 5538 
oMRP3-F 983 BGH-reverse 5640 
oMRP3-seq1 1980   
Restriction site Start site Primer Start site 
EcoRI 955 T7-promoter 882 
EcoRI 1681 oUGT1A1-seq1 1614 
EcoRI 2596 oUGT1A1-RT-F 2299 
  oUGT1A1-RT-R 2569 
